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Abstract 
Background:  The ability to provide quality assured affordable drugs in my country of Ethiopia 
is limited by insufficient medicines regulation, particularly a bioequivalence (BE) evidence gap 
commonly associated with local medicines.  The objective of this PhD program, therefore, was 
to determine whether it was feasible to advance health care providers’ practice in ways most 
beneficial to patients, within the existing regulatory context, by improving local practitioners’ 
confidence in the reliability of locally produced medicines.  
Bioequivalence is a particular concern for drugs which exhibit large pharmacokinetic 
variability, for example, anti-hypertensive medications, as such variability can translate into a 
high variability in treatment response. In this thesis, the feasibility of N-of-1 trials to assess the 
clinical bioequivalence of inexpensive local drugs (anti-hypertensives) in routine clinical 
practice was explored and tested. N-of-1 bioequivalence trials are a method by which two 
formulations of the one medicine are compared in an individual patient. In addition to 
individual treatment effects, when aggregated, this method can provide a population estimate 
of bioequivalence of the two formulations. If contextual threats are identified and addressed, 
N-of-1 bioequivalence trials could be feasible tools to identify and provide quality-
assured, low-cost generic medicines to patients in Ethiopia. A national system for prioritising 
and initiating comparative research on alternative generic treatments does not exist. Evidence 
regarding the feasibility of N-of-1 bioequivalence trials, using local generic drugs, was lacking.  
Therefore, this research program was designed to study their feasibility in three major areas, 
research need, methods and barriers to adoption of N-of-1 bioequivalence trials of local 
medicines in a resource limited country-Ethiopia. 
First, we conducted a qualitative study to assess views of local stakeholders about the use of 
local drugs and knowledge of lack of bioequivalence evidence on these medicines. Overall, the 
study demonstrated that there were concerns about local drugs. However, the regulatory 
authority members believed that there was no concern, but did not comment on the lack of 
evidence on local medicines. Then, a systematic review of barriers to conducting clinical trials 
in developing countries was conducted to focus on those issues that are critical to implementing 
N-of-1 trials. The review showed that lack of funding, lack of skilled human power, and ethical 
and regulatory challenges were the top three barriers. Based on this, a second qualitative study 
was conducted with stakeholders representing patients and physicians, who might take part in 
the proposed N-of-1 study, as well as officials of the Ethics and Regulatory authorities who 
may have to approve the study. The study was used to assess the acceptability and barriers to 
implementation of N-of-1 bioequivalence trials.   The study showed considerable support for 
N-of-1 bioequivalence (BE) methods, and highlighted important impediments, particularly 
regulatory issues, which were very likely to impact the feasibility of N-of-1 BE trials of local 
drugs in Ethiopia.    
Finally, a feasibility study of individual and aggregated N-of-1 bioequivalence trials of locally 
made Enalapril, compared to a version of Enalapril made in Germany, was piloted in a research 
institute-affiliated hospital in Addis Ababa.  The research institute provided an N-of-1 trial 
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service to the hospital through a patient referral-feedback model. A random effects mixed 
model for all patients combined showed that, on a group level, the two Enalapril formulations 
were therapeutically equivalent. In addition, all patients had their BP controlled at all times on 
both forms of Enalapril, but there was considerable inter-subject (subject-by-formulation 
interaction) variability. This pilot study showed that N-of-1 BE trials were ethically and 
methodologically feasible. The local Ethics committee decided that Regulatory authority 
approval was not required. However, the Regulatory authority made an official decision that 
N-of-1 BE studies required approval and oversight at regulatory level, in addition to the 
existing oversight of two ethics committees.  The trial was closed down because this had not 
been obtained prior to commencement.  
Conclusion and recommendation: The feasibility study showed that individual and 
aggregated N-of-1 BE trials are methodologically possible in a resource poor country if 
regulatory challenges are addressed.  Overall, drug formulation difference has no effect on 
treatment response variability in these Enalapril formulations.  Apart from regulatory 
challenges, there were also contextual issues that impacted the feasibility of these studies. 
Recommendations regarding how to address the remaining uncertainties and move these 
methods forward are given.  
In the future, aggregated N-of-1 BE trials could be suitably employed to meet regulatory needs 
and fill BE evidence gaps, ahead of Ethiopia developing formal bioequivalence capacity.  They 
may – and should- improve Ethiopian citizens’ confidence in the use of less costly, effective 
local drugs. In order for any research method to be feasible in a resource poor environment, it 
needs to be relatively easy to conduct, and have the support of relevant regulatory authorities.  
Institutionalizing N-of-1 BE studies has the capacity to empower local research, health system 
and regulatory capacity; and is important to embrace the needs of patients and physicians; and 
to develop a strong, high quality local pharmaceutical industry. 
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CHAPTER 1: INTRODUCTION 
1.1: Background 
Concerns to provide quality-assured, affordable drugs in an environment with insufficient 
medicine regulation (bioequivalence evidence gap in local medicines currently in use) drives 
this program to study whether it is feasible to advance health care providers’ practice in ways 
most beneficial to patients under the existing context. Furthermore, as standard bioequivalence 
relies on average pharmacokinetic responses, it doesn’t predict pharmacokinetic profiles in an 
individual patient. This is particularly a concern in drugs which exhibit large pharmacokinetic 
variability like anti-hypertensive medications, as such variabilities can translate into high 
variability in treatment response. In this thesis, an argument is made on the feasibility of N-of-
1 bioequivalence trials to test therapeutic equivalence of inexpensive locally produced drugs 
in a resource limited clinical setting. If contextual threats are identified and addressed, N-of-1 
bioequivalence trials could be feasible tools to identify and provide quality-assured, low-
cost generic medicines to patients in Ethiopia. N-of-1 tests are double blinded, multiple cycle 
crossover trials by which two formulations are compared in an individual patient comparing a 
test treatment with a comparator. They are indicated whenever there is a need to formally assess 
the bioequivalence of alternative generic treatments. N-of-1 trials are comprehensive 
assessments that have the potential to enhance patient centered care and build trust in effective 
local drugs. In addition to individual treatment effects, when aggregated, this method can 
provide a population estimate of bioequivalence of two formulations of the one drug. 
A national system for prioritising and initiating comparative research on alternative generic 
treatments, specifically, evidence regarding feasibility of N-of-1 bioequivalence trials of local 
generic drugs was lacking. Therefore, the research program was designed to assess three 
feasibility areas for adopting N-of-1 bioequivalence trials in clinical practices of Ethiopia: (1) 
research need/question on local medicines, (2) method acceptability and feasibility and (3) 
barriers to conducting the proposed study. 
In this chapter, N-of-1 tests are defined, the program of research is outlined and, finally the 
structure of the thesis is presented.  
1.2: N-of-1 Trials  
N-of-1 trials are double blinded, multiple crossover comparative trials in individuals. They are 
indicated whenever there is substantial uncertainty regarding the comparative effectiveness of 
different treatments being considered for an individual patient.  Guidelines commissioned by 
the US Agency for Healthcare Research and Quality (AHCRQ), and a recently published book 
have both documented the use of N-of-1 trials as a means of formally assessing the 
bioequivalence of generic drugs 1,2. 
An example of patients who benefitted from N-of-1 bioequivalence trials were three 
hypertensive patients in Canada who were observed to have > 10 mmHg rises in their systolic 
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pressure after switching to a new formulation of Nifedipine 60mg.  These patients underwent 
an N-of-1 trial to compare the therapeutic equivalence of the two formulations of Nifedipine 
60 mg. In all the cases, the newly substituted Nifedipine was not equivalent, and the patients 
were subsequently switched to the original Nifedipine formulation3. The study concluded that 
standard average bioequivalence criteria is not sufficient and emphasized the need for better 
bioequivalence criteria. 
1.3: Program overview 
The main driving force behind the research program was a pharmacovigilance report by the 
Ethiopian medicines authority, banning a locally manufactured drug (without proof of 
bioequivalence data) following claims of ineffectiveness of the drug from various health 
professionals4. The therapeutic response of a medicine is determined by the degree to which it 
achieves appropriate pharmacokinetic and pharmacodynamic parameters. Several factors 
including formulation and manufacturing practice as well as patient characteristics (like 
gender, concomitant diseases, gastrointestinal conditions and drug–drug interactions) can 
affect the pharmacokinetic profile of a generic medicine, with consequences on kinetic-
dynamic relationships that would result in variations in clinical responses of a generic product 
compared to the brand product. Pharmacokinetic (PK) bioequivalence testing optimizes the 
dose of a generic drug by measuring profile of drug concentration in blood over time. While 
proof of bioequivalence is a regulatory requirement in Ethiopia5, in practice, the lack of a 
pharmacokinetic bioequivalence testing facility locally has made enforcing bioequivalence on 
local pharmaceutical companies difficult5.  
Beside the PK BE approach, pharmacodynamic and clinical endpoint studies can also be used 
to demonstrate bioequivalence. For example, patient brand-to-generic switching studies are 
used where concern exists about the substitutability of generic drugs6. To address drug 
substitution issues, in 1997, the United States Food and Drug Administration proposed a new 
individual bioequivalence (IBE) approach which requires demonstration of equivalence at 
individual level7.  This approach provides an average population bioequivalence of a generic 
drug but it also addresses within-subject variability, as well as the subject-by-formulation 
interaction.  
This study proposed that the design of N-of-1 BE trials complies with FDA proposed IBE and 
can be used for this purpose. We hypothesised that, in addition to the individual N-of-1 trial, 
as proxy to the individual BE approach proposed by FDA, individual N-of-1 BE trials (when 
aggregated) can bridge the bioequivalence evidence gap in local medicines and address the 
major criticisms of the standard bioequivalence method: measuring individual bioequivalence 
and therapeutic equivalence. The thesis describes the process and the various research stages 
to adopt N-of-1 trials in clinical practice in Ethiopia. 
Comparative studies concerning available alternative treatment options are evaluated using 
three major feasibility areas: research need/questions, methods for comparative research, and 
infrastructure (barriers and impediments) specific to the proposed research8. Accordingly, if N-
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of-1 bioequivalence trials had to be adopted to test available local generic treatments, three 
feasibility issues need to be identified and addressed: (1) research need/questions relating to 
local medicines, (2) method and feasibility and (3) barriers for their conduct. 
Evidence regarding perception of local drugs, as well as the acceptability of N-of-1 trials of 
untested generic drugs and their implementation is lacking. Before N-of-1 BE trials are 
proposed as an appropriate research method to answer the question of interchangeability, 
evidence of the contextual barriers for conducting such trials needs to be ascertained.  Given 
the complex nature of the intervention (local medicines represent affordable treatment options 
in usual care but without sufficient evidence) and the novelty of the proposed research method, 
specific barriers for this study need to be identified and addressed. Evidence regarding issues 
for the conduct of trials in general (and N-of-1 BE trials in particular) is lacking. 
To address the research need on local generic treatments, evidence is required about clinical 
concerns and agreement on the evidence gap (lack of bioequivalence data) that justifies that 
research is needed on these drugs. Then, evidence on the acceptability of the N-of-1 BE method 
and their implementation approaches is required. The success of addressing knowledge gaps in 
current medical treatment depends upon some agreement among stakeholders about 
interpretation of the state of current evidence regarding bioequivalence and priorities for 
research. Lack of consensus on the current evidence base could lead to dispute about what 
research question is most relevant and confound attempts to design trials9. To address such 
problems, a multi-stakeholder process is recommended to identify questions for comparative 
research of available treatments10. It is also advised that questions need to be consistent with 
changes in the political as well as scientific landscape. 
Therefore, first, we must ensure that relevant stakeholders believe there are issues about local 
medicines in use, and this depends on knowledge and interpretation of lack of bioequivalence 
evidence on these treatments. Second, stakeholders who might take part in the study (patients 
and physicians), and officials of the Ethics and Regulatory authorities who may have to approve 
the study, need to understand and support N-of-1 BE trials as an appropriate method to test 
local drugs.  
Finally, even with an agreement that local generic treatments in use require additional tests, 
and that N-of-1 testing is an appropriate method, several practical methodological and ethical 
issues may still affect the feasibility of N-of-1 use in clinical practice. So far, only two N-of-1 
studies have been conducted in Canada to assess therapeutic equivalence of generic medicines. 
However, both were limited to an individual N-of-1 approach only and did not address whether 
aggregated N-of-1 bioequivalence trials are feasible to generate population level 
bioequivalence information. Moreover, both studies tested interventions of proven 
effectiveness (bioequivalence) on individual patients in a developed country setting. Evidence 
is lacking regarding applicability of the method to evaluate untested generic drugs, which 
represent affordable treatment options in the usual care of patients in resource poor clinical 
settings.  
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Therefore, guided by frameworks for pilot studies conducted prior to large scale randomized 
clinical trials, a series of research studies were conducted to assess and address key feasibility 
areas for adopting N-of-1 bioequivalence trials of local medicines in clinical practices of 
Ethiopia.  
First, we conducted a qualitative study to assess perceptions of local stakeholders about local 
drugs and knowledge of lack of BE data on these medicines. Then, we conducted a systematic 
review of barriers to conducting clinical trials in developing countries, to inform the qualitative 
study as well as anticipate and plan for those issues that might significantly impact the proposed 
study. Based on the findings of this study, acceptability and key uncertainties that impact N-
of-1 BE trials of local drugs were identified using a qualitative method. Once acceptability 
issues were identified and addressed, we were interested in the practical feasibility of N-of-1 
BE trials to evaluate medicines lacking proof of bioequivalence.  Therefore, a series of N-of-1 
trials was conducted to study feasibility of N-of-1 BE trials of two formulations of Enalapril 
used for the management of hypertension. Due to its high prevalence, hypertension was chosen 
for the feasibility pilot trial. A patient referral-feedback model was used to deliver the trial 
service.  
1.4 Outline of this thesis 
Driven by the need for tools to provide quality assured affordable drugs in a resource limited 
setting, the thesis explores practical issues that impact feasibility of N-of-1 bioequivalence 
trials of generic drugs without proof of bioequivalence. The thesis is presented as a series of 
manuscripts and published papers connected together with linking texts.  
The thesis is comprised of nine chapters. Chapter 1 defines N-of-1 trials, outlines the program 
of research and presents the structure of the thesis. Chapter 2 describes the research 
background, critically reviews the current literature, identifies the gaps, develops the research 
idea and formulates research questions. Chapter 3 restates the research problem and outlines 
the research stages and general methods of the program using a framework for pilot studies 
conducted prior to future randomized clinical trials. Chapter 4 is a qualitative study of 
perceptions about locally manufactured medicines in Ethiopia: a study of physicians, patients 
and regulatory authorities. The findings of this research informs Chapter 6. Chapter 5 is a 
systematic review of barriers to conducting clinical trials in developing countries. This 
systematic review provided the data that contributed to Chapter 6. Chapter 6 assesses the 
acceptability and barriers to implementation of N-of-1 trials in a resource – limited country: 
Ethiopia. The findings of this chapter provided data that helped to modify and improve Chapter 
7. Chapter 7 is a protocol on a series of N-of-1 trials to assess therapeutic interchangeability of 
two Enalapril formulations in the treatment of hypertension, Addis Ababa, Ethiopia. Chapter 8 
presents the findings of the pilot trial. Finally, Chapter 9 discusses the implications of the 
results and provides various approaches that could address the remaining uncertainties for 
routine use of N-of-1 BE trials in resource limited clinical settings.   
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CHAPTER 2: LITERATURE REVIEW 
2.1: Introduction 
This chapter describes the research background, critically reviews related literatures, identifies 
the gaps, conceptualizes the research idea and formulates research questions. The chapter 
mainly focuses on the application and feasibility of conducting N-of-1 trials in developing 
countries.  
2.1.1. Overview of Ethiopia - study context 
Ethiopia is Africa’s oldest independent country and one of the world’s oldest civilizations. 
Ethiopia is the second most populous country in Africa. The current population of Ethiopia is 
estimated to be 100,936,943- equivalent to 1.35% of the total world population11. Around 83% 
of the population lives in rural areas, where subsistence farming is the only means of survival.  
Currently, Ethiopia is one of the world’s poorest countries12. The literacy rate in the country is 
low, as 82% of women and 58% of men aged 15 and over are illiterate13. Though the majority 
of the health problems in Ethiopia are attributable to preventable disease conditions, there is an 
increasing prevalence of non-communicable diseases (NCDs)14.  
2.1.2. The challenge of non-communicable diseases  
Globalization and rapid demographic transitions are driving developing countries to bear 
higher burdens of NCDs than high-income countries15. Chronic non-communicable diseases, 
such as hypertension and diabetes, are rapidly increasing and posing a significant burden of 
morbidity and mortality in Ethiopia14. These chronic conditions require regular monitoring, 
and in many cases, lifelong treatments with multiple medications. However, treatment of 
chronic conditions is expensive, and many individuals with these conditions could not afford 
it. 
2.1.3. Local production of generic drugs as a solution to improve access to medicines  
A generic drug is a copy of an original medicinal drug whereby production and marketing are 
made possible by the expiry of the patent covering the innovator product. These drugs represent 
a potentially cost–effective solution to treating non-communicable diseases. The United 
Nations recommends that the world’s poorest countries should improve access to medicines 
through local production of generic drugs which are bioequivalent to brand-name drugs16. The 
government of Ethiopia is committed to support the development of local pharmaceutical 
companies in the country17. Around 30% of National Essential Drugs in Ethiopia is produced 
locally17. 
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2.2. Bioequivalence studies and their approach 
In many countries including Ethiopia5, bioequivalence studies are regulatory requirements to 
ensure therapeutic equivalence between a pharmaceutically equivalent test and reference 
product18-20. Different in vivo and in vitro approaches are used to ensure quality and optimize 
generic medicines.  These include pharmacokinetic, pharmacodynamic, clinical, and in vitro 
studies18-20.   
In general, use of the most accurate, sensitive, and reproducible approach available is a 
prerequisite to demonstrate bioequivalence of a generic drug. Pharmacokinetic (PK) 
bioequivalence testing is considered to be the most sensitive approach to demonstrate 
bioequivalence. Pharmacodynamic (PD) studies are alternative options. However, well 
justified clinical endpoint bioequivalence studies can be used to establish bioequivalence when 
PK-PD studies are not possible5--see figure 2.1. A pharmacodynamic study is one in which 
bioequivalence is demonstrated by using the pharmacological effect whereas clinical studies 
establish the bioequivalence of drugs using clinical effectiveness as an index. 
 
Pharmacokinetic bioequivalence studies employ three approaches: average bioequivalence, 
population bioequivalence and individual bioequivalence. Pharmacodynamic and clinical 
bioequivalence studies include comparative clinical trials like N-of-1 bioequivalence.  The 
subsequent sections of this chapter explain and evaluate these methods in order to determine 
whether a pharmacodynamic N-of-1 bioequivalence approach is the most suitable approach for 
this project. The first section discusses the standard bioequivalence study, challenges for 
conducting such studies in Ethiopia and implications for clinical care, the second section 
discusses population and individual bioequivalence, the third section presents methodological 
requirements of different bioequivalence approaches, the fourth section compares PK and PD 
studies using antihypertensive drugs as an example and the fifth section discusses PD/clinical 
N-of-1 bioequivalence studies.   
2.2.1. The average bioequivalence study 
The average bioequivalence (ABE) is considered to be the standard bioequivalence and 
demonstrates that, on average, a generic formulation has equivalent plasma concentration with 
a reference product (i.e., the 90% confidence interval (CI) of the mean dose ratio, expressed as 
a percentage, is within ±20% of the reference drug)21 - (figure 2.2). Bioequivalence is 
Invitro BE
Clinical 
Endpoint   BE
Pharmacodynamics
Endpoint BE
Pharmacokinetic 
Endpoint BE
Figure 2.1-Hierachy of bioequivalence study approaches 
 
Clinical/Therapeutic Equivalence 
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demonstrated using kinetic responses (AUC and Cmax) which are derived from the measured 
drug concentrations.  
 
2.2.1.1. The role of bioequivalence data in clinical practice and promotion of generic drug use 
2.2.1.1.1. Lack of a bioequivalence centre in Ethiopia 
Ethiopia is one of the Sub-Saharan African countries where poor regulation of medicines poses 
a challenge to the effective clinical care of patients22,23.  For example, unlike many other 
countries, demonstrating evidence of bioequivalence is not a requirement to approve locally 
manufactured medicines in Ethiopia. While bioequivalence certification is a requirement for 
registration of generic medicines5, the lack of a bioequivalence testing facility locally has made 
enforcement of bioequivalence regulations on local pharmaceutical companies impossible. 
While approving locally produced drugs (without World Health Organization (WHO)-
prequalification criteria for therapeutic interchangeability22) is a key strategy to ensuring access 
to affordable medicine locally, the notion of generic drug substitution on economic grounds 
alone could have  negative consequences, and conflicts with the principle of Evidence-based 
Medicine24. A good example of this is the decision made by the Ethiopian medicine regulatory 
authority against a locally manufactured drug for being ineffective, as reported by multiple 
health professionals4. In addressing such issues, WHO 25 emphasized that quality should not 
be compromised at the expense of making drugs financially accessible to poor people. 
2.2.1.1.2. The need for policies and interventions for effective promotion of generic drugs  
Interventions that enhance knowledge about and acceptance of generic drugs are prerequisites 
for promoting effective generic drug substitution in developing countries26.  For example, to 
address concerns about the efficacy and safety of generics and to increase their acceptability, 
European countries have initiated policies that empower physicians, pharmacists and/or 
patients with knowledge of bioequivalence regulatory requirements for generic medicines27. In 
the post-market phase, the US Food and Drug Authority (FDA) advises the use of research like 
individual patient brand-to-generic switching studies where concern exists about the 
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Figure 2.2-An example of 90% CI of PK responses for 3 different 
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substitutability of generic drugs6 .Similarly, Ethiopian drug  policy states that “an appropriate 
system shall be devised for the collection of new information about the harmful and beneficial 
effects of drugs from health professionals, compiled and analysed, the findings shall be 
publicized at national and international level”28. When applicable, N-of-1 BE methods have 
the potential to build trust and use of effective local generic medicines while contributing to 
medicine quality at the same time.  
2.2.1.1.3. A growing interest to improve quality of care in developing countries  
Increasing evidence suggests that quality of care (or the lack of it) must be at the center of 
every discussion about better health in developing countries29-31. In contemporary medicine, 
simple access (historically the focus of developing countries) is not enough and hence the 
system's capacities must be applied skillfully to produce better health29,32. The use of N-of-1 
trials in clinical practice could reduce side effects, increase benefit, and improve outcomes for 
each patient. 
2.2.1.1.4. The way health care providers practice can make a difference to quality of care  
Quality and safety of pharmaceuticals has been and should be a concern for everybody 
(manufacturers, suppliers, regulators) but ultimately health care professionals are responsible 
to provide the best available care to patients33. One common explanation for low-quality care 
in the developing world is related to structural issues (eg. lack of resources)29. However, quality 
of care can be improved significantly by increasing the likelihood that health care providers 
practice in ways most beneficial to patients under the prevailing circumstances29,32  
Evidence demonstrates how process improvement regardless of access to care or cost of care 
can improve health care. Thus, quality improvement tools that target providers’ behavior need 
to be spread to developing countries so as to build local capacity29. An N-of-1 trial is a 
comprehensive clinical tool and has the potential to assist clinicians in developing countries to 
provide optimal treatment for their patients. 
2.2.1.1.5. Poor treatment adherence and poor outcomes in chronic disease 
Though compliance is central for successful management of chronic illnesses, as many as 50% 
of patients are non-adherent to medications and hence cannot realise the full benefits of their 
medications34,35. The magnitude and impact of poor adherence in developing countries could 
be higher.34 36,37.  Compliance with medication is influenced by a number of factors. Medication 
beliefs, side effects and ineffective communication are the major predictors of poor medication 
adherence38,39.  
A recent study reported a reduction in adherence to generic substitution, due to poor efficacy 
and increases in side-effect40. Several other studies have addressed the nocebo effect (negative 
outcomes due to patient’s negative expectations), non-adherence and their relationship related 
to generic substitution41-43. A study assessed the nocebo and placebo effect of substitution by 
testing the effectiveness of β-blocker medications41. All medications used in the study were 
‘placebos’. Compared to patients who continued receiving branded medicine, patients switched 
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to a generic medicine with a different colour tablet were reported to have lower reductions in 
blood pressure and more adverse events.  
Empowering patients, communication and recognizing that patients' economic constraints may 
limit their ability to adhere to their medication is important to address compliance issues44. A 
review made on patient-centered care and adherence reported that patient-centered care 
improves adherence and health outcomes45. The study identified patient involvement in care, 
effective communication of disease and treatment conditions, and individualization of patient 
care as the fundamental characteristics of effective patient centered care. N-of-1 trials enhance 
the provision of patient-centered care.  
2.2.1.2. Concerns about the current bioequivalence criteria  
Although there are a few studies that reported problems related to generic drug substitution in  
antiepileptic and antihypertensive drugs,46,47 several other studies, including systematic 
reviews, reported that there is no evidence of efficacy or side effect differences between 
reference and bioequivalent generic formulations of cardiovascular and epileptic drugs48,49. 
Overall, such evidence demonstrates the significant role of bioequivalence studies in 
determining optimal therapy. Thus, lack of bioequivalence information represents a major 
challenge for proper generic drug substitution.  
Further, the available evidence on generic drug interchangeability is based on population-based 
studies of bioequivalence, not individual bioequivalence. The US FDA identified two 
interchangeability questions related to the application of evidence generated from the standard 
bioequivalence in actual clinical setting7:  
1. Is beginning treatment with a generic drug as safe and effective as with a reference 
drug?  
2. Is it safe and effective to make a substitution from a reference drug to its generic 
counterpart or vice-versa? 
Pharmacokinetics of a generic medicine in patients can be affected by several factors, including 
individual patient factors (gender, ethnicity, comorbid conditions, diet etc); formulation factors 
(excipients and quality and amount of active ingredients used) as well as manufacturing 
practice. Thus, the above problems are partly related to the measurement emphasis of the 
current bioequivalence criteria. The average BE approach focuses only on the comparison of 
population averages of a kinetic responses of interest and does not predict pharmacokinetic 
profiles in a specific patient 7. The standard single-crossover study does not account for the 
following three categories of intra-subject variability: intra-drug due to physiological metabolic 
variability; intra-formulation due to unit to unit or batch to batch variability and inter- 
formulation/subject-by- formulation interaction variance which is due to between-subject 
variation in the average ratio of kinetic parameters between a test and comparator drug7.   
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The literature on bioequivalence or clinical equivalence at individual level is thin. However, 
some PK bioequivalence studies that addressed bioequivalence at the individual level showed 
that despite demonstrating average bioequivalence (90% CIs within the 80–125%1), several 
individual pharmacokinetic ratios fall well outside the accepted  +25% range, resulting in either 
under or over dose50,51For example, a PK bioequivalence study comparing generic and 
reference cyclosporine products found that 38% of individual C max ratios and 18% of 
individual AUC ratios were less than 0.80 despite having 90% CI within the 80–125% limits51-
Figure 2.3 . Two pharmacodynomic bioequivalence studies (including one N-of-1 trial) 
demonstrated that despite proof of bioequivalence, a substituted generic product (Nifedipine 
60mg) failed to demonstrate therapeutic equivalence for individual patients3,52.  
 
Figure 2.3: Variation in individual exposure between generic and branded cyclosporine 
formulations in a bioequivalence study (figure taken from published report51) 
Similarly, a recent study (2017) assessed the adequacy of the standard BE in a developing 
country context (Saudi Arabia), by addressing bioequivalence at individual level using 42 
marketed generics50. The study concluded that 16% and 17% of individual generic/reference 
and generic/generic ratios, respectively, were outside the ±25% range in for AUC, and 32% 
and 32% for Cmax. Moreover, the authors reported that two thirds of generic-reference and 
generic-generic AUC comparisons failed to show average bioequivalence.  
The effect of genetic factors including ethnicity and gender in bioequivalence studies with 
crossover design are considered minimal. Therefore, often pharmacokinetic BE testing is 
conducted in males assuming that intra-subject variabilities are similar between both sexes. 
However, there is evidence that patient factors such as gender can cause pharmacokinetic 
variabilities in bioequivalence of medicines53-55. A commonly cited case is the effect of 
differences in excipient (poly-ethylene glycol) on gender variabilities in bioequivalence55. The 
study concluded that the use of this salt enhances the bioavailability of ranitidine in a dose-
dependent manner by up to 63% among men, whereas it decreases absorption among women 
by up to 24%. Unfortunately, use of similar excipients (inactive ingredients) in generic 
formulation to those in the brand name drug is not a regulatory requirement.  
                                                 
1 NB: Different regulatory agencies use different upper and lower limits- -see section 2.2.5.4  
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Another common criticism is related to the fundamental bioequivalence assumption: which is 
the rate and extent of absorption (as measured by kinetic responses) is predictive of clinical 
outcomes21,56. Because of this assumption (a consistent relationship between PK responses and 
clinical outcomes), demonstration of bioequivalence is based on biologic equivalence of single-
dose formulations in healthy volunteers21,56. That means bioequivalent generic products are 
considered to be therapeutically bioequivalent. However, several studies reported that a 
difference in formulations (including different excipients) is related to a change of 
pharmacologic effect during treatment with the generic formulations57,40,58-60. One of the 
studies compared two formulations of omeprazole and concluded that the products were not 
bioequivalent due to differences in the composition of enteric coating60. Addressing these 
limitations is important. When applicable, N-of-1 BE trials address criticisms of the current 
bioequivalence by directly measuring both individual bioequivalence and therapeutic 
equivalence.  
2.2.2. Population and Individual Bioequivalence 
FDA guidance for bioequivalence7 reports three types of variance in bioequivalence studies: 
(1) Difference in average exposure between a generic drug and a brand-name, (2) Total 
variance or population variability in kinetic responses and (3) inter-subject variability 
(difference due to subject-by-formulation interaction). The purpose of a bioequivalence study 
is to assure prescribability and switchability2. Because of the assumption of BE, clinicians 
consider that generic drug products and the innovative drug product can be used 
interchangeably because they are therapeutically equivalent. In actual clinical practice, 
however, average bioequivalence (ABE) cannot imply either drug prescribability or drug 
switchability7,56,61,62. As the ABE does not take into account population and subject-by-
formulation interaction differences, it is possible that there is a detectable difference in plasma 
drug levels after an individual patient switches from a brand-name to a generic drug and vice 
versa7,56,61,62.  
Therefore, to address such drug interchangeability issues, in 1997, FDA proposed two new 
approaches of BE7: population bioequivalence (PBE) and individual bioequivalence (IBE).  In 
2001, FDA published statistical guidance for these new bioequivalence approaches61.  
Population bioequivalence (PBE) 
To ensure PBE of two generic treatments, the distribution of pharmacokinetic measurements 
should be similar. That means, in addition to the average parameter, the total variability of the 
measure in the population should be similar.  This allows clinicians to prescribe either a test or 
a reference drug with confidence.  In the 2001 Guidance, population equivalence is presented 
in terms of population difference ratio (PDR) for test (T) and reference (R) drugs, which is the 
ratio of the expected squared difference between T and R administered to different subjects 
                                                 
2 Prescribability -Is beginning treatment with a generic drug as safe and effective as with a reference drug? (for 
new patients) 
  Switchability - Is it safe and effective to make a substitution from a reference drug to its generic counterpart or 
vice-versa? (for patients who have been titrated to the most effective dose) 
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versus the expected squared difference between two administrations of reference drugs 
administered to different subjects. 
Individual bioequivalence (IBE) 
Switchability requires evidence that two generic treatments are individually bioequivalent. 
Individual bioequivalence address interchangeability issues at the individual level by allowing 
assessment of intra-individual variance in a bioavailability metric and by assuring that test and 
reference product metrics are close to average within each individual as well as in the 
population. In clinical settings, IBE allows the clinician to switch the prescribed drug from a 
reference drug to the test drug or vice-versa for a subject who has been titrated to the most 
effective dose without compromising the efficacy and the safety of the drug. In the Guidance, 
individual equivalence is presented by individual difference ratio (IDR) which is the ratio of 
expected squared difference between test T and R drugs administered to the same subject and 
the expected squared difference between two administrations of reference drugs (R and R’) 
administered to the same subject. 
2.2.2 1. Population Vs individual bioequivalence 
The major difference between the population and the individual BE approach relates to 
differences in estimating variance terms. In individual BE, after the estimation of the mean 
difference and the variance has been completed, a 95% upper confidence bound for the 
individual BE criterion is obtained7. Two criteria have been proposed to control the three 
pharmacokinetic variabilities: difference in average variability, variance by subject-drug 
interaction and intra-individual difference. These are disaggregate and aggregate criteria. In the 
disaggregate approach, criteria are set for each individual characteristic separately. For 
example, a 75/75 rule that stated that two formulations are equivalent if and only if at least 75% 
of the individuals being tested had ratios (of the various pharmacokinetic parameters obtained 
from the individual results) between the 75 % and 125% limits. In the case of aggregate 
approach, a single rule which controls all three characteristics simultaneously is set7.  
Currently, the aggregate criteria is recommended by FDA61. Specific aggregate models for 
population and individual bioequivalence are presented in figure 2.9.  
Drugs without bioequivalence profile may lead to a lower or higher blood concentration and 
the variability of effect of such generic substitutions could be high. However, the FDA 
proposed PK BE approach is not applicable to settings where bioequivalence infrastructure is 
not well developed. When applicable, N-of-1 trials are pragmatic options to address 
interchangeability issues of generic drugs.  
 
 
14 | P a g e  
 
2.2.3. Assessing bioequivalence using genomic data 
It has been recognized that genetic variants determine a portion of inter-individual variability 
in bioequivalence studies, with the expression of drug metabolizing enzymes and transporters 
playing a key role63,64,65. An alternate solution to the problem of such inter-individual 
variability is to assess bioequivalence using genomic data in order to reduce variability due to 
genetically defined metabolic inter-individual differences. To this end, a number of 
pharmacologically relevant genetic variants relevant to bioequivalence is identified. For 
example, a study evaluated the correlations of pharmacokinetic parameters following oral 
valacyclovir or acyclovir administration with the expression levels of intestinal genes in 
humans tested by employing microarray techniques, and demonstrated a positive significant 
correlation between the AUC (area under the curve in a plot of concentration of drug in plasma 
against time) and the expression intensities of HPT1 (Hypoxanthine-guanine Phosphoribosyl 
transferase) peptide transporters66. 
Furthermore, a couple of statistical models67,68 are proposed to assess bioequivalence using 
genomic data, under a replicated crossover design, assuming there is a well-established 
predictive model between clinical outcome and the biomarker(s). 
 
2.2.3.1. The challenges of adopting personalized medicine in developing countries 
The vast majority of genetic variability remains hidden and the role of genomics in 
bioequivalence needs to be further developed. Developing countries are far from being able to 
develop and utilise such advancements, at least in the short term. The WHO explained this as 
follows: 
“If, as seems likely, genomics does produce major benefits for health, the lack of 
biotechnological expertise in the pharmaceutical industry in the developing world 
will lead to a major exacerbation of the inequalities of health care among different 
countries69” 
Thus, N-of-1 trials remain a pragmatic tool to assess the clinical impact of pharmacokinetic 
differences between generic formulations in individual patients.  
2.2.4. Other strategies to optimize drugs   
Another valuable tool for optimizing the dosage of the prescribed medication to the individual 
characteristics of a patient is therapeutic drug monitoring (TDM) 70,71. TDM is based on the 
assumption that there is a relationship between plasma concentrations and clinical effects. This 
approach addresses inter-individual pharmacokinetic variabilities by maintaining plasma 
concentrations in a pre-defined therapeutic range. Measurement of medication concentrations 
is helpful when switching from one form of a drug to another could lead to therapeutic issues71. 
For example, researchers from India72 who used TDM for optimization of pharmacotherapy 
have identified substandard products by observing low levels of phenytoin in patients otherwise 
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known to be compliant and previously having levels in the therapeutic range before changing 
to a different brand. The study revealed that more than 85% (20/23) children referred for TDM 
service required dose adjustment.  Based on this finding, the authors concluded that the TDM 
service can be used to provide an important early indicator of substandard drugs in developing 
countries72. However, for the majority of medications, therapeutic drug monitoring is not 
feasible and is unlikely to assist management71,73.  
2.2.5. Design and methodological requirements in bioequivalence studies  
There are important methodological issues to be considered in all types of bioequivalence 
studies. In general, methodology for establishing equivalence between pharmaceutical 
products using PD/clinical equivalence trials have not yet been as well developed as the 
pharmacokinetic bioequivalence studies. The next section discusses the different 
methodological considerations based on the local and international guidelines on 
bioequivalence requirements. 
2.2.5.1. Study design in bioequivalence studies 
Two-treatment crossover design is the standard for established PK bioequivalence 
studies5,18,74.  In contrast, in addition to two treatments, WHO18 and Ninth Edition of the 
International Conference on Harmonisation (ICH E9)75 recommend that, where appropriate, a 
third placebo arm should be included to confirm the design validity of PD/clinical 
bioequivalence studies. Proof of a significant difference between each of the treatment arms 
and the placebo is required. This is because of concern for placebo effects in PD/clinical BE. 
When this is not feasible, the response to the test and reference products should each provide a 
statistically significant improvement over baseline. Regarding choice of design, WHO and ICH 
E9 recommend the use of both parallel and crossover designs. Study design requirements are 
not stated in the Ethiopian guideline5.  N-of-1 trials are suitable for this purpose. 
Moreover, the purpose of bioequivalence studies is not to assess treatment response for a 
particular medicine-i.e. they are not drug effectiveness trials which address differences in 
individual subject sensitivity to drugs. Therefore, before commencing the main BE trial phase, 
appropriate mechanisms for identifying and excluding non-responders (e.g. inclusion of a run-
in phase) is required in PD/clinical BE studies. Careful design and conduct of bioequivalence 
studies is also recommended to avoid the tendency of bias towards a conclusion of equivalence. 
For example, ICH advises to give special attention for a washout period when the cross-over 
design is used. The washout periods in crossover studies should be at least 5 times the 
elimination half-life of the parent drug or active metabolites63 .  
2.2.5.2. Choice of the reference drug for bioequivalence studies 
Selection of acceptable comparator drugs is also one of the prerequisites for all bioequivalence 
studies5. The Ethiopian guideline advises that the choice of comparator product should be 
justified by the applicant. According to the guideline, the innovator pharmaceutical product is 
usually the most logical comparator product for a multisource pharmaceutical product because 
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its quality, safety, and efficacy have been well documented in pre-marketing studies and post-
marketing monitoring schemes. A generic pharmaceutical product should not be used as a 
comparator as long as an innovator pharmaceutical product is available, because this could lead 
to progressively less reliable similarity of future multisource products and potentially to a lack 
of inter-changeability with the reference product. 
2.2.5.3. Selection of appropriate Endpoints 
Plasma drug concentration is considered to be the most sensitive in detecting and quantifying 
the degree of formulation difference in bioavailability between test and reference 
products5,18,74. In principle, selection of a sensitive outcome that also fulfils the continuous, 
symmetrical distribution that is required to enable the use of the established general linear 
model that is typically used for PK bioequivalence studies would be preferable. In this regard, 
the Ethiopian guideline for registration of medicines also requires the application of the same 
statistical principles as for the PK bioequivalence if PD/clinical bioequivalence studies are 
considered as being undertaken to prove equivalence5. Several PD markers (like blood 
glucose, levels cholesterol and blood pressure) would satisfy the endpoint requirement for PD 
bioequivalence studies. For example, blood pressure (BP) is one of the predictors of mortality 
and cardiovascular and cerebrovascular events76,77. Concentration effect relation has also been 
established between plasma drug concentration and blood pressure reduction for many anti-
hypertensive drugs. Many bioequivalence and dose-response studies have been conducted 
using blood pressure as a pharmacodynamic response. PK studies focus on the relationship 
between dose and time profile of drug concentration, whereas PD studies establish the 
relationship between dose and treatment effect by measuring pharmacologic responses.    
2.2.5.4- Defining bioequivalence criteria and equivalence limit 
Depending on whether the criterion is scaled to the intra-individual variance of the reference 
formulation or not, there are two ways/criteria to decide the bioequivalence limit: scaled and 
constant/unscaled61. When a generic drug company chooses the unscaled criterion, a constant 
BE limit is defined by the regulatory authority (+ 20 rule - within +20% or 80/125 rule-within 
(80%, 125%)). The use of constant BE criteria for highly variable drugs requires a larger 
sample size.  Therefore, reference-scaled criteria are recommended when the reference product 
within-subject variability (coefficient of variation, CV) is greater than 30%, which corresponds 
to a within-subject standard deviation (SD) ≥ 0.294 of the reference formulation. The method 
allows to widen the acceptance limit based on the within subject variability of the reference78. 
For example, instead of 80 to 125%, a drug with CV, 35 (SD, 0.34) will have BE limit of 71 – 
140%.  
In general, due to the bioequivalence assumption, defining the relationship between acceptable 
bioequivalence limits and clinical differences is difficult. Therefore, in contrast to PK 
bioequivalence studies, there is no standard method for determination of the size of equivalence 
limit for PD/clinical bioequivalence studies74,75,78.  Therefore, the size of the acceptance range 
has to be defined case by case taking into consideration the specific clinical conditions. As a 
general guidance, WHO18, ICH E975, and FDA74 advise that the choice of equivalence limit 
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(clinically acceptable difference) needs statistical and clinical justification with respect to its 
meaning for future patients. If possible, this should be based on prior knowledge of the 
clinically relevant difference of the comparator drugs in placebo control trials.  Generally, the 
ICH guideline advises this to be smaller than the expected clinically relevant difference the 
active drug would have in a placebo-controlled superiority trial designed to establish that a 
difference exists.  
2.2.5.5. The sample size determination in bioequivalence trials 
Several guidelines advise that the sample size of an equivalence trial should normally be based 
on the objective of obtaining a confidence interval for the treatment difference that shows that 
the treatments differ at most by a clinically acceptable difference. The careful choice of the 
clinically acceptable difference is critical to estimate a sample size required to achieve 
sufficient power.  
2.2.5.6. Procedures in the statistical analysis of bioequivalence 
There are three main elements to determine bioequivalence: criteria for comparison, the 
confidence interval and a BE limit. The general procedure is similar for both PK and 
PD/clinical bioequivalence studies61.   
a) A statistical test is undertaken using a hypothesis test  
b) The statement of bioequivalence is stated as the alternative hypothesis and 
c) The significance level is set at 5%, i.e. the probability of an incorrect claim of 
bioequivalence/ therapeutically equivalence.  
H0: Therapeutically inequivalent, H0 is null hypothesis  
HA: Therapeutically equivalent, where HA is alternative hypothesis 
Rejection of the null hypothesis- demonstrating that the difference between two treatments is 
contained within clinically acceptable difference-results in a conclusion of therapeutically 
equivalence.  
2.2.5.7. Pilot Study before full scale 
When necessary, a pilot study in a small number of subjects should be carried out before 
proceeding with a full-scale bioequivalence study74. The pilot study can be used to validate 
analytical methodology, assess outcome variability, determine sample size to achieve adequate 
power, optimize data collection, and determine the length of and determine the washout period 
needed between treatments74. Few studies have studied the feasibility of an N-of-1 clinical 
bioequivalence approach to demonstrate equivalence at individual level. N-of-1 BE trials 
establish therapeutic equivalence using Pharmacodynamics (Biomarker reflecting efficacy like 
blood pressure and cholesterol level) or Clinical Endpoints.  
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2.3. What is the best method? The problem of separating PK-PD studies in assessing 
bioequivalence of drugs – Anti-hypertensive drugs as an example 
Pharmacokinetic bioequivalence studies are often presumed to serve as the “gold standard” to 
assess bioequivalence. These studies assess the relationship between dose and time profile of 
drug concentration. If the pharmacokinetic profile of a generic drug is within acceptable range 
to the reference drug, then it is assumed to be therapeutically equivalent and physicians can 
confidently prescribe and switch a bioequivalent product. But in practice, the fact that these 
studies are not designed to assess treatment responses requires clinicians to re-titrate the 
treatment dose through a trial and error approach. In contrast, pharmacodynamics refers to the 
relationship between drug concentration at the site of action and the resulting effect. Though 
these studies are an indirect approach to assess drug concentration, they more directly assess 
product performance better than do pharmacokinetics. However, often, these studies are 
designed to assess the magnitude of inter-individual differences in the pharmacologic response 
without fully accounting for pharmacokinetic factors79. The effect of separating PK-PD studies 
in antihypertensive drugs has been the subject of debate for decades80.  PD N-of-1 BE studies 
are advantageous because these studies are designed to assess the effect of PK variability by 
evaluating PD responses.     
2.3.1. Variability in response to antihypertensive drugs  
Although many effective antihypertensive drugs are available, blood pressure is controlled 
in <50% of patients81,82 and there are indications that these poor rates of BP control are not 
explained by lack of treatment81,83. A recent major study conducted in hypertensive patients 
in Italy reported that, while around 60% of patients were treated, only 33% of patients treated 
achieved effective blood pressure control81.   
Factors for selection of optimal treatment and optimal dose have been a topic of debate over 
several decades80,84-86. Many of the antihypertensive drugs have large inter-individual 
variability in effect and this wide range of patient responses to antihypertensive drugs is a major 
problem in achieving BP control. However, it remains difficult to identify patient 
characteristics that predict blood pressure response80,84,85. Understanding the cause of 
differences between individuals and within individuals is important to choose the right 
antihypertensive drug and dose. Therefore, if early control of hypertension had to be achieved 
using generic drugs in general and generic drugs without sufficient PK profile, new methods 
to identify optimal drug and dosage are required to improve the existing trial and error 
approach. PD N-of-1 trials are suitable to identify causes of treatment variabilities in generic 
anti-hypertensive drugs and have the potential to individualize these treatments.  
2.3.2. Pharmacokinetics studies and factors  
As discussed in section 2.2.4, appreciation of the large inter-individual variation in 
pharmacokinetics has led to the introduction of therapeutic drug concentration monitoring in 
clinical practice87. Similarly, awareness of inter-subject differences in drug formulations 
(variability due to subject-by-drug-interaction) has led to the development of individual 
bioequivalence (IBE) which requires demonstration of concentration equivalence at individual 
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level. This approach, when implemented, will greatly improve and standardize drug dose 
optimization practice in clinical settings. 
Patient factors including polymorphism of human cytochrome P450 enzymes88,89, 
environmental90 and drug manufacturing factors52 can have profound effects on the 
pharmacokinetics of a drug.  Excipients may influence gastrointestinal transit, absorption, in 
vivo solubility and in vivo stability of the active substance89.  The WHO stressed that any 
change in the excipient, quality of raw materials, and method of drug synthesis may cause 
variations in drug pharmacokinetics and effect25. The importance of vigilance in the post-
marketing stage, especially in tropical areas, is also highlighted.  Quality variations in drug 
formulation after market approval should be within a certain limit: variations in drug must not 
exceed ±10% of the labeled concentration, and bioequivalence should be maintained within 
±20% with the reference drug91. 
A study conducted in Rwanda90 assessed the quality of antihypertensive drugs and the influence 
of tropical storage conditions on 10 different antihypertensive (test) drugs purchased from 
Rwanda with  6 reference formulations purchased from Belgium or France. The study reported 
that 7 of 10 test formulations were substandard for the combined criteria of drug content and 
dissolution, whereas no reference drug became substandard. Similar findings were reported in 
a study comparing Enalapril from a local market (produced and sold in Brazil) with Enalapril 
purchased from the United States92.  Both studies concluded that differences in the drug release 
profiles for these samples could have therapeutic implications and are probably a combined 
effect of different formulation ingredients, manufacturing processes and environment. 
Enalapril is sensitive to higher levels of temperature and humidity.  
However, invitro and pharmacokinetic studies are designed to demonstrate concentration 
quality or equivalence, and do not measure safety and efficacy of generic drugs. Therefore, the 
overall and individual effect of such PK changes is not often measured in actual practice. 
Another limitation of PK studies is that they do not provide evidence of variability regarding 
individual sensitivity to treatment. For example, several pharmacodynamics endpoint clinical 
trials reported genetically-determined variability in anti-hypertensive drug action despite 
equivalent drug concentrations at the receptor site93,94. Hypertensive patients of African origin 
respond better to calcium blockers and diuretics compared to ACE inhibitors and β-adrenergic 
blockers95.   
Moreover, PK studies may not always guarantee treatment effect of a generic substitute.  For 
example, a recent study in Canada showed that the use of different drug release technologies 
can have an important (and highly variable) effect on pharmacodynamics of generic 
antihypertensive treatments in individual patients. The authors conducted a pharmacodynamic 
study of bioequivalence in two Nifedipine products considered to be bioequivalent based on 
pharmacokinetic BE studies. According to the study, on average, formulation switches were 
associated with a certain level of change in population SBP.  However, if we look at the 
individual results, switch was associated with a 39% likelihood of an increase of >6 mmHg 
nocturnal SBP (risking unnecessary therapeutic alterations). For the purpose of comparison of 
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individual effects, we synthesized a graph using data from this study (figure 2.4). The figure 
illustrates that on average, switching increased SBP by 4 ± 1.6 mmHg whereas in individual 
changes are highly variable (SBP may be reduced by ≥ 6mm Hg or increased with 18 mm Hg). 
The authors highlighted that different drug delivery technologies were used in these two 
formulations and these different release mechanisms could affect the rate of drug delivery in 
patients. This study was motivated by a similar result from previous individual N-of-1 
bioequivalence reports on the same drug3.  
In general, the above studies show that, in addition to patient factors, differences in generic 
drug formulations, such as differences in concentrations, excipients, drug synthesis differences 
such as use of different drug release technologies, environment and psychological factors (as 
discussed in section 2.3.2) could have clinically important and variable effect on 
pharmacokinetic variabilities in individual patients. The lack of bioequivalence profile in 
generic drugs in several East African countries including Ethiopia could further increase the 
PK and PD differences of generic anti-hypertensive drugs.  It is crucial that clinicians 
(particularly in developing countries) have a good knowledge of current PK and PD principles 
and relationships to control the consequence of ineffective generic substitutions at individual 
and societal levels. Appropriate methods that can account for local PK and PD factors are 
required to study heterogeneity of treatment effect in antihypertensive drugs. As a result, 
pharmacodynomic studies like N-of-1 anti-hypertensive equivalence studies will have an 
important role to assess the overall and potential variable effect of responses of generic 
treatments with potential therapeutic issues.  
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study was to findout what proportion of patients SBP changed 6 mmHg.
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2.3.3. The pharmacodynamics study 
Often times, pharmacodynomic studies are not conducted to assess the effect of 
pharmacokinetic variability and those conducted for the purpose of demonstrating 
bioequivalence of antihypertensive generic treatments were based on population estimates49,50. 
Large inter-subject pharmacokinetics variability of antihypertensive drugs have been well 
known for decades. However, the idea that this translates into a high variability in response has 
largely been ignored by many studies that investigate the inter and intra subject variability of 
anti-hypertensive responses. Identification of responders and non-responders simply on the 
basis of baseline characteristics has been the focus of many pharmacodynamics research 96-98. 
Individual characteristics like age, ethnic origin and plasma renin activity have been 
investigated but, often, no account has been taken of inter-individual variability in 
pharmacokinetics.  
For example, an N-of-1 trial conducted in 44 adult patients to identify non-responders 
compared 20 mg Enalapril with placebo and concluded that 33 patients were classified as 
responders based on a predefined criterion for a responder, which is a blood pressure fall of  ≥6 
mmHg98.  The study did not account for the underlying plasma drug concentrations and 
considered pharmacodynamics as distinctly separate from pharmacokinetics of the drug. In 
contrast to the above study, several studies conducted on Enalapril using an integrated kinetic-
dynamic model concluded that the response of Enalapril is predominantly dependent on plasma 
concentration99,100.  Similarly, another placebo-controlled dose response PD study concluded 
that Enalapril was well-tolerated and effectively lowered blood pressure and blood pressure 
was reduced in a dose-dependent fashion, with larger doses resulting in a greater reduction101. 
Similar studies conducted on other antihypertensive drugs reported that the circulating 
concentrations are an important determinant of response96,99,102,103,79,80,104.  
A study79 summarized the major shortcomings and practical difficulties with antihypertensive 
treatment in clinical practice as follows: (1) decisions about the most appropriate drug and the 
optimum dose for an individual patient are largely based on a 'trial and error' approach (2) large 
inter- and intra-subject differences in antihypertensive drug response; and (3) the paucity of 
basic information about dose (concentration) response relationships for the common 
antihypertensive. Overall, early scholars expressed no real surprise that little progress has been 
made towards effective management of hypertension in clinical practice. Therefore, 
pharmacodynamic studies like N-of-1 trials need to integrate assessment of pharmacokinetic 
variabilities to address the effect of difference in drug doses and formulations (brand-
generic/generic-generic) in anti-hypertensive drug response. In this regard, concentration-
effect analysis or pharmacodynamic modelling has been introduced as a new therapeutic 
approach based on an individualized choice of therapy105. 
2.3.4. Kinetics-dynamics model in anti-hypertensive drugs 
The Kinetics-dynamics model provides a mathematical description of antihypertensive 
response in individual patients using two measures79: Half maximal effective 
concentration (EC50) and Emax. Emax is the maximum effect of a drug at high concentration 
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and the concentration at which the effect is 50% of the maximum is called the EC50. The result 
takes account of inter and intra subject variability in pharmacokinetics, the magnitude of the 
blood pressure response, placebo effects and time-related changes in blood pressure and drug 
concentration. Difference in response may be due variability in pharmacokinetics, 
pharmacodynamics or both80 (figure-2.5).  Many PK and PD factors could overlap, therefore, 
having standardised for drug concentration, other factors which may influence antihypertensive 
response like age, ethnicity can be assessed more clearly. For example, in 2010, a study was 
conducted to assess the effect of age on PK-PD of Amlodipine and Felodipine-ER in younger 
versus older patients with hypertension106. It was reported that chronic antihypertensive 
responses correlated well with both plasma levels and pre-treatment BP.  Age has only a 
modest impact on the pharmacokinetics but markedly affects the BP response of Felodipine-
ER and Amlodipine.  
Although there are some successful kinetic-dynamic101,107 and placebo controlled dose-
response PD studies101 (without measuring PK responses), many early population-based 
integrated PK-PD studies were not able to characterize the relationship between concentration 
and response for anti-hypertensive drugs. However, several individual based kinetic-dynamic 
studies effectively characterized PK-PD relationships in individual patients for a range of 
antihypertensive drugs of different classes79,96,99,102,103,79,80,104 such as  Enalapril, Verapamil, 
Nifedipine, Prazosin, Doxazosin, Endralazine, and Flusoxolol as well  Amlodipine108 and 
Labetalol109. The studies concluded that much of the inter-subject variability in 
antihypertensive effect was attributable to individual differences in drug disposition and thus 
to plasma and tissue drug levels. These studies also showed that demographic and biochemical 
factors, such as age, sex, plasma renin activity, and plasma noradrenaline, were comparatively 
less important and did not significantly or independently influence the blood pressure 
responses. These early individual based studies documented that there is large individual PK 
and PD variability. Since then, an individual approach has been advocated in the study of anti-
hypertensive drugs. In recent years, this integrated approach has been used to model effect of 
Eprosartan in Black and White hypertensive patients to determine factors for variability of SBP 
between individuals using ethnicity as a useful responsiveness factor110. The authors reported 
that the model is suitable and allows the quantification and explanation of variability of 
antihypertensive response.  
In summary, several concentration-effect studies reported high PK variability and different 
dose requirements among individual hypertensive patients. Even though increasing availability 
of generic drugs is an opportunity to improve treatment access, the use of these drugs might 
have an impact on variability of anti-hypertensive drug responses as the current dose 
optimization practice is slow and largely depends on skill of individual clinicians. Even when 
there is evidence of BE, clinicians should be aware of the possibility of different PK responses 
among different formulations as a certain level of PK variability is allowed within the BE range. 
While understanding PK-PD relationships in generic anti-hypertensive drugs is important for 
every practicing clinician, it is highly imperative for clinicians who work in developing 
countries like Ethiopia where inadequate regulatory structures such as lack of bioequivalence 
facilities present an additional challenge to management of hypertension.  
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However, this integrated kinetic-dynamic mathematical model requires concentration testing 
and is difficult to apply in routine clinical practice. The main advantage of PK-PD model is 
that it can effectively separate the variability in response associated with differences in drug 
exposure from other factors known to cause variation in response. PD N-of-1 BE studies are 
suitable for these purposes.  
 
Figure 2.5 - Pharmacokinetic and Pharmacodynamic variability accounts for the large inter- 
and intra-individual differences in cardiovascular treatment responses (figure taken from 
previous published article80).  
2.3.5. Pharmacodynamics N-of-1 BE studies  
While the FDA proposed IBE approach accounts for individual difference in PK response, 
analyses of individual kinetic responses is similarly based on concentration measurement i.e. 
PK bioequivalence studies assume that PK response is a predictor of treatment response, which 
is not always true. Pharmacodynamic response studies that can assess both treatment 
responsiveness and bioequivalence of generic medicines which account subject-by-
formulation interaction are required.  
Pharmacodynamic N-of-1 BE studies are suitable to assess the effect of generic 
antihypertensive drugs. These studies can be conducted in the absence of a concentration test. 
In pharmacodynamic N-of-1 BE studies of anti-hypertensive drugs, the factor to be investigated 
would be formulation difference and the effect to be measured would be pharmacodynamics 
response.  Specifically, the overall and subject-by-formulation interaction differences for 
different formulations would be modelled as a covariant and variability in blood pressure would 
be modelled as the dependent variable. Unlike PK bioequivalence studies, identification and 
exclusion of non-responders is a methodological requirement in PD/ clinical BE studies (see 
section 2.1.4.5.1. below). Therefore, by taking advantage of the methodological requirements 
for BE as well as the unique strength of N-of-1 study design, it is possible to maximize the 
contribution of N-of-1 PD N-of-1 bioequivalence studies.   
Ideally, PD N-of-1 BE studies would comprise two phases: an initial treatment responsiveness 
phase followed by a bioequivalence assessment phase. During the first phase, non-responders 
will be identified and excluded and in the second phase, the effect of formulation difference 
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would be investigated. The exception to this would be drug switching studies conducted on 
patients who have already been taking a particular dose of a medicine for which they have 
effectively been controlled. In both first and second phase of PD N-of-1 BE study, treatment 
response factors like age, ethnicity and others can be taken into account. For example, the PD 
An N-of-1 study that compared 20mg Enalapril with placebo to assess individual 
responsiveness would be a component of the initial phase98 of a PD N-of-1 BE study. Whereas, 
comparison of different formulations (eg. The Ethiopian version Vs the German version111) 
would represent the main trial phase. This integrated PD N-of-1 approach can be used to assess 
the effect of different doses and classes of anti-hypertensive drugs. In conclusion, similar to 
the kinetic-dynamic models proposed for antihypertensive drugs, PD N-of-1 BE studies are 
suitable to identify non-responders early and assess the effect of formulation in individual 
patients, and can be combined to provide population estimates (figure 2.6).    
 
 
 
Figure 2.6 - Pharmacodynamics N-of-1 bioequivalence studies in relation to  
PK-PD studies 
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2.4. What are N-of-1 trials?  
N-of-1 trials are double blinded, multiple cycle crossover trials, comparing a test treatment 
with a comparator112.  N-of-1 tests provide the strongest possible evidence of treatment efficacy 
for an individual participant113.  As a principle, they require relatively stable symptoms or 
diseases, medications with short half-lives, and reliable means of measuring responses112. They 
are indicated whenever there is substantial uncertainty regarding the comparative effectiveness 
of different treatments being considered for an individual patient - Figure 2.7. Guidelines 
commissioned by the  US Department of Health and Human Services, and a recently published 
book have both documented the use of N-of-1 trials as a means of formally assessing the 
bioequivalence of generic drugs1,2. Two N-of-1 therapeutic equivalence trials have been 
conducted to assess therapeutic equivalence of generic medicines3,114.  
 
 
 
 
 
 
 
 
 
2.4.1. Aggregated N-of-1 trials 
In addition to their use in providing evidence on efficacy of treatments for individual patients, 
results from individual N-of-1 studies can be aggregated to produce a population estimate of 
effect similar in strength to randomized controlled trials but requiring fewer participants115,116. 
In aggregated N-of-1 trials, each individual N-of-1 study is considered as series of RCTs in an 
individual. If each person participating does a three cycle N-of-1 trial, they contribute three 
sets of data for the test treatment, and three for the comparator. This means, each participant 
provides multiple datasets to each side of an RCT. There is a dramatic increase in the 
accumulation of trial data with the addition of each new person to such a trial2.  
2.5. Level of bioequivalence evidence among various BE approaches  
N-of-1 trials are considered to be the highest level of evidence for a treatment decision in an 
individual117. We compared the level of evidence precision of three clinical trial approaches 
against three PK BE approaches. Except for the parameter to be measured, the parameter 
measures (components of variability between two treatments that are included in the evaluation 
criteria) are similar in both aggregated N-of-1 trials and individual bioequivalence proposed by 
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the FDA - Therefore, these two approaches are equivalent with respect to level of evidence for 
demonstrating bioequivalence of two treatments (see figure 2.8).  
 
2.6. Statistical models to demonstrate bioequivalence  
General linear models like ANOVA and Linear Mixed Model are the standard analysis methods 
in BE studies.  When PD/Clinical endpoint BE studies do not satisfy requirements of 
continuous and symmetrical distribution (if a categorical outcome variable is used), the typical 
generalized linear model cannot be used. In this case, the use of other alternatives (eg logistic 
regression) that may provide a sound alternative to the established model is recommended.  
In figure 2.9, we summarized the statistical analysis models used to demonstrate equivalence 
for four types of BE approaches: Average BE, population BE, individual BE and aggregated 
N-of-1 trial BE approaches. For purpose of comparison, we presented the model used for 
aggregated N-of-1 trials with a continuous outcome variables (eg. blood pressure). Similar to 
the individual bioequivalence approach proposed by FDA, aggregated N-of-1 trials use 
aggregate metrics to estimate overall treatment effect, drug-subject interaction variance and 
intra-individual variability (figure 2.9). 
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Figure 2.9: Method of analysis for bioequivalence (Aggregated N-of-1  vs FDA new models) for a test (T) and reference (R) 
product 
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ratio of the test to the reference drug lies within a predetermined BE of range of the reference drug 
(usually 25%) 
 
The 95% CI for treatment 
difference lies within a 
predetermined limit ( MICD) 
28 | P a g e  
 
2.7. N-of-1 trials in developing countries 
2.7.1. Undeveloped potential of N-of-1 trials 
As part of this thesis,  a systematic review of N-of-1 clinical trials (in developing countries)118 
published in journals indexed by the PubMed, CINAHL, Web of Science, and Cochrane 
Central Register of Controlled Trials, publications from grey literature and unpublished sources 
from International Trial Registry Platforms was conducted using the terms N-of-1, single case 
trial, single subject research, single case experimental design, single patient study, single 
patient trials, single case trials, and single patient trial.    
The review revealed that the number and the scope of N-of-1 tests in developing countries is 
low. Of the 131 N-of-1 articles identified, only 6 (4.5%) were conducted in developing 
countries. Five of them were conducted in China and one was conducted in Brazil. Seventy-
two patients, with a range of 1-47 participants in each study, were involved in the studies. The 
review also showed that N-of-1 trials are feasible and useful to address clinical uncertainties in 
resource limited clinical settings.  
2.7.2. N-of-1 trials in developing vs developed countries 
First, the clinical uncertainties for using the trials and the interventions for which N-of-1 trials 
were applied vary. Five out of six studies assess the feasibility and use of N-of-1 trials (83%) 
in evaluating traditional medicine. In contrast, many developed countries (Australia, New 
Zealand, Canada, United States and countries in Europe) have been involved in a range of N-
of-1 tests of modern medicines119. This difference is due to the high reliance on traditional 
medicine in developing countries, but with insufficient evidence of their effectiveness120.  
Second, completion rates and the impact of the trials on subsequent treatment decisions were 
better in developing countries. The overall completion rate was 93%, which is better than the 
figure reported in a previous review of N-of-1 tests in the medical literature (80%)119. Slightly 
higher than two thirds (69%) of participants changed their medication in a direction consistent 
with the trial results (shown in Appendix K, table 3), which is also slightly higher than that 
reported in a 2011 systematic review of all N-of-1 studies119,  which reported that 54% of 
participants made subsequent treatment decisions consistent with the results of the trial. These 
figures are indicators that show N-of-1 tests are feasible and useful in the context of resource 
limited clinical settings.  
Third, key methodological issues that impact practical feasibility are more critical in the 
context of developing countries. Though using N-of-1 studies to test traditional and 
complementary Medicine (TCM) in clinical practice is feasible, several issues that need further 
modification were identified. A particular concern of these studies was the possibility of a 
‘carry-over’ of treatment effect the intervention under investigation: there was a lack of 
pharmacokinetic data that were critical to making appropriate decisions regarding onset, 
duration of treatment and washout periods. Because of the unique perception, taste, and smell 
of TCM, it is extremely difficult to find a control drug completely consistent with the test drug. 
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Developing statistical analysis of N-of-1 trials that incorporates these methodological issues 
for evaluating interventions with limited prior RCT evidence is challenging.  
Appendix A gives the conditions and drugs, reasons for conducting the trials, basic design 
parameters and outcomes of n-of-1 trials conducted in developing countries between 1985 and 
September 2015.  Overall, the review shows that this method is feasible and useful in 
addressing clinical issues related to lack of evidence on therapies, while at the same time 
providing patient centred medicine for patients in resource limited countries. However, 
information about the purpose and procedures regarding N-of-1 research methods is also 
lacking in Ethiopia. The review also demonstrated the methodological issues that have the 
potential to impact the feasibility and the validity of these trials in clinical practice of 
developing countries.   
2.7.3. Potential benefits of N-of-1 trials in developing countries clinical practice  
In our systematic review118, we identified and discussed four opportunities to apply N-of-1 
trials in resource limited countries. These include individualized patient care, medicine quality 
assurance, identification of cost effective medications and establishing a population level 
estimate for a therapy. In this review, two of the trials conducted in China121,122 reported a 
population treatment effect by meta-analysis.   
2.7. 4. Are N-of-1 BE trials of local generic treatments feasible in Ethiopia? 
Bioequivalence studies are comparative studies among different formulations of the same 
medicine. In 2010, the National Heart, Lung, and Blood Institute (NHLBI) held a workshop to 
develop recommendations on research topics, methodologies, and resources for comparative 
effectiveness research (CER) that will guide clinical decision making about available treatment 
options8. The workshop participants identified three key areas to assess comparative research 
of available treatment options: identification of research need/questions, methods for 
comparative research, and infrastructure (barriers and impediments) specific to the proposed 
research8. Based on these recommendations, the subsequent sections of the literature discusses 
different feasibility components of N-of-1 BE trials of local drugs.  
2.7.4.1. Is research needed on local drugs?  
A study regarding research needs for an improved primary care response to chronic non-
communicable diseases in Africa highlighted that where there is incomplete information 
regarding treatment, research is needed to fill the gaps123. The success of addressing knowledge 
gaps in current medical treatment depends upon some agreement among stakeholders about 
interpretation of the state of current evidence and priorities for research. Lack of consensus on 
the current evidence base could lead to dispute about what research question is most relevant 
and confound attempts to design trials9. To address such problems, a multiple stakeholder 
process is advised to identify questions for comparative researches of available treatments10. 
Research questions also need to be consistent with changes on the political as well as scientific 
landscape10. 
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However, there is limited evidence regarding views of stakeholders about evidence gaps and 
concerns locally manufactured drugs in Ethiopia. There is one documented example in which 
the Ethiopian medicine regulatory authority banned the production of one locally manufactured 
drug following receipt of claims of ineffectiveness of the drug from multiple health 
professionals4. One survey reported that only 46% of prescribers believed that locally produced 
and imported medicines were therapeutically equivalent124. However, the focus of the paper 
was on rational use of medicines in general among prescribers only and didn’t address 
knowledge and views on lack of BE evidence for local medicines.     
2.7.4.2. Are N-of-1 trials methodologically feasible bioequivalence approaches?   
Two studies using N-of-1 bioequivalence trials have been conducted in Canada to assess 
therapeutic equivalence of generic medicines3,114. One was a case report comparing two generic 
Nifedipine 60mg formulations on 3 hypertensive patients.  The other compared a generic 
formulation of Warfarin with the brand Coumadin in 11 patients using INR as a primary 
outcome114. However, both were limited to an individual N-of-1 approach only and didn’t 
address whether aggregated N-of-1 bioequivalence trials are feasible to generate 
bioequivalence information for generic medicines. Moreover, both tested interventions of 
proven effectiveness (bioequivalence) on individual patients in a developed country setting. 
Evidence is lacking regarding applicability of the method to evaluate untested generic drugs, 
which represent affordable treatment options in the usual care of patients in resource poor 
clinical settings. 
2.7.4.3. Are N-of-1 trials methodologically feasible for hypertension studies?    
We have identified three N-of-1 studies (two from developed and one from a developing 
country) conducted on hypertension.  In 1995, Cathellier examined whether N-of-1 
methodology, supported by a precise measurement method, improved the quality of 
hypertension management at the individual level and concluded that follow up of hypertension 
using home blood pressure measurement is possible98. After 14 years, motivated by their 
observation of > 10 mmHg rises in patients systolic blood pressure after switching to a new 
formulation of Nifedipine, researchers conducted a therapeutic equivalence test, using N-of-1 
trials to prove therapeutic interchangeability of two different formulation of generic nifedipine3 
and concluded that the newly substituted Nifedipine was not equivalent. During the same year, 
researchers from china used N-of-1 trials to evaluate the dose-effect relationship of TCM 
(Niuhuang-Jiangya) in the treatment of mild to moderate essential hypertension and concluded 
that the research method is useful in deciding treatment for Chinese medicine121. 
2.7.4.4. Barriers for conducting N-of-1 trials   
2.7.4.4.1. Evidence from developing countries 
Though there has been underdeveloped research potential on N-of-1 method, there is no 
empirical evidence that documents barriers for conducting N-of-1 in trials in developing 
countries. Researchers who conducted an N-of-1 review in China125, suggested some factors 
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that might contribute to the scarce number of published N-of-1 trials. These included lack of 
financial support and doctor’s lack of knowledge, skill and interest in N-of-1 trials.  
 
2.7.4.4.2. Other studies that report on barriers  
The ground work for an N-of-1 service is established and some developments have also been 
made in using N-of-1 method in developed countries’ clinical practice. However, the research 
has not been widely applicable. Little research has been conducted to identify barriers, but it 
has reported the following factors impeding wider uptake of n-of-1 trials; doctors’ time, 
doctors’ acceptance, drug companies’ acceptance, patient willingness, and cost126 127,128. 
 
2.7.4.4.3. Ethical and regulatory issues  
Whether N-of-1 tests require even ethical approval or not is a source of debate in the literature 
regarding the ethics of N-of-1 tests,119,129. The general principle is, where the intent is to 
generate generalizable knowledge, IRB approval should be sought. If the intent of the N-of-1 
study is to assist in the conduct of patient care, then IRB approval should not be required.   In 
a recent study on whether N-of-1 tests require IRB approval or not, more than half of the 
responding IRBs regarded N-of-1 tests as meeting the definition of  clinical research which 
require IRB approval, while the other half considered them to be clinical tools not requiring 
ethical and regulatory oversight129. A systematic review of 108 N-of-1 trials reported that most 
trials (69%) received IRB approval51. Our systematic review of N-of-1 trials in developing 
countries shown that all the trials obtained IRB approval118. 
Apart from debate regarding the need for IRB approval, imposing strict regulatory approval 
has not been raised as a main challenge in conducting N-of-1 trials. However, a recent study in 
Netherlands130 reported lack of consensus among health authorities on interpretation of 
aggregated N-of-1 trials data. The authors studied whether aggregated N-of-1 trials are feasible 
and suitable for use in licensing and reimbursement decisions using off-label use medicine 
(ephedrine) for a rare disease (myasthenia gravis) and concluded that the study was feasible 
and suitable. The Dutch National Health Care Institute advised that it could potentially make 
reimbursement decisions.  However, the authority (Dutch Medicines Evaluation Board) 
believed that N-of-1 design is a last option for demonstrating benefit and this method alone 
does not provide enough evidence on potential risk. 
2.8. Choice of condition and treatment for this project 
N-of-1 tests are only suitable for patients with certain chronic stable conditions. Hypertension 
is a growing public health challenge in Ethiopia 131,132. In 2008, the Ethiopian Federal Ministry 
of Health (FMOH) identified hypertension as the seventh leading cause of mortality133. This 
makes it the single most important cause of mortality from non-communicable diseases in 
Ethiopia. Therefore, hypertension was chosen to pilot N-of-1 tests. Enalapril is commonly used 
to treat hypertension in Ethiopia134. Both locally produced Enalapril and imported Enalapril are 
readily available. However, imported Enalapril is very expensive.   
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Summary 
The review has demonstrated that there is limited evidence of research need among local 
generic treatments. It also demonstrated that N-of-1 trials are feasible and useful in addressing 
contextual clinical challenges in developing countries. The review also showed that the method 
is not available in most developing countries including Ethiopia. The few N-of-1 trials 
conducted in these countries were concentrated in China and Brazil, with majority of them used 
to evaluate TCM. Only two individual N-of-1 trials have been conducted to test the therapeutic 
interchangeability of different generic formulations in Canada.  
Based on the review, the research problem that needs further exploration was: 
How feasible are N-of-1 trials in testing the clinical bioequivalence of local drugs in Ethiopia 
clinical setting, with particular reference to the use of enalapril in Hypertension? 
The next chapter restates the aim, identifies feasibility components of the project and describes 
the framework used to guide the research stages and general method of the research program. 
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CHAPTER 3: AIM, PROGRAM COMPONENTS AND APPROACHES 
3.1. Overview of aim and feasibility components of the program 
The previous chapter demonstrated the potential of N-of-1 trials in establishing therapeutic 
equivalence and the lack of data regarding feasibility of conducting these trials in resource 
limited settings. This research program is designed to study whether N-of-1 BE trials are 
feasible to assess equivalence of local drugs in routine clinical practice in Ethiopia. Based on 
literature, the research problem (feasibility) is categorized into three: research need, research 
method and barriers for conducting the proposed study-see figure 3.1. 
Study feasibility components and the overall research process are guided by the research 
problems, frameworks and guide for qualitative method in feasibility studies for randomised 
controlled trials. This chapter presents feasibility components, the research questions and 
general methods along with the study conceptual framework.  
3.2. Feasibility components of N-of-1 bioequivalence trials of local drugs 
I-Research need: Identification of the problematic therapeutic area and prioritization of 
research question is the first critical step in the decision making process for conducting clinical 
trials of current interventions8. Comparative studies should reflect timely topics of clinical 
concern and be responsive to expressed needs of patients, clinicians, or other stakeholders10. In 
this study, the need for research was addressed by exploring views on local drugs and basis for 
the study, which is an evidence gap on bioequivalence. 
II-Methodological feasibility of N-of-1 bioequivalence trials 
A-Acceptability of method and its implementation approaches: N-of-1 trials have not been used 
Ethiopia. Comparative research on available treatments should involve stakeholders in the 
design, conduct, and dissemination of results of studies8. 
B- Method feasibility: this includes: (a) design, (b) protocol adherence and (c) recruitment and 
completion rates of the study. A guide for N-of-1 trials2 identified five elements of a well-
designed N-of-1 trial: balanced sequence assignment, repetition (the number of crossovers 
needed to optimize statistical power), washout, blinding, and systematic outcomes 
measurement (of symptoms or a valid biomarker). Also, decisions about selection of the 
reference drug, study endpoint(s), acceptable clinical difference to defining bioequivalence 
limits and statistical approaches, need be made in accordance with specific bioequivalence 
methodological requirements. In addition to design, feasibility trials also need to assess 
protocol adherence and recruitment and completion rates. 
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III-Barriers for conducting N-of-1 bioequivalence study 
Barriers for the conduct of N-of-1 bioequivalence study include: (a) ethics (ethical feasibility 
and ethical requirements), (B) regulatory (regulatory feasibility and regulatory requirements) 
and (c) other implementation barriers including structural and operational issues for conducting 
the study.   
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       Figure 3.1: Framework for evaluating feasibility of N-of-1 bioequivalence study 
 
3.3. Conceptual framework for the research program   
Where there is uncertainty about future RCT feasibility, in addition to the use of theory and 
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feasibility study for a future definitive RCT asks whether the future trial can be done, should 
be done, and, if so, how. Pilot studies are a subset of feasibility studies but have a further 
dimension-to see whether it can be done in practice.  
The overall research program is informed by the work of Eldridge et al135 who developed a 
framework with three distinct categories of feasibility studies, designed to identify the different 
research questions and methods of feasibility studies that are conducted prior to 
definitive/routine RCT: (1) Feasibility studies that are not pilot studies- an example might be 
studies to assess evidence gaps about an intervention and the acceptability of a particular 
method, or other aspect of the trial (without introducing the intervention). (2)  Randomised 
pilot studies –are those studies in which the future RCT, or parts of it, are conducted to assess 
feasibility of design and performance parameters. (3) Non-randomised pilot studies.  
The first two categories of feasibility studies are included in this research program. First, a 
qualitative study was conducted to assess research need regarding local generic medicines. This 
is reported in Chapter 4. Also, before introducing the intervention, a second qualitative 
feasibility study was conducted to assess the acceptability of potential N-of-1 trials of local 
drugs and identification of barriers that might impact on their conduct. This is reported in 
Chapter 6. The study is based on a published systematic review that identified barriers to 
conducting clinical trials in developing countries, reported in Chapter 5. The results of this 
study are presented in Chapters 5 and 6. The results of this study informed the next phase of 
the program-a randomised pilot study to assess practical feasibility of N-of-1 tests of local 
drugs, and is reported in Chapters 7 and 8. Figure 3.2 shows the modified study framework. 
3.4. Qualitative method in feasibility studies of randomised controlled trials 
When choosing what type of feasibility study to conduct, due attention needs to be given to the 
major uncertainties that exist in relation to the trial or intervention. The context in which an 
intervention study is conducted is important. Contextual threats to trial conduct are often subtle, 
idiosyncratic and complex, and therefore best explored using qualitative research137,10. 
Researchers commonly use qualitative research to address the acceptability and feasibility of 
the intervention138,139 or its perceived benefits139,140. 
Alicia et al138 developed specific guidance that focuses on how to maximize the use of 
qualitative research within a feasibility study undertaken prior to a fully randomised controlled 
trial where the aim is to improve the intervention or trial conduct for the full trial. Within this 
guide, the first step for designing a qualitative feasibility study is to look for and/or conduct a 
systematic review to inform and identify key uncertainties that need to be addressed by the 
qualitative study. The qualitative work is informed by this guide-see figure 3.2. 
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Figure 3.2: Project Framework for N-of-1 bioequivalence feasibility study modified from Eldridge et al 2016 
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3.5. Research phases and approaches 
The three research problems – need for research, research method and barriers-were explored 
in three phases: a qualitative study with relevant stakeholders regarding views about local 
generic treatment and their lack of evidence, a second qualitative study informed by a literature 
review with relevant stakeholders regarding acceptability and barriers of N-of-1 trials; and 
finally a pilot N-of-1 bioequivalence study to assess practical feasibility.  
3.5.1. Phase one-research need related to local generic medicines  
Before N-of-1 tests are proposed as an appropriate research method to answer the question of 
interchangeability, evidence on clinical concerns regarding local medicines in use needs to be 
ascertained. Evidence regarding prioritization of evidence gaps on local generic treatments in 
use is lacking, therefore, a qualitative research study was conducted to assess the views and 
perceptions of key stakeholders. 
3.5.2. Research programs and approaches in phase two 
The purpose of stage two of the project was to explore and address acceptability issues and 
barriers to implementation of N-of-1 bioequivalence trials in resource-limited settings.   
Systematic reviews are appropriate to identify contextual issues that could be best addressed 
by the qualitative study. As evidence regarding issues for the conduct of N-of-1 trials in 
particular is lacking, we conducted a systematic review of barriers for conducting clinical trials 
in developing countries.  Though the classical trials vary in many ways from N-of-1 trials 
(including scope and complexity of the processes), both share several planning, development 
and conduct standards that are impacted by contextual issues. Therefore, findings of this study 
will provide relevant data regarding contextual issues that would be emphasized by the 
qualitative study. Besides, the review is useful to focus on those issues that might significantly 
impact the proposed study.   
Then, informed by the systematic review, the acceptability of N-of-1 bioequivalence methods 
and practical barriers for their implementation was explored using a second qualitative study - 
figure 3.2. To maximize informed discussion, an educational session regarding this novel 
research method and its application were part of the acceptability study, and preceded the 
formal focus groups. Details of the methodology and research procedures used in each study 
are presented in chapter along with each respective study.    
The following sections present details of research packages and approaches in the second 
phase. It also highlights major challenges encountered during phase one and two, the decision-
making process of the transition (to phase 3) and their implications.  
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Progression to phase 3-challenges and their implications 
The first and second phases of the program were designed to explore and address issues related 
to the proposed study and decide whether the pilot trial can be done, if so how.   At this stage, 
the qualitative feasibility studies identified a number of feasibility issues. It is time to critically 
review them and proposed solutions in order to make informed decision whether to proceed to 
piloting the proposed trial or not.   
Most of the acceptability issues and barriers identified by the qualitative feasibility study could 
be overcome through further development and protocol amendments.  However, the process 
also revealed that regulatory issues regarding the proposed trial were complex to address. First, 
members of the regulatory authority were not willing to participate in the educational session 
aimed at introducing N-of-1 studies to potential focus group members. Second, following an 
invitation letter (with brief description about the proposed study) from the local host institute, 
only two senior members of the authority were willing to provide brief interviews. However, 
with the brief interviews with the regulatory authorities having been conducted, it became clear 
that the authority was not interested and open enough to engage in any further exploration and 
discussion regarding ethical and regulatory aspects of the proposed trial. The implication of 
these views, in the absence of debate and transparent discussion, led to frustration regarding 
whether to decide to proceed to the pilot trial phase or not. Below is a summary of the main 
brief responses/views of members of the authority. 
1. The authority is confident that local drugs are as effective as other approved drugs in 
the market. However, regarding lack of bioequivalence evidence, they reported that 
they wouldn’t comment on national matters.  
2.  Such studies may have a negative consequence on patients, local companies and the 
regulatory authority itself. 
3. Regarding approval requirements, on one hand, they commented that regulatory review 
and approval is required, on the other hand, they highlighted that they would not discuss 
or comment on future applications and that all applications should follow the 
conventional route of application- ie ethical approval and then application to the 
regulatory authority.   
The decision-making process to proceed to the trial or not /choices and trade-offs  
From the above responses, it was unclear whether to proceed to the proposed pilot trial or not. 
As further communication was not possible, we had to make the difficult decision of whether 
to progress to the pilot trial or not, based on the above brief responses. Therefore, in 
collaboration with the local host institute, we decided to critically examine each of the above 
findings as follows, to guide our decision-making process regarding the proposed study.  
Analysis of responses on research need and acceptability: Given the fundamental role of local 
drugs in the usual care, if we assume that remarks about the acceptability of the study were 
made after thorough discussion within the authority, its potential implication in usual clinical 
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practice and the need for readiness to change/improve quality of local drugs, then the challenge 
faced could be serious.  Further work that enhanced understanding of the benefits of the study 
(with the inclusion of other parties they trust) could be a possible solution. That meant the 
proposed pilot trial could face the risk of rejection by the authority after a lengthy period.   
On the other hand, from experience, such views are often personal and are associated with lack 
of knowledge on the topic-hence are commonly subject to change with increasing awareness. 
One of the challenges of studies of available treatments regarding research questions is dispute 
among experts about interpretation of the state of current evidence and priorities for research. 
That is: whether there is insufficient evidence that warrants the study9? This is due to, in most 
cases, such established therapies having evidence of effectiveness and safety before they are 
approved for use. In this particular study, however, the views of the two authority members 
regarding research need were not consistent with the local guideline for registration of generic 
medicines5, which requires bioequivalence data as proof of therapeutic equivalence. That is in 
part the reason why they didn’t comment on local gaps in evidence.  Moreover, because 
comparative effectiveness research (CER) of available treatments aims to address patient and 
provider needs, health systems should embrace the need to perform CER and recognize its 
value10. There is also an emphasis to focus the model for setting research priorities to a broader 
patient and clinician input141. The qualitative study on the proposed study demonstrated 
reasonable support from patients, physicians and IRB members.  
Analysis of responses about regulatory requirements: Based on our examination of the 
responses regarding regulatory requirements, we decided that the issues raised were important 
but manageable. It was our opinion that the trial constituted a “choice” experiment – providing 
evidence for a patient and doctor to make an informed choice between two forms of the one 
medicine - Enalapril. Both forms already had regulatory approval, and were to be used for the 
purpose for which they were approved (hypertension). Participants had to have their 
hypertension controlled long term for months before the test. As we were not conducting a 
clinical experiment to test the effectiveness of a medicine, we did not think regulatory approval 
was required for this research. 
Based on the experience of the local host institute, there has always been frustration in the 
initial phase of any research where novel approaches were being introduced into the country, 
commonly due to lack of knowledge and experience.   Also, this view could be fuelled by their 
interest in regulating such trials so that they can develop strategies to communicate potentially 
negative study results among patients, physicians and local companies (whose drugs had 
already been approved by the authority).  
The local host institution’s opinion regarding following the conventional standard of approving 
clinical trials in the country- ethical approval first and then application to the regulatory 
authority next- was more appealing as we and they could do something about any objections 
they might have. Hence it was the IRB’s duty to define whether N-of-1 tests required regulatory 
approval or not. If the IRB decided that the study protocol did not need further regulatory 
approval, the authority would not be approached for study approval. If this option was to be 
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successful, initiating and guiding discussion between IRB members and the local hosting 
institute was important. The idea was that by providing the local IRB with appropriate 
information and the available evidence (books, guides and articles) regarding ethics of this 
novel research method, we would maximize the chance of them making an informed decision. 
Whatever decision was made by them would be respected by us. The University of Queensland 
Ethics committee had already given ethical approval to the project. 
Three IRB members we interviewed before (one medical scientist, one senior physician and 
one sociologist) supported the study and believed that IRB approval suffice for the conduct of 
the study, given that suggested amendments were made.  They believed that IRB approval 
should be sufficient for the reasons stated above, and the basis of this was that the proposed 
study was in reality a “choice” trial between two medicines that already had regulatory 
approval.  
It is important to differentiate between the need for regulatory authority approval and the need 
for ethics committee approval and oversight. Two types of research are possible: 
Comparative equivalence testing using N-of-1 for clinical decision making: Here, the research 
question is about the decision-making process, not the bioequivalence of the drug itself.  It can 
only tell us if the local version can be used interchangeably in each individual patient who has 
been involved in the test. According to the Ethiopian National Ethics Review Guideline, such 
N-of-1 BE trials to prove the interchangeability of drugs which are already in use by patients 
constitutes a quality assurance activity. Regulatory approval would not be appropriate such 
studies.  
Comparative equivalence testing to produce population level bioequivalence data: the case of 
aggregated N-of-1 be trials. Aggregation of N-of-1 trials could be used to generate data on 
therapeutic efficacy of drugs, in this case about the efficacy of locally produced Enalapril. Here, 
appropriate oversight- definitely ethics oversight and possibly regulatory authority approval 
should be sought. Aggregated N-of-1 trials could be possible in the future once feasibility is 
demonstrated, which is one component of the proposed study.  However, at the moment, the 
design and the statistical methods of aggregated N-of-1 trials for the purpose of verifying 
therapeutic equivalence of drugs are not developed. So, this N-of-1 test can’t provide 
unequivocal evidence on the equivalence of the two brands of Enalapril, outside of the 
individuals in whom the trial has been conducted.  The purpose of the study is to confirm 
whether aggregation for this purpose can be done, and to determine appropriate statistical 
methods to be used in a larger trial. 
In summary, due to reasonable support for the proposed study, and given that ethical issues 
regarding the proposed the study can be addressed, we concluded to proceed to the pilot trial 
phase. Also, our ambition to study the practical issues (methodological, ethical and regulatory) 
and demonstrate feasibility of the N-of-1 tests in clinical practice of Ethiopia contributed 
positively in the decision-making process.   
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The next three chapters present the three studies conducted in the first phase of the program in 
the form of manuscript.  This phase is started by assessing research need regarding local generic 
medicines in Ethiopia. Therefore, Chapter 4 presents results of the study. 
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Introduction 
Even though local medicines are cheaper treatment options, their approval for use is not 
supported by evidence.  While, clinical trials to obtain regulatory approval for new intervention 
is high priority for pharmaceutical companies, pragmatic clinical trials mainly focus on clinical 
questions that are relevant to the shared decision of patients and physicians.  Hence, research 
need on local medicines and collaboration among the diverse group of stakeholders including 
patients and physicians are essential to conduct the proposed clinical trial. Consensus regarding 
research need is fundamental to determine to proceed to trial conduct –and addressing research 
needs around local generic treatments require evidence about clinical concerns and agreement 
on bioequivalence evidence gap on these treatments. Using a qualitative method, chapter 4 
explores perceptions of local stakeholders (patients and physicians, officials of the Ethics and 
Regulatory authorities) about local drugs and knowledge of lack of BE data on these medicines. 
The final section concisely summarizes the main findings. 
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Abstract  
Background: Because of their cost, the use of locally produced, bioequivalent, generic drugs 
is universally recommended. In Ethiopia, while the government is committed to raising the 
market share and use of locally produced drugs, the process is hampered by the lack of a 
bioequivalence testing centre to strengthen the regulatory environment and deliver quality-
assured local medicines. The purpose of this study is to assess the views and perceptions of key 
regulatory stakeholders, physicians and patients about locally produced generic medicines. 
Methods: A descriptive qualitative study, using focus group discussions and key informant 
interviews, was conducted.  Five key informant interviews (two senior regulatory authority 
members and 3 institutional review board members) as well as 4 focus group discussions (2 
with physicians and 2 with patients) were held.  Data were analysed using an inductive, 
thematic process.  
Results: Four major themes emerged: awareness of lack of bioequivalence profiles associated 
with local medicines, perceptions about the quality and effectiveness of local medicines, 
quality and efficacy of imported medicines from developing countries and quality and efficacy 
of cheaper medicines.  All institutional review board members were aware of bioequivalence 
issues. However, many physicians lacked detailed knowledge about bioequivalence, its clinical 
relevance and the lack of bioequivalence data for local medicines. All institutional review 
board members, physicians and male patients, but not female patients, were concerned about 
the quality and effectiveness of local medicines.  Female patients were more confident about 
the locally produced drugs.  In addition, some physicians and patients were not confident about 
the quality and effectiveness of cheaper drugs and drugs imported from developing countries.  
Government officials believed that local drugs are reliable. 
Conclusion: The success of promoting the use of inexpensive local medicines and changing 
the perception of the community depends not only on increasing the domestic market share 
held by local companies, but also on the capacity of the regulatory environment and companies 
to produce quality assured medicines and to overcome misconceptions. Among other 
initiatives, establishing an accredited bioequivalence centre in the country needs to be 
addressed urgently.   
Keywords: local generic medicines, lack of bioequivalence data, perceptions, Ethiopia 
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Background  
Around one third of the world’s population encounters difficulties in accessing medications 
because of high prices16. One of the strategies advocated to minimize the costs of medicines is 
the encouragement of greater use of generic medicines143. For example in the United States 
alone, $9 billion (11% of total prescription costs) was saved from 1997 to 2000 through the use 
of generic medicines144. Generic medicines are substitutes for original medicines. They are 
required to have the same quality and efficacy as the brand name medicines. Despite different 
regulatory guidance for marketing approval of generic medicines in different countries, 
bioequivalence testing is a fundamental regulatory requirement for approval of generic 
medicines145. Generic products are considered to be bioequivalent only if their rate and extent 
of absorption do not show a significant difference from the reference product143.  
The impact of the high cost of medicines is more pronounced in developing countries16. The 
United Nations recommends that the world’s poorest countries, such as Ethiopia, improve 
access to medicines through local production146.  The current population of Ethiopia is around 
101, 000, 000, which is equivalent to 1.35% of the total world population11.  However, the local 
pharmaceutical industry in Ethiopia comprises only 15% of the total domestic market 17. To 
address lack of access to affordable medicines by poor people, the government of Ethiopia is 
committed to raising the share of the domestic market held by local pharmaceuticals to 50%17.  
Despite the major advantages offered by generic medicines, their use all over the world is 
limited by lack of knowledge and negative beliefs among consumers and medical 
practitioners147,148. Lack of knowledge on bioequivalence and regulation of generics were the 
main factors affecting healthcare stakeholders’, i.e., physicians, pharmacists and patients, 
attitudes towards generics substitution149. Therefore, many countries are implementing 
educational interventions, evidenced-based guidelines and generic drug policies that assist 
healthcare professionals to appropriately perform generics substitution150-153.   
Promoting generic drug substitution in developing countries like Ethiopia is a challenge for a 
functioning and reliable medicine regulatory system26,154-156. There are concerns about the 
quality of medicines in Ethiopia4,22,23. For instance, though proof of bioequivalence of a generic 
drug product is an essential element of prequalification for effective generic drug 
substitution157, locally produced generic drugs in Ethiopia are approved without proof of 
bioequivalence22. This is due to lack of bioequivalence testing facilities in East Africa 
(including Ethiopia). 
An insufficient medicine regulation system in Ethiopia could have a significant negative effect 
on the perceptions of physicians and patients about generic medicines. Moreover, use of 
generic drugs whose quality is not guaranteed, could lead to under-treatment and serious health 
consequences. For example, there is one documented case in which the Ethiopian medicine 
authority banned the production of one locally manufactured medicine after receiving claims 
about the ineffectiveness of the medicine from various health professionals4. Therefore, in 
addition to addressing supply issues (increasing the share of local pharmaceutical companies), 
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identifying and managing demand (physician and patient) issues is important to promote the 
use of cost-effective locally-made drugs.    
This study is part of a larger study assessing the feasibility of the implementation of pragmatic 
tests, namely N-of-1 tests, to confirm the therapeutic equivalence of marketed local drugs with 
imported drugs in Ethiopia. N-of-1 tests are double blinded, multiple cycle crossover trials, 
comparing a test treatment with a comparator. N-of-1 tests are indicated whenever there is 
substantial uncertainty regarding the comparative effectiveness of different treatments being 
considered for an individual patient. 
The successful implementation of the N-of-1 equivalence test and the impact of the test on use 
of local medicines largely depends on the prior views held by the relevant stakeholders 
(patients, physicians, ethics and regulatory authorities) regarding the regulation and quality of 
local medicines. However, little is known about these perceptions.   
What is known is that the few studies conducted on rational medicine use in Ethiopia report 
low level of knowledge and negative perceptions about generic medicines158,159. Only 22.4% 
of patients were knowledgeable about generic medicine and barely 32% of patients had a 
positive attitude towards generic medicines.  
A qualitative approach was chosen for this study because it allowed an in-depth exploration of 
the views and perceptions regarding the quality of local medicines and the unique contextual 
factors that shape the perceptions of people, specifically about the lack of proof of 
bioequivalence for marketed local medicines (which represent a cheaper treatment option in 
the usual care). Findings from this study will be used to inform the design, approval and 
implementation of a pilot study of N-of-1 therapeutic equivalence trials in Ethiopia. 
Our research questions were: 
a. What are the perceptions of stakeholders about the effectiveness and quality of locally 
produced medicines? Do participants trust their local products? If not, why not? 
b. What are the views of stakeholders on bio-equivalence and lack of bioequivalence of 
local medicines compared with imported medicines? 
Method 
This qualitative research examined perceptions about local medicines regulation and the 
quality of locally manufactured medicines.  It was conducted using focus groups with medical 
practitioners and consumers as well as individual interviews with key informants responsible 
for the approval and conduct of N-of-1 tests in Ethiopia. The study was conducted in the All 
Africa Leprosy and Tuberculosis Rehabilitation and Treatment (ALERT) complex. It is one of 
the government owned institutes located in the capital city, Addis Ababa, in Ethiopia. The 
complex comprises the ALERT specialized hospital and the Armauer Hansen Research 
Institute (AHRI) and Training Centre. The study was approved by The University of 
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Queensland ethics review committee (approval number: 2016-SOMILRE-0158) in Australia 
and by ALERT and AHRI ethics review committees locally (approval number: PO28/16).    
Focus groups 
CA, with a trained facilitator, collected data using a digital-recorder and field notes. Both data 
collectors are male native speakers.  Four focus group discussions, two with physicians and 
two with patients (one comprising male patients and one comprising female patients) were 
undertaken. The number of participants in each focus group ranged between six and eight, total 
26.  Interviews lasted from 24-45 minutes and focus groups lasted from 35 to 104 minutes.   
A purposive sampling method was used to ensure inclusion of differing perspectives from the 
different stakeholders who would be involved during the pilot implementation of N-of-1 tests. 
Unifying the ALERT hospital and AHRI (a research facility), ALERT centre provides all-in-
one flow of patients, clinicians and researchers. Because of our intention to pilot N-of-1 tests 
on hypertension, only hypertensive patients, who were being followed up at the ALERT 
hospital, were selected to participate in the patient focus group discussions. 
The chronic care outpatient unit (CCOPU) in the hospital provides follow-up care for 
hypertensive patients. Most of these patients have at least a monthly visit schedule. We 
requested the CCOPU to obtain and invite a varied sample of patients during their hospital visit 
using the following inclusion criteria: adults between 18 and 70 years; both male and female; 
and have had at least three months of follow up in the hospital. A total of 45 identified patients 
received invitation letters along with information sheets and informed consent forms. Finally, 
the CCOPU sent us the lists of 16 patients who signed the informed consent form. However, 
two of the patients chose not to participate because they were sick and two were too busy to 
attend the discussion. Thus, twelve patient participants, six females and six males were enrolled 
in the group discussions. Male and female group discussions were conducted separately to 
avoid conversations being dominated by men and encourage open dialogue among female 
participants.  
To recruit physicians, we approached the hospital director to assist in recruitment of physicians 
who worked/are working in the chronic care unit. Physicians in the hospital often work in 
different departments - there is a constant rotation of work schedules across different 
departments. In collaboration with the hospital, the principal investigator physically contacted 
16 physicians who have experience of working in chronic care unit. Then, invitation letters 
which included information sheets and informed consent forms were provided to them. Out of 
the 16 physicians invited, 14 of them responded to the invitation. Both patient and physician 
FGD schedules were arranged in consultation with participants and were conducted in AHRI. 
Key informant interviews 
Five key informant interviews, with members of the institution review board (IRB) (n=3) and 
Food, Medicine and Healthcare Administration and Control Authority of Ethiopia 
(FHMACAE).  (n=2), were also conducted. The purpose of the key informant interviews was 
to obtain perspectives regarding the quality of local generics from both ethical and regulatory 
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authorities, which were needed before designing the trial. IRB members were selected because 
of their role in the IRB of the ALERT complex. The two key informants representing the 
regulatory authority were senior officials involved in the approval of medicines and conducting 
of clinical trials in Ethiopia.  
Data collection techniques among the key informant interviews were not consistent. While the 
key informants from FHMACA provided informed consent, they did not consent to the use of 
a digital recorder and detailed probing techniques. They also did not participate in the 
education sessions provided to other participants on the relevance and technical aspects of N-
of-1 tests. We were only able to collect their very brief responses using field notes. All other 
participants engaged with no limitations. 
The following issues were explored during the group discussions and interviews: 
 What is a bioequivalence study?  What are the regulatory and clinical uses of these 
studies? 
 What are the issues associated with proof of bioequivalence of local medicines?  
Describe your understanding of reasons for lack of bioequivalence profiles for locally 
produced medicines in Ethiopia?  
 Do you trust locally produced medicines? What is your perception about their quality 
and efficacy? 
Data collection and analysis 
The interviews were conducted in the local language (Amharic), transcribed verbatim, and then 
translated into English. Brief notes were taken during the interviews with the respondents from 
the regulatory authority. On completion of each interview these notes were expanded.  The 
expanded field notes were then incorporated with transcriptions, where available, to facilitate 
generation of themes. After familiarization with the data through repeated reading of the 
transcripts, a thematic framework40 was developed using emerging ideas and a priori questions 
drawn from the objectives of the study.  Specifically, transcripts were open coded for themes 
relating to interviewee views and perceptions, and included any other emerging themes, using 
an inductive, thematic process. The coding framework included four major themes.  
Trustworthiness 
To enhance rigor, detailed description is provided of the sample, data collection, analysis and 
result. Maintaining reflective journal and documenting decisions were part of the research 
process to reduce the risk of being misled by our own experiences and expectations. To ensure 
different perspectives are represented, we examined similarities and differences across 
explanations and participant groups. Selected quotations from participants are included to 
allow the reader to judge interpretations and credibility of the analysis. Credibility was ensured 
by maintaining an audit trail. CM carried out the initial analysis.  A sub-set of transcripts and 
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field notes were analyzed by AC, and themes were discussed with all research team members 
who had qualitative research expertise. 
The same focus group data were used to address additional topic ‘Acceptability and barriers to 
implementation of N-of-1 trials in resource-poor clinical settings: Ethiopia as a case study’, 
reported in chapter 6. 
Results 
This study involved a total of 31 participants: 5 key informant interviews (two senior regulatory 
authority members and 3 IRB members) and 26 participants (14 physicians and 12 patients) in 
the focus group discussions (see Table 4.1). Participants’ ages ranged from 32 to 65 years. Of 
the total participants included (31), 11 were females.  While two thirds of male patients had 
formal education, only one third of female patients had any formal education. Of the 3 ethics 
committee members, one had a senior physician role, one had a post-doctoral researcher 
position and the third one had an administration role at a government health office.  
Table 4.1: characteristics of study participants 
Participants Focus 
group  
Number of 
people  
Gender  Age Education  
Physicians   1 6 Male 35 – 59 Attend higher education (6) 
2 8 Male 
(6) 
32 – 54 Attend higher education (8) 
Patients 1  6 Male  51– 6 Attend higher education (2) 
Secondary school (1) 
Primary School (1) 
2 6 Female 48-57 Primary School (2)  
Illiterate (4) 
Ethics and 
regulatory 
authorities 
  Key      
  Informant  
I interview 
Overall (5) 
Ethics (3)                                               
Regulatory (2) 
  Female (3)    36 – 56 Attend higher education (5) 
Using thematic analysis, we identified four major themes; awareness of lack of bioequivalence 
profiles associated with local medicines, perception about quality and effectiveness of local 
medicines, quality and efficacy of imported medicines from developing countries, and quality 
and efficacy of cheaper medicines. Quotes supporting each theme are presented, along with 
unique identification numbers of participants in brackets.  
Theme 1-Awareness of lack of bioequivalence profiles associated with local medicines 
Two key informants from the medicines regulatory authority, who are in charge of medicine 
approvals, were asked about the lack of bioequivalence requirements for locally produced 
generics. Neither of them was willing to comment on the lack of bioequivalence testing. One 
of them reported that they wouldn’t comment on national issues. They gave the impression that 
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they believed the government follows its own direction to promote the availability of affordable 
medicines and that information on bioequivalence could affect the local companies and the 
public negatively.  
Other IRB members and physicians were, however, willing to discuss their understanding of 
bioequivalence.  They were asked whether they were aware of bioequivalence studies, the 
clinical relevance of such studies and the lack of proof of bioequivalence for locally 
manufactured medicines. All IRB members were aware of the bioequivalence requirement and 
its significance in determining therapeutic equivalence, as well as approval, of generic 
medicines. They were also aware that local medicines are marketed without any bioequivalence 
profile. 
‘Bioavailability of two medicines is studied using [bioequivalence] study. Before 
marketing generic medicine, companies conduct a [bioequivalence] study to test the 
standard of their medicine against the original product.’ (P3, IRB interview) 
‘I consider [bioequivalence] study as one of the regulatory requirements especially to 
ensure quality… local pharmaceutical companies have gaps in this regard. However, 
there are ongoing efforts to make the test available in Ethiopia.  (P1, IRB interview) 
The responses were varied among physicians. While the majority of the physicians were aware 
of bioequivalence studies, few had a detailed knowledge about its clinical relevance and 
whether there is a lack of bioequivalence regulatory requirements on local medicines or not. 
Few physicians reported awareness of the role bioequivalence studies play in relation to how 
generic medicines companies operate.  
‘Some years after the original medicine has (been) manufactured and used, the generic 
manufacturer could produce their (own) but they have to pass through bioequivalence 
study to compare with the brand medicine. After equivalence is confirmed, the company 
has the right to distribute the medicine in to the market. I also know that this is not the 
case in our country. ‘(P1, Physician FGD 1) 
‘I know it is a medicine concentration test to prove the clinical efficacy of generic 
medicines’ (P4, Physician FGD 2) 
Some physicians reported a lack of bioequivalence as a reason for the prevailing concern that 
people had about local medicines.  
‘I mean the regulation and bioequivalence system in our country is very backward. We 
haven’t done much. To do bioequivalence [studies] is a better way to increase trust on 
local medicines.’ (P6, physician FGD 2) 
 ‘I used to believe that our medicines have similar effects.  But recently I recognized 
that local generic medicines are marketed before their equivalences is evaluated. ‘(P4, 
physician FGD 1) 
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However, some physicians lacked detailed knowledge about bioequivalence studies and 
whether bioequivalence studies were a regulatory requirement or not. 
 ‘I know that there are different companies like Germany and Indian that produce 
similar medicines but I have no clear idea about the [bioequivalence] study’ (P2, 
Physician FGD 1) 
  ‘Personally, I don’t have the information whether [bioequivalence] study is a 
regulatory requirement or not’ (P1, Physician FGD 2) 
There were also some myths about the role of bioequivalence studies and their clinical 
relevance.  For example, one physician pointed out that they are taught that, regardless of where 
a medicine is manufactured, it is the same, implying bioequivalence. 
‘We learnt that every medicine has similar bioavailability whether it is from Germany 
or India. Our senior staffs taught us that every medicines has equal effect. We are told 
that whether it is manufactured in Ethiopia, Western countries or Asia, Ceftriaxone is 
Ceftriaxone’. (P2, Physician FGD 1) 
One other physician noted that traditionally, and in practice, foreign manufactured medicines 
were preferred over locally manufactured medicines. 
‘I had never understood the science of bioequivalence but traditionally I know that we 
prefer Germany medicine or England’ (P2, Physician FGD 2) 
Reasons for lack of bioequivalence test on local medicines 
All IRB participants and some physicians indicated that there was a lack of resources to 
establish a bioequivalence testing facility, as well as a lack of regulatory enforcement to ensure 
the bioequivalence requirements for local medicines are met.    
‘The country doesn’t have the resource to conduct bioequivalence study. The country 
is poor, I think that is the major reason’ (P2, IRB interview) 
It is not only resources that are lacking; there is also a lack of regulatory enforcement to ensure 
the bioequivalence requirements for local medicines are met.    
‘In our setup, the regulation doesn’t enforce the implementation of bioequivalence 
testing. That is why local pharmaceutical companies are not forced to make this test’ 
(P7, Physician FGD 2) 
Theme 2-Perceptions about quality and effectiveness of local medicines 
Participants across groups were asked about their perception of the quality and efficacy (or 
otherwise) of locally produced drugs.  
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The government officials interviewed believed that all medicines are approved for use after 
fulfilling a certain quality standards and they treat all medicines in the market, either local or 
imported, equally.   
By contrast, most other participants across physician and patient groups reported that they were 
not confident about the quality and effectiveness of locally produced drugs, and all IRB 
members reported that they had concerns about the effectiveness of local drugs. 
For example: 
‘Yes, there is a big concern regarding the quality of medicines. Because if you look at 
the medicines in the market you will notice a range of medicines from highly effective 
medicines to useless medicines with the same generic name being distributed for the 
clients. Some of the medicines are not more than a candy’ (P2, IRB interview) 
I think the Food, Medicine and Health Care Administration and Control Authority of 
Ethiopia (FMHACA) do some effort to regulate quality medicines from local companies 
but I don’t think it is adequate. Whether local medicines are effective or not is really 
an issue’ (P3, IRB interview) 
Physician’s responses were similar to those of the IRB members: 
‘I am not confident with medicines produced in our country. I had used both generic 
and brand medicines to manage my patients. From my observation, some generic 
medicines are not effective and safe’ (P3, Physician FGD 1) 
‘We do have the concern on local medicines. It is something we repeatedly think of. 
Even personally, I think about it repeatedly… I don’t prescribe them to patients as long 
as they can afford to buy other medicines’.  (P4, Physician FGD 2) 
The perception of patients about the effectiveness of locally manufactured medicines varied by 
sex.  While most male patients reported perceiving a lack of quality and had a lack of trust in 
the local products, most female patients had relative confidence in local medicines.  
 These gender based differences can be seen in the following responses: 
‘Medicines which are produced in our country have quality problems. I do not know 
exactly but they are not curative as expected’ (P3, male FGD) 
 ‘We do not trust medicines that are manufactured in our country. When we take it, it 
is not as curative as the foreigners.’ (P2, male FGD) 
On the other hand, female patients reported that they trust local medicines and were optimistic 
about taking local medicines. Views on medicines was related to level of education among 
female group, with a higher proportion with lower levels of education. 
‘What I am going to say is, ours (Ethiopian medicine) is better if it is right for all of us 
with the disease. Ours will be enough, all things from us’ (P2, female FGD) 
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‘If the medicine is the same with ours, ours will be good “yehagerun serdo behageru 
berie”*, if it is produced proportionally, we prefer ours’ (P3, female FGD).  [* This 
phrase is a local proverb and it translates to “local products for the local people.”] 
 
Quality control 
Some male patients commented on their expectations about the quality control of medicines 
and about getting the appropriate medicine for their need. They wanted physicians and the 
government to take control of the quality control issues. 
 ‘The physicians are responsible to recommend better medicines for us. Having a good 
medicine plays a key role in our health’ (P3, male FGD) 
‘There should be an organization which makes a comparison study sustainably for the 
benefit of the community’ (P5, male FGD) 
Theme 3 – Variability in the quality and efficacy of imported medicines from developing 
countries  
In addition to the quality of local medicines, several participants thought that developing 
countries in general were not capable of producing drugs equivalent to those produced in 
developed countries.  Some physicians and patients believed that medicines which are imported 
from eastern countries, for example, India, were less effective than medicines imported from 
western countries. Some of the responses were surprising.  One physician gave a practical 
example of the difference in effectiveness of drugs imported from India compared to those 
imported from Europe.  
‘There was a cryptoccocal meningitis patient who had frequent vomiting and we gave 
her plasil (metoclopramide) of Indian brand but the vomiting continued. However, with 
one injection of another plasil brand, the vomiting stops immediately because it was 
from Italy. After that I recognize the difference’ (P4, physician FGD 1) 
‘As of my informal knowledge and lesson from lectures, we are thought that Germany, 
England or other Western medicines had a better quality than medicines imported from 
India or China. I advise patients to use the western ones’ (P1, physician FGD 2) 
‘Honestly speaking, the product of Germany and British medicines are preferable. 
…they have a better capacity to produce better medicines.’ (P5, male FGD) 
 Theme 4-Quality and efficacy of cheaper medicines 
The general belief that expensive medicines are superior contributed to the perception that the 
affordable local medicine options are not as effective as imported expensive medicines.  .   
Though the medicines are in use in clinical practice, there were concerns about effectiveness. 
‘Cheaper medicines are dispensed in the pharmacy because patients cannot afford to 
buy other than these medicines. The price of medicines differs based on the country it 
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is produced. Those medicines produced in our country are cheaper because they have 
lower efficacy than the others. This is what we think’ (P6, physician FGD 2) 
‘Whenever the medicine become cheaper and cheaper, the efficacy is also goes down. 
We have such thinking among clinicians’ (P6, physician FGD 2) 
‘Medicines which are imported from America, Germany and other rich countries are 
curative enough, people trust in these medicines. However, they are too costly. … 
Actually, there are certain medicines which are manufactured locally but they are not 
as curative (do not work as well) as medicines imported from those countries’ (P6, male 
FGD) 
However, some participants did not agree that cheap drugs or drugs from eastern countries 
inevitably had lower quality than their western counterparts.  
‘Drugs which are highly effective and useless drugs are in the market. Cheaper drugs 
could be as effective as the expensive ones. … When I work as a pediatrician in XXX 
Hospital, ceftriaxone is one of our drugs of choice for the treatment of infection. We 
usually prescribe drugs imported from Europe but most people couldn’t afford them so 
we would change it to Indian brand. Unbelievably, there is a big difference in price like 
5 [Birr*] to 100[Birr] for the same drug. From clinical practice, I experimented and 
noticed that drugs from India have also the same effect. … So why would I prescribe 
expensive drug while the cheaper one has the same effect?’ (P3, IRB interview) [* The 
Birr is the local currency. There are approximately 16 Birr to $AU 1] 
 ‘Affordable medicines are preferable for us.   Basically, there is a big difference in 
price. What we buy with 4 or 5 Birr may cost 150 to 160 Birr for foreign medicines’ 
(P1, female FGD) 
Discussion 
Even in those countries with the resources and regulatory requirements in place to undertake 
bioequivalence studies, generic medicines are often viewed as inferior in quality and efficacy 
when compared to original brand medicines by medical practitioners160-162. One of the central 
debates is the issue of bioequivalence160-162. For this reason, several initiatives are underway to 
improve knowledge and perceptions of generic medicines and their regulation, and facilitate 
their prescribing in different countries150-153. 
This present study was conducted in an environment where generic medicines are commonly 
approved without proof of bioequivalence. All IRB members and some physicians were 
knowledgeable about bioequivalence and its clinical and regulatory significance for assuring 
the quality of generic medicines, as well as about lack of bioequivalence profiles of locally 
produced medicines. But many physicians lacked detailed knowledge about bioequivalence 
issues.  Similarly, low levels of knowledge of the regulatory requirements for bioequivalence 
have been reported in previous studies conducted with medical practitioners from other 
developing countries163-165, whereas 86% of physicians in United States of America (USA) 
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reported that they could explain bioequivalence to their patients. As mentioned above, there 
are initiatives in place to empower physicians and promote use of generic drugs in western 
countries150-153.    
This study also showed the presence of misconceptions by a few physicians about the role of 
bioequivalence studies and their clinical relevance, and demonstrated the limitations of medical 
education and the importance of clinical experience and clinical wisdom in Ethiopia.  
Our study revealed that all IRB members and physicians have concerns about the effectiveness 
of local medicines. Physicians in this study did not believe that local generic medications 
approved by the government were therapeutically equivalent to their corresponding brand 
medication. This is in contrast to studies conducted in the USA and Saudi Arabia which both 
reported that 80% of physicians were confident about the effectiveness of local generic 
medicines30, 166. Although there were some misconceptions, the high level of negative 
perceptions about local medicines was primarily linked to the belief that there is insufficient 
medicine regulation in the country-and is not surprising given that medicine regulation in the 
country has been assessed as insufficient by WHO22.   
Contrary to the other groups, and although they would not comment about bioequivalence, 
regulatory authority officials believed that locally produced medicines have similar quality to 
that of comparable branded medicines.  Their views may be shaped by their intention to foster 
the development and acceptance of local pharmaceutical companies, given the fundamental 
role of cheaper local drugs in the usual care. Local drugs have come to be used without 
appropriate bioequivalence test. Therefore, the regulatory authority need to first become aware 
of and acknowledge concerns of doctors and patients. Uncertainties regarding already approved 
drugs may not be high priorities to drug companies167. However, physicians and many patients 
were concerned regarding therapeutic equivalence of locally produced generic drugs. 
Appreciating such differences between the priorities of society and industry is a critical step in 
addressing evidence gaps in local drugs. 
For a number of the physicians, lack of trust in local medicines was part of the general belief 
that cheaper medicines have lower quality and efficacy than expensive ones. The most common 
reason for supporting local generics reported by both physicians and patients in this study, was 
cost.  Other studies have also found that price differences influence physician prescribing of 
generics122,168. 
Gender differences in beliefs about locally manufactured generic medicines were evident in 
this study. On the one hand, most male patients were concerned about quality and efficacy 
whereas most female patients were relatively confident about local medicines. This variation 
in perspective could be due to differences in the levels of education between males and females 
in Ethiopia. Until recently, females had much lower access to information and educations. This 
could likely impact females knowledge regarding regulatory requirements and risks associated 
with the use of drugs whose quality is not guaranteed. Moreover, female’s positive perception 
and optimism about taking local medicines may have been related to nationalism. 
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Some participants also had concerns about the efficacy of imported medicines from developing 
countries.  Some physicians and patients believed that medicines imported from eastern 
countries, for example, India are less effective than medicines imported from western countries. 
Similar reservations about generic medicines manufactured in eastern countries, including 
India and China have been expressed by healthcare providers169. However, this perception is 
further reinforced by a recent study that found increasing numbers of poor quality medicines 
are being imported from India.  According to the study, generic medicines sold in Africa by 
some Indian pharmaceutical medicine manufacturers are of substandard quality compared with 
the same medicines that the companies distribute for selling in India and non-African 
countries170.  
This study involved a range of stakeholders: medical practitioners, the regulatory authority and 
consumers. Although this study highlights a number of very important issues, there are also a 
number of limitations. The small number of key informant interviews, and focus group 
discussion participants who were purposely selected from a single hospital, could not represent 
the views of the whole population of stakeholders involved. The use of a male facilitator for 
the female patient focus group discussion may have influenced the willingness of the 
participants to express their views, particularly because females are not empowered in 
Ethiopian society.  Female participants may have been more critical if a female facilitator had 
led the discussion. Because of a lack of detailed responses particularly from the regulatory 
authority, the findings reported here cannot be regarded as representing the views of the 
Ethiopian medicines regulatory authority. Moreover, the order in which questions were asked 
(questions on bioequivalence first followed by questions on quality of locally produced drugs) 
might have influenced responses - the more specific questions on bio-equivalence might have 
influenced responses to the more general questions on quality and trust of locally produced 
drugs. However, the insights gained across the various groups involved in the study provide a 
basis for generics manufacturers, policymakers and other stakeholders involved in establishing 
a bioequivalence centre in Ethiopia, to change perceptions and improve confidence in the use 
of local generic medicines. Strengths of the study included involvement of the broader 
stakeholders; drug prescribers, consumers and relevant decision-makers in drug regulation.  
Conclusions 
In conclusion, the study showed that the majority of participants, including IRB participants, 
have little confidence in locally manufactured generic medicines. Unlike male patient 
participants, female FGD participants supported the use of local medicines. Brief responses 
from government officials indicated that local drugs are reliable; demonstrates the need for an 
open-discussion to deeply understand contextual motives of the views of the regulatory 
authority. To enhance the availability and use of effective, affordable local products, as well as 
increasing the local market share of these products, implementing measures that encourage 
physicians and patients to be confident about the use of local generic medication should be a 
priority for government. Raising physicians’ awareness about bioequivalence and other 
regulatory requirements that ensure quality has been a major initiative in many countries. 
Changing the perceptions of physicians and patients in Ethiopia requires an assurance that these 
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cheaper local alternatives are interchangeable and can be used confidently. Ensuring 
availability of quality assurance mechanisms including bioequivalence tests, combined with 
information dissemination, are crucial to changing perceptions of both physicians and patients. 
The Ethiopian medicine registration guidelines document the need for proof of clinical 
equivalence, when pharmacokinetic bioequivalence data is not available5. One such practical 
measure is to adapt a pragmatic tool that can assess the therapeutic interchangeability of locally 
produced medicines. To this end, a study is currently being conducted to assess the therapeutic 
equivalence of locally and German-produced Enalapril using N-of-1 tests111.  
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Chapter summary 
This chapter assessed research need and demonstrated there was lack of confidence in locally 
produced drugs in Ethiopia. The clinicians, male patients and ethics committee members were 
concerned about the quality and effectiveness of local medicines. Many physicians lacked 
detailed knowledge about bioequivalence and its clinical relevance. IRB participants were 
aware of the lack of BE evidence about local medicines. However, the regulatory authority 
officials believed that locally produced medicines were as effective as the other generic 
medicines available in the market but they would not comment on the lack of bioequivalence.  
The lack of evidence about local medicines and concerns expressed by the majority of 
participants in this study indicate the need for additional quality assurance studies. N-of-1 
bioequivalence trials can ensure proper substitution and promotion of local medicines, thereby 
addressing concerns related to these treatments. This research also enhances the contribution 
of the proposed N-of-1 BE trial to generate evidence that can better guide local generic 
medicine practice. The next chapter is a systematic review of barriers to conducting clinical 
trials in developing countries. 
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Introduction 
As described in the chapter 2 and 3, feasibility of adopting pragmatic comparative clinical trial 
methods are affected by several factors including methodological feasibility of the trials and 
barriers for conducting them.  Due to the unique contextual factors, the conduct of clinical 
trials is particularly challenging in developing countries. Hence, if conducting a clinical trial in 
these countries is being considered, then identifying barriers and designing context-appropriate 
strategies for their conduct are essential. This chapter reviews the existing literature to describe 
barriers to conducting clinical research in developing countries. Then it discussed possible 
strategies for addressing these barriers. The final section briefly summarizes the main findings. 
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Abstract 
Background: Clinical trials for identification of efficient and effective new diagnostic and 
treatment modalities are needed to address disproportionately high burden of communicable 
(e.g., HIV/AIDS, tuberculosis, and malaria) and non-communicable diseases (e.g., diabetes) in 
developing countries. However, gross under-representation in global clinical trial platforms 
contributes to sustained health inequity in these countries. We reviewed the literature on 
barriers facing clinical researchers in developing countries for conducting clinical trials in their 
countries.  
Methods: Literature indexed in PubMed, Embase, CINAHL and Web of Science, WHO Global 
Health Library were searched. Grey literature was also searched. Search key words included 
barriers, challenges, clinical trials and developing countries. Articles within the scope of this 
review were appraised by two reviewers.  
Results: Ten studies, which are reported in 15 papers, were included in this review. Following 
critical review we identified five unifying themes for barriers. Barriers for conducting clinical 
trials included lack of financial and human capacity, ethical and regulatory system obstacles, 
lack of research environment, operational barriers and competing demands.  
Conclusion and recommendation:  There were substantial barriers at system, organization 
and individual level. We propose that to address this problem, instituting a system for wider 
implementation of local investigator-initiated trials is warranted. These trials are more 
applicable to local populations because they build on local healthcare knowledge. They are 
more demand-led, influence policy and responsive to a country’s needs because they are driven 
by a local or national agenda. 
Keywords: Barriers, clinical trials, developing countries 
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Introduction 
Developing countries represent the majority of the world’s population13. These countries host 
nearly 90% of the worldwide burden of disease, most of which comprises preventable 
infectious diseases24. There is also an increasing prevalence of non-communicable diseases 
(NCDs). The transition imposes a double burden171 on the already pressured resources in 
developing countries.  
These countries’ health care systems need evidence to guide decisions about the most efficient 
and cost-effective interventions for them. The shortage of resources in developing countries 
paradoxically increases the need for reliable healthcare evidence to prioritize the use of their 
scarce resources61. According to the World Bank, most developing countries have a Gross 
National Income per capita of under US$4,03664. Although developing countries bear the 
greatest burden of disease in the world, substantial research and development activity to 
address this inequity is lacking. These countries are under-represented in research due to lack 
of commercial viability and research capacity65,66, yet it is in these poorest regions where 
research-led solutions could bring the greatest impact to high rates of early mortality67,68.  
Moreover, addressing context-specific questions is fundamental to designing interventions that 
improve health outcomes125. Medical treatments need to reflect biological and non-biological 
variations that exist across the world. Clinical trial research, particularly systematic studies in 
human subjects (including patients and other volunteers) are required in order to discover or 
verify the effects of and/or identify any adverse reaction to investigational products in diverse 
populations172. There are great differences in cultures and perceptions across the globe, and 
what is appropriate in one place might not be in another173. For example, some interventions 
shown to be efficacious in high-income countries are not similarly effective when used in other 
contexts174,175. 
At the same time that the priorities of developed countries drives the research agenda of 
pharmaceutical companies, there is a disturbing underrepresentation of research addressing 
priority issues for developing countries135,136. Diseases of relevance to high-income countries 
are investigated in clinical trials seven to eight times more often than diseases whose burden 
lies mainly in low-income and middle-income countries176. More than 80 % of clinical trials 
listed onclinicaltrials.gov138 are conducted in the developed world.   
In addition, some of the trials being conducted in developing countries are seek to answer the 
questions of the developed world. A recent review indicated that about one-third of 509 clinical 
trials sponsored by US-based companies from 1995 to 2005 were conducted outside the USA, 
many in poor and low-income countries139, without targeting diseases prevalent in these 
countries.  Another study also found that only 10 of 1556 new drugs produced between 1975 
and 2004 were targeting diseases specifically prevalent in poor and low-income countries4. 
There is also a growing realisation that many countries in the developing world, have not been 
exploiting the enormous research potential offered by their health care services18, to answer 
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research questions of the developed world. This potential includes reduced cost and time to 
recruit patients68,158 and increased incidence of diseases (eg cardiovascular diseases, diabetes, 
cancer) 159 of interest to the developed world.  
A systematic review of barriers for conducting clinical trials by clinicians in developed 
countries identified several major barriers. These include time constraints, lack of staff and 
training, worry about the impact on the doctor-patient relationship, concern for patients, loss 
of professional autonomy, difficulty with the consent procedure, lack of rewards and 
recognition, and an insufficiently interesting question177. Barriers for conducting clinical trial 
vary between countries, and barriers to conducting clinical trials not normally considered by 
research institutes (local structural, infrastructural, and procedural aspects) may affect 
investigators more in poorer settings than in developed countries167. Even within the paucity 
of literature on conducting clinical trials in low resource countries, the literature mostly relates 
to ethical issues139,178-180. 
Recently there have been calls from within the developing countries for more ownership 
over priority setting and research conducted in line with national health strategies67,181. 
If enhancing clinical trials in developing settings is being considered, then identifying barriers 
and designing context-appropriate strategies are essential.  
The objective of this study is to conduct a systematic review that assesses barriers for 
conducting clinical trials in in developing countries. 
This review will enable entities contemplating clinical research in these countries to 
prepare and plan ahead, to minimize the impact of barriers, and thus contribute to a greater 
proportion of the world’s trials being conducted where the majority of people reside. 
Conducting more clinical trials in these environments will build confidence in the ability 
to perform them well, and many under-resourced people will benefit in the long term.  
Methods 
This review is prepared based on the Preferred Reporting Items for Systematic Reviews and 
Meta- Analyses (PRISMA) statement checklist and flow diagram182, modified for health 
service reviews183. The PRISMA checklist can be found in Additional file 1. A PRISMA flow 
chart outlined the study selection process182 (see figure 1). 
Eligibility criteria 
Included studies must:  
1. Report on barriers/challenges for conducting research, specifically clinical trials 
within developing countries 
2. Be published empirical, peer reviewed research studies (commentaries, editorials 
and literature reviews were excluded). 
3. Published in English.  
4. Published between 1995 and October 2015. 
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The Commission on Health Research for Development is an international initiative to study 
the status, effect, and needs of research on the health problems of developing countries. In the 
early 1990’s, the commission stated that the rapid expansion of country-specific health research 
to meet health needs of these countries was a necessity to encourage better health status for 
more people in settings with sometimes severely limited resources184. In 1995, WHO published 
Guidelines for Good Clinical Practice172, the world’s first standard for reporting clinical trials. 
We selected this as a logical starting point for assessing clinical trials from the modern era. In 
2015, a review findings regarding the distribution of global clinical trials was released185. This 
report concluded that despite the overall increase in clinical trials over the last two decades, the 
progress of clinical trials in developing countries was particularly slow and challenging. This 
milestone was accepted as a good point to conclude the search.  
Search strategy 
The search strategy aimed to find both published and unpublished studies. A three-step search 
strategy was utilized. An initial limited search of MEDLINE was undertaken followed by 
analysis of the text words contained in the title and abstract, and of the index terms used to 
describe the article. A second search using all identified keywords and index terms was 
undertaken across all included databases, including a range of terms such as barriers, 
challenges, clinical trials and developing countries. Thirdly, the reference list of all identified 
reports and articles was searched for additional studies. To maximize sensitivity, a broad search 
strategy without country economic context was also used. 
The databases searched included: PubMed, Embase, CINAHL,Web of Science, and WHO 
Global Health Library. Grey literature was identified by searching through the Network Digital 
Library of Theses and Dissertations, ProQuest Dissertations and Theses, and Google Scholar. 
For example the PubMed search was: 
((((Barriers [Title/Abstract]) OR Challenges [Title/Abstract])) AND ((clinical trials [MeSH 
Terms]) OR clinical trials [Title/Abstract])) AND ((((developing countries [Title/Abstract]) 
OR Third world countries [Title/Abstract]) OR Low income countries [Title/Abstract]) OR 
Middle income countries [Title/Abstract]). 
Titles and abstracts of all the retrieved bibliographic records were screened two independent 
reviewers (CMA, JN). Full texts of potentially eligible records passing the title and abstract 
screening were retrieved and examined according to the eligibility criteria.  
Assessment of methodological quality  
Eligible papers were assessed by two independent reviewers (CMA, JN) for methodological 
validity prior to inclusion in the review. Quality of each selected quantitative study was 
assessed using criteria adapted from the Newcastle-Ottawa scale for cross-sectional studies186. 
The scale gives a maximum of eight stars to each study: five stars for the representativeness of 
the sample: three stars for the adequate ascertainment of the outcome. We defined studies of 
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high quality as those that scored the maximum 7 or 8 stars on the Newcastle-Ottawa scale; 
studies of medium quality scored 5 or 6 stars.  
Critical appraisal of qualitative studies was made using criteria proposed by Kuper187. The 
criteria contains six major questions that address different key areas (design, sample, data 
collection, analysis, reporting), each of which are answered as ‘good’, ‘fair’ and ‘poor’. Based 
on literature188, a quality score for each question was given using the following definitions: 
Good: Sufficient details/information are provided and well justified. Fair:  most information is 
given and justified but some are missing.  Poor: No or few descriptive details are provided.  
The purpose of the quality assessment was not to establish thresholds below which studies were 
excluded, rather to distinguish between studies in terms of overall contribution to the review188. 
Any disagreements that arose between the reviewers were resolved through discussion, or with 
a third reviewer (GM). 
Data extraction and synthesis 
We carried out the synthesis in two stages: a general mapping which described the 
characteristics and key findings of individual studies; and an in-depth review synthesizing the 
findings across all studies.  Evidence was synthesized using a thematic analysis/synthesis189, 
where important or recurrent themes were identified by tabulating key information across 
studies. To avoid potential restrictions (from using predetermined themes) and to allow the 
possibility of including emergent key concepts, we used the study findings themselves to 
conduct a thematic analysis. 
First two reviewers (CM and JN) independently identified key concepts, then compared and 
analyzed them to identify predominant/recurrent themes across studies. The process of finding 
key concepts in each study was not always straightforward in the qualitative studies. This was 
particularly difficult in studies that made relatively simple analyses of their findings by 
describing what their participants reported, without reporting further analysis that identified 
key findings. As this process was dependent on the judgement of the reviewers, we repeated 
the process as a group. Through the group discussion, abstracted key concepts and subsequent 
themes were examined and changes made as necessary. This process was repeated until 
consensus was reached regarding the sufficiency and appropriateness of the themes and 
subthemes developed to explain barriers for conducting clinical trials in developing countries.  
The synthesis approach allows significant findings of the review question to be summarized 
under thematic and sub thematic headings. Meta syntheses offer novel interpretations of 
findings190. However, due to the widely diverse settings as well as variations in methodological 
approaches across studies (which are important considerations in developing a more 
generalized model190,191), we did not conduct a meta-synthesis. Finally, as the key findings 
were similar across studies, we chose to present and discuss the unifying themes and include 
both for the quantitative and qualitative studies in each theme.  
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Results 
The Embase search returned the highest number of publications (1076).  Web of Science, 
PubMed, Cinhal and WHO Global Health Library returned 760, 712, 267 and 191 publications 
respectively. Additional applicable papers were included using the reference lists of these 
publications. After removing duplicates, the topic and abstracts of 1,915 published articles were 
screened to check if they were eligible for this review. 1900 articles were excluded as they 
were out of the scope of this review (see Figure 5.1), leaving ten studies reported in fifteen 
papers to be analysed192-205. 
 
 
Figure 5.1. PRISMA 2009 flow diagram for study selection  
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Selected studies 
Ten studies, which were reported in 15 eligible papers, included in this review. One study193 
included seven countries (four from low and middle income countries (LMIC) and three from 
high income countries (HIC)), with a separate publication of the responses from each of the 
representatives of included countries. Therefore, we included the four papers from LMIC194-
197.  Two of the studies included in this review192,193 were global studies. Though these studies 
had a global focus, they assessed and clearly presented their results regarding barriers and 
facilitators of clinical trials in developing countries. (See table 5.1). 
Regarding health conditions, six (60%) of included studies assessed barriers of conducting 
clinical trials on non-specific health conditions. The remaining four studies assessed barriers 
to conducting clinical trials in cancer192,203, reproductive disease193 and acute coronary 
syndrome199. Of ten articles included studies, six used qualitative methods193,198-202 such as 
focus group discussion and individual interviews, and four articles192,203-205 used quantitative 
methods.  
Quality of included studies 
We assessed the quality of all included studies and incorporated studies in the review. We 
believed that, given the paucity of literature on the topic, an inclusive approach would increase 
the collection of the diverse perspectives and experiences in a largely unexplored area. 
Of the four quantitative studies, one study was high quality, two were medium quality and one 
was low quality. Of the medium quality studies, one had a low response rate (92 out of 404- 
23%) 203. In the other study, sample size was not justified and there is no description of the 
sampling strategy204. The study considered to be of low quality showed a high risk of selection 
bias secondary to purposive sampling procedure for participant selection as well as a low 
response rate (27 %). Moreover, a comparison between respondents and non-respondents was 
not provided as demographic data were obtained only for the respondents192. 
Most of the included studies193,198-202 relied on qualitative methods. For the majority of 
questions, all except one study41 scored “good” for most criteria. The proposal41 which led to 
publication of participants’ views from each represented country194-197 did not present some 
important aspects of qualitative studies: the specific qualitative approach was not described 
and the research report did not describe the process of data collection, analysis and 
interpretation.  
Barriers to conducting clinical trials 
Barriers to conducting clinical trials in developing countries were:  lack of financial and human 
capacity, ethical and regulatory system obstacles, lack of research environment, operational 
barriers and competing demands (see Table 5.2). 
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 Lack of financial and human capacity:  Financial and human capital barriers were reported 
across all articles. Limited capacity in terms of funding were reported in all except two204,205 
studies conducted in Saudi Arabia52,53. Regarding human capacity, both lack of skilled 
personnel192,194,196,197,200-202,204,205 and lack of awareness  and of motivation to participate 
195,197,200,201,204,205 were reported as barriers. 
Ethical and regulatory system obstacles: Delays in regulatory and ethical review were 
mentioned in most articles.192,194,197,198,200,201,204. The time from initiation of all regulatory 
procedures to the actual start of the trial was very long. Describing the exact period was not 
common but one study stated that it was not uncommon for grants to expire before all approvals 
were in place.  Four articles reported that the presence of unskilled authorities in the review 
process posed a barrier to conducting clinical trials194,197,200,201. Over-complex and 
unreasonably strict ethical and regulatory systems were also reported in some articles200,201,203. 
Lack of research environment: Absence of suitable research infrastructure was stated by 
many articles197,199-202 . Lack of research materials for conducting clinical trials192,198,199 and 
lack of conducive scientific atmosphere (including policy) 195,197,202 were also reported. One 
article reported lack of policymakers’ understanding of the importance of research as barrier202.  
Operational barriers: The majority of the articles195,197,199,200,203,204 stated that the 
administrative environment was characterized by lengthy and complex logistic and financial 
systems that hampered the conduct of clinical trials. Some articles reported difficulty in patient 
recruitment192,196,199 as a barrier for conducting clinical trials.  
Competing demands: Many articles reported that lack of time40,48,51,53 and other competing 
priorities related to the competing demands of working multiple jobs and their attendant 
responsibilities192,195,197,198,200,51,53  was an issue. Most senior staff for conducting clinical trials 
were clinicians or academic staff whose primary jobs still had to be prioritised. 
 
Comparison of barriers by stakeholders 
Two major stakeholder groups were identified from the included studies: researchers and 
health professionals.  Four40, 47,51,53  of the ten included studies reported findings from health 
professionals, the remaining six studies involved health researchers193-197,198,200,200,201,202,204. We 
compared themes and subthemes across these groups to identify similarities and differences. 
With the exception of concerns around time40,48,51,53, reported barriers for conducting clinical 
trials were similar between these two groups, with financial and human barriers being the most 
common in both groups. There were, however, a considerable variation regarding lack of time 
as a barrier, with most (3 out of 4) studies that reported views of health professionals40,51,53 
putting more emphasis on lack of time and only one study48 that involved clinical researchers 
reporting lack of time as a barrier. 
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Discussion 
Although clinical trials are important to address sustained inequity that results from high 
burden of disease in developing countries, these countries are grossly under-represented in 
global clinical trial platforms. Currently, less than 20% of clinical trials are being conducted in 
developing countries138, and only 1% of the recently discovered drugs are aimed at 
management of tropical diseases206.  
We reviewed the literature on barriers facing clinical researchers in resource-poor settings, and 
found only a small number.  Clinical researchers conducting clinical trials in low resource 
settings faced a range of substantial barriers at all levels, starting from the system level, to the 
institute level, to the individual level. The greatest challenge that faced researchers in 
developing countries was lack of financial and human capacity. In addition, several other 
themes emerged from the research literature: ethical and regulatory system obstacles, lack of 
research environment, operational barriers, and competing demands.  
By contrast, a systematic review related to physician barriers in RCTs for cancer and other 
illnesses in the developed world identified lack of time as a major barrier177. Another systematic 
review identified barriers as system-organization barriers (time involvement and resource 
issues), trial design-related barriers, and physician-related barriers207.  
Although many of the issues confronting clinical trialists working in resource-limited settings 
are the similar, the human and other resource capacity of developing countries lags far behind 
that available in wealthier nations208. Based on their experience, several authors who have 
worked as a clinical investigator in developing countries have published their perspectives 
regarding challenges for conducting clinical trials.  Ethical and regulatory issues, 
administrative issues, lack of finance, lack of infrastructure, poor data quality, and lack of 
training curricula focusing on clinical research were the major bottlenecks68,209. One article 
discussed the regulatory challenges associated with conducting multi-country clinical trials in 
resource-limited settings (Africa, Asia, South America, and the Caribbean) 210. The authors 
reported that the regulatory processes in resource limited countries hinder the efficient 
implementation of multi-site clinical trials, delaying research important to the health of 
populations in these countries and costing millions of dollars a year.  
Lack of funds was the most commonly cited reason reported in the included studies. This is 
reflective of the 10/90 gap, in which less than 10% of health research funds in the world are 
directed toward problems that affect 90% of the world’s population, and an even smaller 
percentage go to fund researchers and health problems indigenous to developing 
countries65,66,211. Funding for clinical trials in developing countries comes mostly from Western 
countries and the pharmaceutical companies based there212. In most low-income countries, 
research is a luxury because of economic constraints213. Scarce resources in developing 
countries are nearly all spent on program implementation, and allocating funds for research is 
almost out of the equation in most development plans. Contrary to existing beliefs and 
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practices, the lack of resources in low- and middle-income countries paradoxically increases 
the need for reliable healthcare evidence to prioritize the use of these scarce resources61.  
Highly qualified personnel are needed to propose, initiate and implement clinical trials. Such 
human resource development requires relatively stable, well-resourced research and higher 
education institutes, and well established science governance systems, which is not the case in 
developing countries212. Medical schools and teaching hospitals in LMIC have poorly prepared 
their graduates to conduct scientific trials and clinical research. In India for example, though 
there are half a million physicians with 50-60 physicians per 100 000 people, fewer than 200 
have been trained in Good Clinical Practice (GCP) 206. Moreover, mobility of highly skilled 
human resources due to the growing internationalization of the labour market is creating a 
permanent brain drain212. Other studies also reported numbers of qualified researchers not 
reaching critical mass, inadequate research infrastructure, and inconsistent and limited funding 
opportunities214,215 as factors that hampered the conduct of research in these countries. The 
Global Forum for Health Research report emphasized that strengthening research capacity in 
developing countries is one of the most effective and sustainable ways of advancing health and 
development in these countries and of helping correct the 10/90 gap in health research211 . 
Building scientific capacity is much more than simple science and technology transfer from 
the developed world to the developing world. The key to scientific success resides in human 
resources. The emphasis must therefore be on training in an equitable, respectful way and on 
establishing long-lasting, sustainable partnerships213. 
Ethical and regulatory system obstacles emerged as the second most important barrier. Lengthy 
ethical and regulatory review time created delays in implementing grants and sometimes led 
grants to expire before recruitment started. Other studies also reported lengthy or ill-defined 
approval processes, significant bureaucracy, and lack of regulatory staff with expertise in 
reviewing216,217.  Ethics and regulatory review procedures are critical for protection of the safety 
and interests of the participants. However, complex and overly strict ethical and regulatory 
systems could worsen the negative feedback loop between limited research capacity and small 
numbers of trials conducted. European experience showed that over-management and over-
regulation might negatively affect research and how important it is to harmonize and not 
overregulate the field of clinical research218,219. To address these problems in the ethics and 
regulatory approval systems, some capacity strengthening activities have been initiated through 
grants from the developed world220.  
Moreover, an inadequate research environment and various operational barriers, including 
complex and lengthy financial and logistic systems, appeared in many studies. Challenges 
related to patient recruitment were also reported.  These are all very important barriers for 
sponsors and researchers as they may directly influence the time and budget allocated to run 
trials. For example in Europe, because of the substantial increase in costs and administrative 
burdens for implementation, international collaboration in academia-driven clinical research 
has decreased221. 
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In general, barriers for conducting clinical trials were similar between health professionals and 
researchers However, this review found a considerable variation regarding lack of time as a 
barrier between these two groups. For studies that involved health professionals, competing 
demands (particularly lack of time) appeared to be the second predominant theme. Lack of time 
was a less important barrier for clinical researchers. It is well known that most clinicians around 
the world have competing priorities that require them to engaging on caring for patients. For 
example, one systematic review regarding barriers for participation of doctors in clinical trials 
in developed countries identified lack of time as a major barrier177. Physicians in the developing 
world are already overstretched with responsibilities of patient care. However, the potential 
of scaling up clinical research in developing countries is unlikely to be attained without greater 
involvement of physicians. To keep a perfect balance between the clinical practice and 
research, it is proposed that the busy physicians should develop separate specialized teams for 
providing high-end clinical care as well as conducting quality research, wherein he/she plays 
the role of a leader to supervise and guide them222. Leadership commitment to practicing 
clinicians can also improve the degree of clinical-trial participation through supportive 
managerial functions, including time and space allocations and individual recognition222,223. 
Exploiting the enormous research potential in developing countries has a double contribution 
as it can address some of the challenges that face the conduct of clinical trials in the developed 
world.    Recruitment of trial participants is easier than in the developed world; large outcome 
trials that require enrolment of thousands of patients could make huge savings for the sponsor 
if the trial is conducted outside of developed countries224.  Subject recruitment is responsible 
for around 23% of total trial costs, and 87% of US trials fail to meet temporal recruitment and 
enrolment milestones225.  Moreover, the availability of large numbers of tertiary qualified 
workers and the relatively low salary base in these countries reduces the cost of running clinical 
trials.  A recent review indicated that about one-third of 509 clinical trials sponsored by US-
based companies from 1995 to 2005 were conducted outside the USA, many in poor and low-
income countries139. One reason for outsourcing is that international clinical trials often cost 
less than they do in the US.   
While outsourcing and globalization of clinical trials is good for LMIC, funding should also 
extend to promoting investigator driven research by the local researchers. Developing countries 
should encourage clinical trials that primarily benefit their local population.  
To realize this, instituting a system for wider implementation of local investigator-initiated 
trials is warranted. These trials are more applicable to local populations because they build on 
local healthcare knowledge226. They are more demand-led and responsive to a country’s needs 
because they are driven by a local or national agenda227. Besides, they are more likely to 
influence policy and sustainably link research to action195 
International collaboration both from the developed world as well as within the developing 
world is crucial to foster research development in less developed countries. For example, India 
is one of the world’s fastest-growing clinical research destinations. The number of registered 
international clinical trials that include India have increased by 30% each year for the past three 
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consecutive years for many of the reasons outlined above228,229. Learning from and adapting 
best practices at all levels (system, organizational and individual) could be beneficial. 
Establishing a national level support group is warranted to address the various aspects of 
challenges in conducting trials, by providing mentoring support for the entire trial process from 
grant procurement to final report writing, and to play an advocacy role in streamlining funding 
and regulatory processes198. 
This review has limitations and strengths. It is obvious that most of the developing countries 
were hardly represented in the literature.  Barriers may vary widely depending on the context 
in which the clinical trials are conducted. There are several inter-country differences in culture, 
socioeconomic and political contexts, therefore our findings may not reflect the situation in 
any specific country.  Because of the limited number of articles in the review, our analysis did 
not examine the similarities and differences between barriers among the different developing 
countries. Most of the included studies were qualitative studies with small sample size and 
narrow diversity of participants. We excluded papers which were not written in English. This 
is because the cost of translation was not feasible. However, we believe the rigorous 
compilation of stakeholder view and experiences lays the foundation to guide future studies.  
There are wide variations within developing countries with respect to barriers in clinical trial 
initiation and implementation in these regions. Similarly, concerns may be different for foreign 
led versus local investigator initiated trials.  Therefore, further studies need be conducted and 
should include diverse views from the different developing countries and various stakeholders.   
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Table 5.1: Summary of included studies  
Author, location Subjects (n) Type Focus Main findings 
Seruga, Africa: 4 
countries, Asia: 5 
countries, Central/ 
South America: six 
countries and 8 
developed 
countries192 
 Oncologists with clinical trial 
experience (39 from LMICs 
and 41 from HICs ) 
Quantitative/
Web based 
survey 
 
Barriers Lack of funding, lack of competent authorities and 
ethical procedures,  lack of research materials, lack of 
time or competing priorities, concerns about   
insurance/indemnification coverage, lack of trained 
personnel, lack of patients/patient accrual 
 
Schlaff, Latin 
America (Chile), the 
Middle East 
(Egypt), Europe 
(Greece), China, 
India, Australia, and 
the, United 
States193-197 
Senior and accomplished 
investigators (7 participants, 
one from each country) 
Qualitative Barriers India: Funding is limited, regulation impediments, 
misinformation about research 
Egypt: lack of funding, lack of a scientific 
atmosphere, and ‘‘brain drain’’ of scientists 
China: Combine the clinical with basic research 
Latin America: Less value for scientific research, 
insufficient allocation of human and economic 
resources. 
 
Siegfried, South 
Africa198 
Investigators and other clinical 
stakeholders (19) 
Qualitative/ 
Key 
informant 
interviews 
Barriers and 
need for 
additional 
training  
Impediments in ethics processes, high cost of trials, 
the potential burden of trial conduct on clinical care, 
insufficient skilled researchers 
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Ranasinghe, China 
199 
Health professionals conducted 
(40) 
Qualitative/in
-depth 
interviews 
Barriers Lack of leadership support for implementing quality 
improvement, lack of resources, fears of patient 
disputes and litigation, healthcare funding 
constraints, high out-of-pocket expenses, and 
patients’ refusal to participate 
Franzen, Ethiopia200 Health researchers and 
stakeholders with research 
interest (20) 
 
Qualitative/ 
in-depth 
interviews 
(n=7) and 
focus group 
discussions 
(n=3). 
Barriers and 
facilitators 
Barriers: Human and material capacity, regulatory 
and other administrative bottlenecks, operational 
hurdles, awareness, confidence and motivation 
 
Franzen, Ethiopia 
and Cameroon200,201 
Local health-researchers, 
senior stakeholders and 
regulators (72) 
Qualitative/ 
in-depth 
interviews 
(n=22), focus 
group 
discussions 
(n=9), and 
process 
mapping 
exercises 
(n=7) 
Barriers and 
facilitators 
Shared barriers: System and organisational barriers 
like low resources, weak regulatory and 
administrative systems, few learning opportunities, 
little human and material capacity, and few incentives 
for doing research.  
Ethiopia: lack of awareness, confidence, and 
motivation to undertake trials 
Cameroon: environments that discourage personal 
initiative were more problematic.   
Cardoso, Sub-
Saharan Africa 
(n=46), 2015202 
303 key-informant interviews 
(clinical researchers and other 
clinical trial stakeholders)  
Qualitative/k
ey informant 
interview and 
Status and 
barriers  
Levels/sustainability of funding, policymakers’ 
understanding of the importance of research, 
infrastructure in research institutions and Human 
resources available. 
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literature 
review 
Gomez, Latin 
America countries 
(n=15), 2015203 
92 medical oncologists Quantitative/
Survey 
Barriers Complex regulatory process, low budgets, high 
costs, poor financial management, and time 
constraint.  
Sulthan, Saudi 
Arabia, 2015204 
100  
 clinical researchers 
Quantitative/
Survey 
Perception and 
barriers  
Long approval process, shortage of human resource 
and lack of the institutional support, lack of 
encouragement, lack of awareness among the 
research professionals and the general public 
Al-Dorzi, Saudi 
Arabia, 2013205 
186 medical staff Quantitative/
Survey 
Interest and 
barriers 
lack of time, financial compensation and 
encouragement  and lack of training of research 
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Table 5.2: Thematic and sub thematic presentation of barriers and facilitators for 
conducting clinical trials 
No Barriers for conducting clinical trial 
Thematic barriers Sub-themes References 
1 Lack of financial and 
human capacity 
Lack of funding  192-203 
Lack of skilled personnel 192,194,196,197,200-
202,204,205 
Lack of awareness and 
motivation 
195,197,200,201,204,205 
2 Ethical and regulatory 
system obstacles  
Delay of approval decisions  192,194,197,198,200,201,204,53 
Unskilled authorities 194,197,200,201 
Complex and strict ethical and 
regulatory system 
200,201,203. 
4 Lack of research 
environment 
Lack of infrastructure 197,199-202 
Lack of research 
materials/facilities  
192,198,199 
Lack of conducive scientific 
atmosphere  
195,197,202 
5 Operational barriers Unsupportive administrative 
system   
195,197,199,200,203,204 
Lack of/difficult patient 
recruitment  
192,196,199 
6 Competing demands Lack of time  40,48,51,53 
Other competing priorities 192,195,197,198,200,51,53 
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Chapter summary 
This chapter described the system, organizational and individual levels barriers to conducting 
trials in developing countries. Limited financial and human capacity as well as regulatory 
obstacles were identified as barriers which have the most impact to conducting trials in these 
countries. The findings of this review enabled us and other prospective researchers to prepare 
and plan ahead, to minimize the impact of barriers, and thus contribute to successful 
implementation of clinical trials in these countries.  
The other key contribution of this review is the identification contextual challenges that need 
further study using a qualitative study a head of the proposed N-of-1 bioequivalence trial.  For 
example, complex, non-transparent and overly strict ethical and regulatory systems need to be 
assessed with respect to the proposed pragmatic N-of-1 trials.  Moreover, challenges related to 
patients, physicians and research infrastructure could be contextual and are likely unique to N-
of-1 BE trials. Qualitative studies are helpful to explore contextual uncertainties to trial conduct 
which are often subtle and complex. Using a qualitative method, the next chapter explored 
acceptability and implementation barriers to conducting N-of-1 trials in Ethiopia 
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Introduction 
Chapter 4 highlighted the need for additional evidence of clinical equivalence to build trust in 
cheaper locally made drugs in Ethiopia. There are also cases when the Ethiopian regulatory 
authority itself reported that it received several complaints of drug infectiveness from health 
care providers. Quality and safety of medicines are the concern of several stakeholders 
including medicine regulatory authorities. However, clinicians are ultimately responsible for 
providing the best available therapy to patients. Appreciating such roles of clinicians in 
standardizing and advancing patient care, many countries including Ethiopia have designed a 
system for the collection and sharing of clinically relevant new information about medicines.  
Quality improvement tools that target clinician’s behavior such as N-of-1 trials are needed to 
support and facilitate the above functions. By advancing generic medicine practice of 
clinicians, N-of-1 trials have the potential to build local capacity in developing countries.   
However, the use of N-of-1 BE approach to test local medicines required that this novel 
research method was acceptable to the local stakeholders.  Moreover, feasibility of N-of-1 BE 
trials of local medicines depends on proper identification of contextual barriers and strategies 
to overcome them. These issues are explored in the next chapter. The work builds on findings 
of barriers for conducting clinical trials in developing countries (Chapter 5).  
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Abstract 
Background: Locally produced generic drugs offer a cost–effective alternative to imported 
drugs to treat patients in Ethiopia. However, due to lack of bioequivalence testing, additional 
assurance tests are needed to build trust in cheaper locally made drugs. By testing 
bioequivalence of local drugs to gold standard, N-of-1 trials have the potential to promote 
Patient Centred Quality Use of Medicines. 
Objective: To assess whether it is acceptable and explore barriers to conduct N-of-1 trials to 
evaluate local medicines in a resource limited clinical setting. 
Method: A descriptive qualitative study, using focus group discussions and key informant 
interviews, was conducted.  Five key informant interviews (two senior drug regulatory 
authority members and three institutional review board members) as well as four focus group 
discussions (two with physicians and two with patients) were held.  The interviews were audio 
taped and transcribed verbatim. Data were analysed using an inductive, thematic process. 
Results: Five major themes were identified; (1) Appropriateness of N-of-1 tests to determine 
the therapeutic equivalence of local drugs, (2) N-of-1 therapeutic equivalence tests: clinical 
care or research? (3) Ethical and regulatory requirements, (4) Potential barriers to 
implementing N-of-1 tests and (5) Possible solutions to identified challenges.    
Conclusion: The study demonstrated considerable support for using N-of-1 tests for clinical 
equivalence studies between local and imported medicines, but important impediments were 
very likely to impact feasibility of N-of-1 tests as a means of assessing this in Ethiopia. Key 
informants from the regulatory authority did not support additional tests on local drugs. There 
were also mixed opinions regarding ethical requirements for conducting N-of-1 tests. The 
Institutional Review Board (IRB) members believed that IRB approval was sufficient to 
conduct N-of-1 tests, however, the regulatory authority members considered that N-of-1 tests 
constituted a clinical trial, and required approval at the regulatory level. There were key 
uncertainties that could impact the feasibility of this approach in testing local drugs in Ethiopia. 
Therefore, a number of protocol amendments to address contextual threats and regulatory 
challenges, would be needed before progressing to conducting these tests. 
Keywords: generic drugs, bioequivalence data, N-of-1 therapeutic equivalence trials, 
Acceptability, Institutional Review Board, drug regulation authorities 
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Background  
Ethiopia is the second most populous country in Africa with a population of 100,936,943230. 
Non-communicable diseases disproportionately affect developing countries including 
Ethiopia171 and there is limited capacity for people to afford treatments16. Generic drugs 
represent a potentially cost–effective solution to treating non-communicable diseases. The 
United Nations recommends that the world’s poorest countries improve access to medicines 
through local production of generic drugs which are bioequivalent to brand-name drugs16. 
Around 30% of the National Essential Drugs in Ethiopia is produced locally17. 
The existence of rigorous drug approval and monitoring systems in the developed world has 
made generic substitution more reliable48. However, lack of sufficient medicine regulation in 
sub-Saharan Africa (including Ethiopia) poses difficulties in guaranteeing effective generic 
drug substitution22,25. 
Lack of a bioequivalence centre in Ethiopia 
Ethiopia is one of the Sub-Saharan African countries where the poor regulation of medicines 
poses a challenge to the effective clinical care of patients22,23.  For example, bioequivalence 
tests which are taken for granted in many countries are not available22. Bioequivalence forms 
the basis for approval of generic drugs18,231,21. While bioequivalence certification is a 
requirement for registration of medicines in Ethiopia (in principle) 5, lack of a bioequivalence 
testing facility locally has made enforcing bioequivalence on local pharmaceutical companies 
difficult.  Hence, locally made medicines are marketed without fulfilling the World Health 
Organization-prequalification criteria for therapeutic interchangeability22. 
There is one documented case in which the Ethiopian medicine regulatory authority banned 
the production of one locally manufactured drug following receipt of claims of ineffectiveness 
of the drug from multiple health professionals4.Though there is limited evidence about the 
views of local physicians on locally manufactured drugs, in one survey only 46% of prescribers 
agreed that locally produced and imported medicines were therapeutically equivalent124.  
Interventions that enhance acceptance of generic drugs are highly desirable for promoting 
effective generic drug substitution26,27,114,166,232. For example, the US Food and Drug Authority 
advises research (eg. individual patient brand-to-generic switching studies) to obtain additional 
data in therapeutic areas where concern exists about the substitutability of generic drugs6. In 
the absence of bioequivalence data, additional tests that evaluate therapeutic equivalence are 
needed to ensure that patients have the option to substitute cheaper local drugs confidently and 
to access effective and high quality treatment in Ethiopia. 
Clinical endpoint bioequivalence studies test the clinical bioequivalence of a medicine in 
patients148,233. They can be used to establish the bioequivalence of drug products when 
pharmacokinetic studies are not possible5. Quality of care can be improved significantly by 
increasing the likelihood that health care providers practice in ways most beneficial to patients 
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under the prevailing circumstances (process improvement) 29, 234, 235. Thus, quality 
improvement tools must be consistently shared among developing countries to build local 
capacity29,236,237 
 N-of-1 Trials 
N-of-1 trials/tests are double blinded, multiple cycle crossover trials, comparing a test 
treatment with a comparator112. Guidelines commissioned by the US Agency for Healthcare 
Research and Quality (AHCRQ), and a recently published book have both documented the use 
of N-of-1 tests as a means of formally assessing the bioequivalence of generic drugs1,2. N-of-
1 trials have been used to prove therapeutic interchangeability of generic drugs with brand 
drugs114,3.  
By establishing bioequivalence information on local drugs, N-of-1 tests have the potential to 
provide affordable patient-centered care and promote quality use of medicines. Compared to 
pharmacokinetic bioequivalence tests, N-of-1 therapeutic equivalence tests require less 
technology and can be done at the point of care.  
This study is designed to determine the acceptability of N-of-1 tests as one approach to 
assessing the bioequivalence of untested, but approved, generic drugs in use in a resource 
limited setting.  Developing interventions without adequate consideration of how the target 
population will accept them puts their implementation at risk238,239. The context in which an 
intervention study is conducted is important. Contextual threats to trial conduct are often 
subtle, idiosyncratic and complex, and therefore best explored using qualitative research176. 
Qualitative research within a feasibility study is useful in preparation for clinical trials in order 
to explore contextual uncertainties and ascertain the acceptability of the design and the 
intervention to be evaluated240. Obtaining the views of relevant stakeholders who might take 
part in the study, and officials from the ethics and regulatory authorities who may need to 
approve interventions, is a critical component for successful implementation241-244.  
This study provides a formative evaluation of a proposed study using qualitative research. To 
the best of our knowledge, this is the first study to assess the acceptability of N-of-1 therapeutic 
equivalence tests to provide bioequivalence information of untested generic drugs in a resource 
poor country. The study sought to answer the following research questions: 
a. What are the views of stakeholders regarding the use of N-of-1 tests as a means of 
assessing the interchangeability of generic and brand name drugs in Ethiopia? 
b. What are the practical barriers to conducting N-of-1 tests in Ethiopia? 
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METHOD 
Setting 
The study was conducted in ALERT centre, a medical research centre which comprises 
ALERT hospital and the Armauer Hanson Research Institute (AHRI) in Ethiopia. The study 
was approved by The University of Queensland ethics review committee (approval number: 
2016-SOMILRE-0158) in Australia and by ALERT and AHRI ethics review committees 
locally (approval number: PO28/16). The same focus group data were used to address multiple 
topics – presented in this chapter and in Chapter 4. 
Description of the proposed intervention/clinical test 
The project introduces N-of-1 therapeutic equivalence tests in clinical practice to test local 
generic medicines used for the management of NCDs. Hypertension is the single most 
important cause of mortality from non-communicable diseases in Ethiopia and Enalapril is the 
commonly used first line treatment option. Therefore, we chose Enalapril for hypertension as 
the clinical scenario to pilot N-of-1 tests at the point of care. This feasibility study will 
determine whether N-of-1 studies can be used in a developing country to identify affordable 
drugs that are proven to work, thereby improving clinical decision making and medicine 
compliance. The proposed N-of-1 test will be piloted in a research institute affiliated hospital 
in Ethiopia.   
Design and data collection methods 
This qualitative study was conducted to inform future implementation of the proposed N-of-1 
tests of local drugs. Data were collected in April and May, 2016. Semi-structured focus group 
discussions, and key informant interviews were undertaken. The principal investigator, along 
with a trained facilitator, collected data using an audio tape-recorder and field notes. Data 
collection was conducted in the local language (Amharic) then transcribed and translated into 
English. The principal investigator is an Ethiopian and native Amharic speaker and did the 
transcriptions.  
Participants and recruitment methods 
Four focus group discussions, two with physicians and two with patients who had controlled 
hypertension (one comprising male patients and one comprising female patients) were 
undertaken. The number of participants in each focus groups ranged between six and eight.  
Five key informant interviews were also conducted.  Three were with institutional review 
board (IRB) members and two were with drug regulatory authority employees.  Participants in 
the IRB group were members of ALERT/AHRI Ethics Review Committee (AAERC). AAERC 
is a vibrant ethics review committee that operates in ALERT centre. The two key informants 
representing the regulatory authority were senior officials involved in the approval and conduct 
of clinical trials in Ethiopia. 
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A purposive sampling method was used to ensure inclusion of differing perspectives from the 
different stakeholders who would be involved during the pilot implementation of N-of-1 tests. 
Physicians were purposively selected based on their position and experience in ALERT 
chronic care services. Because of our intention to pilot N-of-1 tests in hypertension, only 
hypertensive patients, who were being treated at the ALERT hospital, were invited to 
participate in the patient focus group discussions. 
Educational material and education sessions 
Because the idea of N-of-1 tests is a new concept in the Ethiopian context, pre-reading 
material, which explained the rationale for the study, the proposed N-of-1 tests and their 
implementation strategies, was circulated to all participants before conducting discussions and 
interviews.  The educational material covered a number of topics including bioequivalence, 
local generic drugs and N-of-1 tests and their implementation. The content of the material 
provided to the different groups of participants was adapted to meet the specific needs of each 
group. 
Before conducting the focus group discussions, education sessions (with questions and 
answers) were held to enhance participants’ understanding of N-of-1 tests and the proposed 
study, with the intention being to have the focus group discussion focus on the research 
questions rather than be side-tracked by explanation of the method.  
Data Collection and Analysis 
Interviews lasted from 24-45 minutes and focus groups lasted from 35 to 104 minutes. The 
focus group discussions and three of the key informant interviews were audio taped and 
transcribed verbatim. The two senior key informants from the regulatory authority did not 
consent to being recorded but did agree to be interviewed.  Brief notes were taken during these 
two interviews.  On completion of each interview these notes were then expanded.  The 
expanded field notes were then incorporated with transcriptions to facilitate generation of 
themes.  
After familiarization with the data through repeated reading of the transcripts, a thematic 
framework245 was developed using emerging ideas and a priori questions drawn from the 
objectives of the study.  Transcripts were open coded for themes relating to discussion and 
interviewee views and perceptions, including any other emerging themes, using an inductive, 
thematic process. A sub-set of transcripts and field notes was coded by a second author and 
any discrepancies were discussed and resolved by all authors. The coding framework included 
five major themes. An inductive, thematic analysis approach was used to assess the barriers 
and enablers of the proposed intervention. 
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Results 
This study involved 31 participants: five key informant interviews (two senior regulatory 
authority members and three IRB members) and 26 participants (14 physicians and 12 patients) 
in focus group discussions. Participant age ranged from 32-65. Eleven of the 26 participants 
were female (see Table 6.1). While two thirds of male patients had attended formal education, 
only one third of female patients had any formal education. Of the three IRB committee 
members, one had a senior physician role, one had a senior researcher role and the third one 
had an administrative role at a government health office.   
Table 6.1: characteristics of study participants 
Participants Focus 
group  
Number of 
people  
Gender  Age Education  
Physicians   1 6 Male 35 – 59 Attend higher education (6) 
2 8 Male (6) 32 – 54 Attend higher education (8) 
Patients 1  6 Male  51– 6 Attend higher education (2) 
Secondary school (1) 
Primary School (1) 
2 6 Female 48-57 Primary School (2)  
Illiterate (4) 
Ethics and 
regulatory 
authorities 
  Key      
  Informant  
I interview 
Overall (5) 
Ethics (3)                                               
Regulatory (2) 
  Female (3)    36 – 56 Attend higher education (5) 
Descriptive extracts of the data, categorized into five themes, are presented below. The 
following five themes are discussed consecutively and quotes supporting each are presented: 
(1) Opinions about the appropriateness of using N-of-1 tests to test the therapeutic equivalence 
of local drugs, (2) N-of-1 therapeutic equivalence tests: clinical care or research? (3) Ethical 
and regulatory requirements, (4) Barriers to implementing the study and (5) Possible solutions 
to address challenges.   For each quote, unique identification numbers of each participant, along 
with the data collection technique used, are given in brackets.  
Theme 1: Appropriateness of using N-of-1 tests to determine the therapeutic equivalence of 
local drugs 
There was a considerable amount of support for the N-of-1 approach from the different groups 
of participants.  Almost all believed the study was an important way to identify better drugs 
and provide better patient care. Their impression was that N-of-1 tests could be a pragmatic 
solution to address uncertainties in the clinical care of patients. In particular, there was 
considerable support from IRB members and also from focus group participants. 
 ‘It (N-of-1) is really a great strategy to check the comparative effectiveness of our 
drugs’ (P3, IRB interview) 
 ‘I am really very happy. Such kind of study has a lot of contribution to check drugs 
produced in Ethiopia.’ (P1, male FGD)   
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Most participants across groups believed that N-of-1 tests represent a pragmatic approach to 
improve patient care. They noted that identifying ineffective drugs and selecting drugs that 
work for individual patients are key components of providing better patient care. 
Physicians and stakeholders could see the benefits for patients: 
 ‘It is good to rule out the ineffective drugs. This project is good to differentiate which 
drug is really useful for the patient. It is all about the patient. I think this study is good 
and is useful for the patient’ (P1, physician FGD 2) 
‘When a patient claims that a drug is not working, the doctors must consider such 
studies. … I think it will help to successfully treat those patients who are not benefited 
from the drug both physically and psychologically. (P2, IRB interview) 
N-of-1 tests were considered important as one method for potentially promoting the use of less 
costly drugs. Changing the mindset of physicians to show that cheaper drugs could be as 
effective as expensive ones could overcome a barrier to providing cost effective treatment 
options for patients. Tests that compared treatment effects of different brands of drugs were 
identified as particularly influential in addressing this challenge, thus assisting physicians to 
decide which generic brands to prescribe.    
Often times, physicians prescribe drugs imported from Europe but most people couldn’t 
afford them.  There is a big difference in price among different brands of the same 
drug….I think this project is helpful to prescribe cheaper drugs as long as they have 
the same effect as the expensive drugs. (P3, IRB interview)  
There was also recognition that N-of-1 tests could benefit physicians in somewhat unexpected 
ways, for example as one physician said. 
‘Actually, we physicians will benefit more from the study. We will develop our research 
experience and we could improve the care of our patients’ (P5, physician FGD 1) 
There was also some indication that these tests might improve the quality and drug options 
available in the local market. 
‘The study may encourage our local companies to improve their quality and we will 
have options of many local drugs with affordable costs.’ (P1, physician FGD 1) 
N-of-1 tests could have an impact on the physician – patient relationship. A few physicians 
warned that testing the comparability of local drugs against imported ones could affect the 
patient-physician interaction negatively if the local drug was shown to be less effective. This 
is because those patients who could not afford the more costly drugs might lose their faith in 
their physician. 
‘There will be some obstacles to run this project in our country… our participants 
couldn’t be able to buy alternative drugs because of financial problems. If we follow a 
chronic patient with one drug (generic) in N-of-1 trial and if the drug doesn’t work, the 
patients could lose his confidence upon the physician, not only on the drug’ (P6, 
physician FGD 1) 
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However, it also raised an important issue regarding the implications of using ineffective drugs. 
 ‘If the local company produce a drug with 40% effectiveness while the [imported] 
brand is 80% effective, prescribing the local drug means doing nothing. Even if the 
patient couldn’t afford it, we may use other options like government exempted services. 
This all could be solved with studies like this.  If the drug we prescribed is not effective 
we are doing futile exercise. … our patients are complaining against the practitioners, 
not the drugs. Therefore the study could minimize these gaps’ (P2, physician FGD 1) 
There were a small number of key informants who did not support testing local drugs. One 
indicated that the authority approves effective and safe medicines, and claimed that such 
studies could have negative consequences on patients, companies and the regulatory authority 
itself.  
Theme two: N-of-1 therapeutic equivalence tests: clinical care or research? 
The issue of how best to conceptualise N-of-1 tests at the point of care, that is whether they 
need to be treated as a clinical care tool, as clinical research or as a conventional clinical trial, 
was raised. The distinction between what constitutes clinical care, clinical research or a clinical 
trial was clear to the participants.  Whether N-of-1 studies constituted clinical care, research or 
a clinical trial was an important issue, because this would affect the need for an official 
approval from ethics and regulatory authorities, and in turn, influence physicians’ use of N-of-
1 tests in their daily clinical practice. There was considerable diversity of opinion from the 
participants.    
The majority of stakeholders (including IRB members) considered that N-of-1 tests could be 
both a clinical care tool and clinical research.  While the purpose of the test was considered to 
be clinical care, the processes and procedures involved (randomization, blinding and the way 
outcomes are selected, assessed and reported) were considered to be clinical research. 
 ‘…since it involve a randomization, blinding and recording of results, and using 
results as an outcome, it is a research tool. But we can see the research in a different 
way. What you are doing has some clinical care component.’ (P 3, IRB interview) 
‘…we can take it as a part of clinical care because the doctor make his own research 
as to whether the drug is applicable or not. …It has also a clinical research character 
because we are intentionally introducing/changing the drugs. …Though it is used for 
clinical care purpose, I think it will also be considered as clinical research.’ (P4, 
physician FGD 2) 
By contrast, several considered this test only to be a clinical care tool.  The type of study 
(involving only one participant), the study setting and parties involved (patients and physicians) 
and its purpose (collecting data to improve patient’s own care) were the basis for making this 
distinction.  
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‘From the study type, it is more of a clinical care. Because only one participant is 
involved and data is taken from the participants and the beneficiary are the participant 
themselves. So, I think it’s clinical care.’ (P2, physician FGD 2) 
‘I also believe that is about clinical care improvement. It is an interaction between the 
patient and the physician, not beyond. …We need to use many options to manage our 
patient. So that it is a clinical care not a research.’ (P1, physician FGD 1) 
Some key informants, however, considered N-of-1 tests in individual patients to be clinical 
trials.  They noted that, according to the Ethiopian medicine regulations, irrespective of the 
degree of risk associated with the study and whether the drugs are approved for use or not, any 
comparative study involving drugs in humans is considered to be a clinical trial. They noted 
that the proposed N-of-1 tests do not satisfy the definition of standard clinical care in Ethiopia 
as they could involve the testing of different drugs sequentially in one patient.   
Theme three: Ethical and regulatory requirements 
Whether N-of-1 tests require ethical approval depended on the intention of the test; that is, 
whether the aim was to provide clinical care or to conduct clinical research. Ethical approval 
was needed if the intention of the test was to generate generalizable data. N-of-1 tests often test 
drugs with established efficacy and safety profiles based on clinical trials.  
Key informants from the IRB and the regulatory authority were asked whether IRB approval 
is sufficient or whether additional regulatory approval was required as in the case of classical 
clinical trials. They believed that IRB approval was sufficient. One of them also suggested that 
requirements should be strict as the method represents a new approach in the country. One 
participant reported that the term ‘trial’ could be sensitive to the regulatory authority. 
‘I don’t think you need this (regulatory approval). Because these drugs are already 
registered by Food, Medicine and Health Administration and Control Authority 
(FMHCA) and are being used nationally.  It is a registered drug, you are not going to 
import it. People are [already] using it, so I don’t think it requires a strict clinical trial 
requirements. But still there are some trial components like randomization and 
blinding. So it needs IRB approval.’ (P 3, IRB interview). 
The term '‘trial’ alone could be a sensitive issue.   
 ‘My fear would be just the name trial.’ (P1, IRB interview) 
Not surprisingly, key informants representing the regulatory authority believed that the 
proposed N-of-1 tests would be considered to be a clinical trial and hence would require 
approval at the regulatory authority level. Although they expressed their view of the regulatory 
requirements clearly, these participants were unwilling to discuss and explain the ethical 
procedures they felt needed to be taken. They noted that they would not discuss and comment 
on future applications and that all applications should follow the conventional route of 
application – i.e. ethical approval and then application to the regulatory authority.   
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Theme four:  Potential barriers to implementing the study 
The participants were asked about challenges they could see arising when implementing the 
project. They responded from a number of perspectives.   
Most physicians mentioned concerns about work load and lack of time in their daily practice. 
Some mentioned lack of experience with research and changing the mindset of physicians 
about research (some physicians have already developed an impression that research has no 
direct benefit in their daily patient care). A few mentioned rotating/shifting work schedules and 
a fear that the study might interfere with the doctor-patient relationship.  
‘Especially the issue of physician’s time, work burden and patient’s condition should 
be assessed. We are not also aware of research.’ (P2, physician FGD 1) 
‘One thing I want to add is that physicians are busy and the mentality is not often good 
for research.’(P6, physician FGD 1) 
Several possible barriers for the approval and conduct of the study were suggested. For 
example, N-of-1 tests were new for the country, there was, therefore a lack of experience and 
framework to decide how to monitor the study.  
 ‘IRB will focus on the advantage from the patient perspective. It might be a bit hard 
for you. The IRB may want to make strict follow up as it (N-of-1) is new. Such studies 
are not common, so the practicability of the project needs to be given due attention.’ 
(P2, IRB interview) 
Identifying participants suitable for inclusion in the trial was also raised as an issue. Patients’ 
suspicions about the study, lack of interest in drug switching and low patient literacy potentially 
limited patients’ understanding of the study process. The extent of their capacity to record their 
own blood pressure measurements could also represent a challenge for the study.  
 ‘Patients in our set up are suspicious, so they might not take the drug.’ (P3, physician 
FGD 1) 
‘If the patients have to record their BP by themselves, they might be illiterate.’ (P7, 
physician FGD 2) 
Patients’ focus was on lack of time and on financial issues, as well as logistic problems related 
primarily to transport. This is because many patients struggle to support their own as well as 
their family’s needs. Therefore, they cannot afford additional transportation, medical and other 
related costs that might be involved in being participating in such studies. 
 ‘We are busy at home for our daily life and don’t forget that we are poor.’ (P6, Female 
FGD) 
 ‘We may have shortage of time and transportation problem.’ (P6, male FGD) 
The patient groups were also asked if they would be willing to participate in the coming N-of-
1 test. The majority of the patients reported they would participate in the pilot trial if invited. 
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‘I need to be a participant of the research since the finding will help me to find better 
drug’ (P4, male FGD) 
The sensitivity of the disease chosen was also raised as a potential barrier. One participant was 
concerned about the disease selected for piloting N-of-1 therapeutic equivalence tests. Because 
of lack of bioequivalence testing, substitution of local drugs could ay represent a risk for 
patients with hypertension if ineffective.  
 ‘What I want to say is that hypertensive patients need to take their drug properly. If 
you give a drug which is useless, blood pressure cannot be controlled, so there will be 
subsequent result if you don’t control the blood pressure. A patient might develop 
cerebral hemorrhage after taking drug which is not effective.’ (P3, IRB interview) 
Theme five: Possible solutions to address challenges  
After discussion of problems that could impact the acceptability and feasibility of the proposed 
pilot trial, participants identified potential solutions that could address ethical and operational 
barriers.  Three levels of strategies that could enable effective implementation of N-of-1 tests 
were identified. 
Doctor related strategies:  Included selection of interested physicians, incentives for 
participation, and well-coordinated training for trial staff. 
‘Priorities for training…we can easily notice the importance of training… It is also 
good to incentivize those professionals who participate in the study.’ (P6, physician 
FGD 1) 
 ‘There are a lot of things, but the physician should involve themselves and devote their 
time and the project should consider incentives and train them as well.’ (P3, physician 
FGD 2) 
Ethics and regulatory strategies:   Included a workshop or training to enhance awareness, 
preparation of a standard protocol and case report forms, and the involvement of senior 
physicians during the planning and conduct of the trial.  
 ‘To minimize that kind of hassles as a researcher and applicant, I advise you to call 
for a three or four days of workshop for those who are working in the regulatory bodies 
and brief what your study is all about’ (P1, IRB interview) 
‘Regarding the ethical process, it might take time, you need to think thoroughly and 
prepare the protocol well…the follow up needs to be rigorous. You might need to 
involve seniors for patient follow up’ (P3, IRB interview) 
Patient related strategies: Suggested strategies to address participant challenges included 
compensation for transport to the hospital for visits relating to the test, promoting awareness 
of the project, and the provision of free drugs. 
 ‘We will participate in the study if you consider transportation costs and something to 
buy bread for our children when we get back to home from hospital visit’ (P2, female 
FGD) 
 108 | P a g e  
 
 ‘Firstly, awareness creation regarding the benefit of the study for patients is 
important.’ (P6, male FGD) 
Discussion  
A qualitative study using focus group discussions and key informant interviews was conducted 
to assess the acceptability of N-of-1 trials as a practical, low cost means of assessing therapeutic 
equivalence of local generic medicines used to treat non-communicable diseases in individual 
patients in Ethiopia.  
Most participants supported the concept of using N-of-1 tests to test local generics, and 
highlighted important concerns about using this approach in testing local drugs in Ethiopia. 
Respondents across categories highlighted several benefits of N-of-1 tests: their capacity to 
potentially identify better drugs that cost less, to check efficacy of drugs, to improve the doctor-
patient relationship, to improve physician research skills and to address issues related to 
branding of drugs. These potential uses were identified by previous researchers1,2.   
As the major purpose of the study was to explore key uncertainties associated with conducting 
the trial, we have summarized the learnings from this study to inform any future trial (see Table 
6.2). The subsequent sections discuss threats to feasibility; major threats are discussed first, 
followed by issues that represent minor threats.  
Stakeholders from the regulatory authority did not support testing local generics in clinical 
settings. This was considered to be the major threat to the feasibility of proposed research. They 
emphasized the potential negative consequences the test might have on patients, drug 
companies and the authority itself. Addressing lack of access to affordable medicines is a major 
priority for developing countries like Ethiopia. Negative results from such therapeutic 
equivalence tests may be a threat as they could lead to loss of confidence in local companies. 
Usual care (particularly for those who cannot afford expensive imported medicines) is 
dependent on local drugs and the government cannot afford to replace those drugs.  Besides, 
pharmaceutical companies may also bring claims (to the authority) against study results as 
their products are already approved by the authority. The regulatory authority has banned 
medicines in the past when strong evidence of ineffectiveness was reported from multiple 
sources. Hence the risk of litigation is quite low246. In some cases, the attitude of avoiding 
potential problems by not identifying them (lack of transparency) stems from a culture where 
it is important not to lose face247. 
The issue of how N-of-1 tests need to be treated - clinical care, research or clinical trial - at the 
point of care was also identified as a major threat. In contrary to other groups ( who believed 
N-of-1 tests are at best clinical care and research tools and that IRB approval sufficed to 
conduct them), key informants from the regulatory authorities said that N-of-1 tests would be 
treated as clinical trials in Ethiopia, requiring their approval and hence very onerous extra 
conditions prior to conducting them. This is in contract to medical researchers who advocate 
the routine use of N-of-1 tests, arguing that N-of-1 tests employing randomization, blinding, 
and objective outcome assessment can be simply an enhanced form of clinical care, and do not 
automatically translate into research requiring regulatory authority approval248.   
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Whether N-of-1 tests require even ethical approval or not is a source of debate in the literature 
regarding the ethics of N-of-1 tests119,129   However, requiring formal regulatory approval has 
not been raised as a main challenge in conducting N-of-1 tests in the literature, because N-of-
1 tests are commonly used for approved therapies. The general principle is, where the intent is 
to generate generalizable knowledge, IRB approval should be sought. If the intent of the N-of-
1 study is to assist in the conduct of patient care, then IRB approval should not be required.   In 
a recent study on whether N-of-1 tests require IRB approval or not, more than half of the 
responding IRBs regarded N-of-1 tests as meeting the definition of  clinical research which 
require IRB approval, while the other half considered them to be clinical tools not requiring 
ethical and regulatory oversight129. The idea of further regulatory approval to conduct N-of-1 
tests in Ethiopia implies that the generally accepted rules relating to ethics of N-of-1 trials may 
not apply in the context of developing countries.  In this regard, implications of the findings 
could also be important considerations.  
We also reviewed local literature to examine and compare these perspectives4,249. We believe 
individual N-of-1 tests to prove the interchangeability of marketed drugs which are already in 
use by patients largely constitutes a quality assurance activity.  
In addition to the above major threats, many minor impediments to feasibility were identified. 
Although local drugs are approved for use by patients, IRB respondents expressed their 
concerns about involving patients whose blood pressure is not controlled. They stated that 
safeguards were important, particularly stringent oversight on their part. The main barriers 
reported by physicians included work load and lack of time in their daily routine. Some also 
mentioned lack of experience in research and research having a bad reputation. A few 
physicians were also concerned about the effect of the test on the physician-patient relationship, 
if the local drugs were shown to be less effective. Financial difficulties in covering the daily 
costs of life and medications, and lack of time to come to the hospital were raised by patients. 
Lack of experience and knowledge of people working at regulatory level, the name ‘trial’ and 
the fact that the N-of-1 concept was new to the country were the major challenges reported by 
IRB members. Many of these barriers were also identified as challenges for expanding N-of-1 
clinical care in developed countries250.  
Participants also suggested solutions for the above barriers to successful implementation of the 
trial. Suggested solutions to address barriers related to physicians included; selection of 
interested physicians, provision of training and incentives. Participants suggested 
compensation for transport, creating awareness, provision of free drugs and a convenient time 
schedule to address challenges related to patients.  
This is the first study to assess acceptability and issues that impact acceptability of clinical 
therapeutic tests using the principle of N-of-1 to assess therapeutic equivalence of untested 
generic drugs in a resource poor setting. However, the study has some limitations. Apart from 
the regulatory members, all participants were recruited from a single institute. The intention of 
this study was to inform the design, approval and implementation of a pilot N-of-1 test in 
Ethiopia. In this sense, as is typical of feasibility studies, internal validity was prioritised at the 
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expense of external validity. Many patients had no formal education. As there is a common 
belief by patients that ideas of educated people are positive and beneficial, patient participants 
may have been especially motivated to take part in the proposed trial. They also may have been 
prone to social desirability bias in response to questions about the acceptability and benefits of 
the proposed N-of-1 tests. However, we did recruit from a wide range of participants to 
maximize representativeness of the sample. 
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Table 6.2: key insights from the qualitative research on future N-of-1 therapeutic equivalence tests on local generic drugs  
Area of uncertainties  Sub-category The learnings/what should be done on the proposed test 
Intervention  Regulatory authority 
members did not support the 
need for testing local drugs 
 
This is a key uncertainty that should addressed prior to the planned test.  It 
demonstrates the need for creating a deep understanding by relevant authorities 
of the relevance of testing local drugs and its implications to improve clinical care 
through continuous education and discussion. 
IRB members were 
concerned about the 
potential unintended 
consequences of providing 
local drugs to unstable 
patients 
(1) Designing  strict eligibility criteria to include stable patients only/patients 
whose condition is controlled is important 
(2)  Strict and regular patient follow up is required 
(3)  Data safety monitoring board need to be established 
 
 
Develop clarity of the 
approval process 
Regulatory authority wanted application through the normal channels. That is, if 
the IRB indicated that regulatory authority was deemed necessary, then approval 
from the authority would be sought. If not thought necessary, the authority would 
not be approached. 
 
Trial design, 
conduct and 
processes 
Issues 
related to 
N-of-1 test 
Regulatory authority 
members did not accept the 
test in principle 
The need for further work to increase awareness of the potential role of N-of-1 
tests in supporting the regulatory quality assurance system and improving clinical 
care 
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A potential negative impact 
on the health care system if  
local drugs (which are cost 
effective) turn out to be less 
effective 
This is a major issue. Local drugs represent an affordable option in usual care.   
The findings of the proposed tests may require a change from usual practice.   
 
Further work, including meetings and workshops that enhance understanding and 
benefits of the study (with the inclusion of other parties they trust), could be a 
possible solution. This work should emphasize (1) Short term and long term 
negative consequences of using medicines that are not proven to work (2) the 
contribution of N-of-1 tests to patient care and advancement of the health care 
system (3) designing strategies that can anticipate and respond to findings of the 
proposed N-of-1 tests are imperative, eg. a system regarding who should pay if 
local drugs do not work on an individual patient and the patient cannot afford 
alternative drugs. Also dialoguing with medicine manufacturers on the benefits of 
identifying the cause of the problem(s) and correcting it. 
Recruitment 
and 
retention 
 
 
 
 
 
 
 
 
 
 
 
 
Doctors are too busy and 
lack research skill to recruit 
and make follow up patient 
assessments. 
Due to high patient load and lack of research culture in hospitals, establishing an 
N-of-1 testing service in universities and research facilities could be a pragmatic 
solution. Then, provide an N-of-1 test service to the hospitals through a patient 
referral-feedback model, a service that clinicians are used to (referral from 
hospital, test, and report back to the hospital). 
Most patients are poor, so  
cannot afford trial related 
costs 
Financing of N-of-1 tests deserves attention as patients alone cannot afford 
additional costs of these tests. Apart from the government and patient-centred care 
advocators, insurance and local pharmaceutical companies should be involved in 
this matter 
 
Patients are busy in their 
daily life 
Limit patient follow up and use health technologies as much as possible in the 
proposed test 
 
Most patients are illiterate -
they can’t read,  or 
Recruit only patients who are literate or have a literate assistant for the duration 
of the study. 
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 understand and record on 
trial documents 
 
 
Ethical and 
regulatory 
issues  
Mixed views on ethical 
requirements  
The IRB members believe that N-of-1 tests on local drugs (which are already 
approved) is part of quality assurance, and hence IRB approval suffices. Whereas 
key informants of the regulatory authority emphasised the need for regulatory 
approval so as to monitor potential unanticipated negative consequences of the 
proposed test. Posing these regulatory requirements negatively affects the 
feasibility of using N-of-1 tests in daily clinical care.  
 
These issues can be addressed by (1) including education of patients and doctors 
regarding interpretation and scope of individual N-of-1 study results in the 
proposed study as a possible option to reduce/avoid the risk of biased negative 
perceptions about local drugs (2) As mentioned above, meetings and workshops 
involving members of both IRB and regulatory authority are needed to address 
the tension of mixed views regarding ethical requirements and to develop a mutual 
guideline regarding the level of endorsement required for future N-of-1 tests on 
local drugs.  
 
Develop clarity of the 
approval process 
The regulatory authority stated that they would only be involved in applications 
presented through the normal channels. That is, if the IRB indicated that 
regulatory authority was deemed necessary, then approval from the authority 
would be sought. If the IRB did not think it was necessary, the authority would 
not be approached. 
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Conclusions  
In conclusion, the study highlighted key uncertainties that impact the feasibility of using this 
approach in testing local drugs in Ethiopia. Therefore, a number of changes that address 
contextual threats and regulatory challenges, would need to be made before progressing to the 
conduct of the test (see Table 2). There is a need for openness for an in-depth discussion of key 
issues in order to appropriately inform subsequent decision-making processes after a qualitative 
study. Finally, we acknowledge that the political will to ensure that quality becomes a top 
priority on the health reform agenda is also critical to improve quality of clinical care in 
developing countries29.  
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Chapter summary  
The study showed considerable support for N-of-1 bioequivalence methods. We have shown 
that patients were interested in participating, and physicians were enthusiastic to collaborate in 
the implementation of the proposed pilot trial. However, a few physicians were cautious 
regarding the impact of the study on the patient-clinician relationship.  The study also identified 
potential impediments in four areas of the study intervention: the N-of-1 bioequivalence 
method itself, ethical and regulatory aspects, recruitment, and retention.   
The major contribution of this qualitative feasibility study is that it informs the conduct of the 
proposed trial. It identifies potential strategies for addressing the various barriers reported by 
the study participants. Based on findings and learnings from the study, several changes were 
made to respond and overcome identified barriers for conducting the proposed trial. Lack of 
consensus between IRB members and regulatory officials regarding ethics of N-of-1 trials was 
a major challenge. Thus, based on views of the regulatory officials, considerations and plans 
were made to follow the national clinical trial approval system. However, due to lack of 
willingness to participate in a transparent and open dialogue (on the regulatory authority side) 
regarding regulatory matters, we made a decision to explore practical feasibility through 
piloting the proposed trial in the face of some uncertainty (the detail of major challenges 
encountered, the decision-making process of the transition (from the qualitative studies to pilot 
trial is available in the methodology chapter, section 3.5.2).  
The qualitative studies included the various stakeholders who will be involved in the proposed 
trial, and were conducted in the setting where the future trial will be piloted. Hence, the study 
will stimulate public discussion ahead of the planned N-of-1 BE trial and will facilitate 
engagement of the study site and participants who participated in the qualitative studies.  
Finally, the findings of this study helped the research team to develop feasibility parameters 
that would indicate when the risks/challenges outweighed the opportunities/proposed solutions 
of moving forward with the planned trial. That is- to halt the progress of the trial if: (1) IRB 
approval would take much longer than anticipated and (2) further regulatory approval and 
oversight would be needed following IRB approval.  
If N-of-1 BE trials are to be used to demonstrate the BE of local medicines, they need to be 
practically feasible. Thus, the final phase in this feasibility project is the actual conduct of the 
planned pilot trial. This is covered in the next chapters – Chapter 7 and 8.  
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Introduction  
This feasibility project explored the practicality of the proposed N-of-1 BE trial in three phases.  
The first two phases included review of literature regarding barriers for conducting trials and 
two qualitative studies with relevant stakeholders regarding views on the intervention (local 
medicine) and the proposed research method. Findings of these studies were fundamental to 
answer the major questions, which were to determine whether the proposed N-of-1 BE trial 
should be done, can be done, and, if so, how.  They were very helpful to address the potential 
uncertainties and improve conduct of the proposed trial.  
However, even with an agreement that local generic treatments in use required additional tests, 
N-of-1 was an appropriate method and that appropriate implementation strategies were 
identified, several practical methodological and ethical issues may still have affected the 
feasibility of N-of-1 use in clinical practice. Thus, whether the proposed trial could be done in 
practice was still unknown. The next two chapters explored if N-of-1 bioequivalence trials 
were practically feasible (ethical, regulatory and methodological) in Ethiopia. Enalapril, a 
commonly prescribed anti-hypertensive medicine was chosen for the case study. Chapter 7 
presents the published protocol and chapter 8 describes the findings of the study. The report 
presented in chapter 8 concludes with a summary of the challenges and the subsequent 
unanticipated decision by the Ethiopian regulatory authority. The final chapter –Chapter 9- 
discusses the key feasibility findings, regulatory challenges and final decisions, followed by 
recommendations to move the implementation of N-of-1 BE trials in Ethiopia forward.   
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Abstract 
Background 
Hypertension is one of the leading causes of morbidity and mortality in Ethiopia.  It requires 
regular monitoring, and in many cases lifelong medication use. Enalapril is a common drug 
for the treatment of hypertension in the country. However, the drug is expensive and therefore 
there is limited capacity for people to afford the treatment. Locally produced Enalapril is a 
cost–effective solution to treat the disease. However, as there is no sufficient medicine 
regulation (eg bioequivalence tests on locally produced drugs), physicians and patients have 
expressed the need for assurance about the effectiveness and safety of local generics. 
Therefore, evidence on therapeutic equivalence is needed on these untested local drugs.  
Method 
This is a hospital based, randomized, partially blinded, three-cycle crossover trial in single 
patients. Patients involved in this trial are not blinded. Study medications are prepared by an 
independent pharmacy unit. There will also be patient education to maintain unblinding of 
study investigators. Each N-of-1 trial will consist of three successive 14-day treatment pairs, 
each pair comprising 7 days of 5-20mg Envas and 7 days of 5-20mg Ena-Denk taken once 
daily in the morning. The primary outcome will be the average difference in systolic blood 
pressure as measured by home blood pressure measurements.  
Discussion 
The numbers of local pharmaceutical industries that market their products such as Enalapril 
without proof of bioequvalence are dramatically increasing. By bridging the information gap 
on bioequivalence, the trial will give rigorous evidence on therapeutic equivalence of locally 
produced Enalapril in the treatment of hypertension .If there is no difference, the hypothesised 
result, then patients can take the local cheaper medicine with confidence. This trial will also 
will determine whether aggregated N-of-1 studies are feasible to provide a population level 
estimate of clinical equivalence for untested generic drugs in resource limited countries where 
bioequivalence testing centres are unavailable.  
 
Trial registration number 
 
Australian and New Zealand Clinical Trial Registry, ACTRN12616001088437p. Registered 
on 12/08/2016 
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Background 
Ethiopia is the second most populous country in Africa with a population size of 100,936,94311. 
In 2011, the World Health Organization (WHO) estimated that 34% of the Ethiopian 
population die from non-communicable diseases, with a national cardiovascular disease 
prevalence of 15%171. In particular, hypertension is a major public health challenge because of 
its high frequency and associated risks. Ethiopian studies have found a significantly high 
prevalence of hypertension at the work place (27.3%)131 and in an urban community (30%)132. 
In 2008, the Ethiopian Federal Ministry of Health (FMOH) identified hypertension as the 
seventh leading cause of mortality133. This makes it the single most important cause of 
mortality from non-communicable diseases in Ethiopia.  
Drug therapy for hypertension involves the use of a series of drug classes and often requires 
taking multiple drugs, which makes the treatment expensive in economic terms. With the 
purpose of providing  better access to affordable drugs, the Ethiopian government legalized 
production and commercialization of generic drugs locally. Because of their lower cost, use of 
generic drugs is supported by healthcare systems, which recommend physicians to prescribe 
them, rather than brand-name drugs251-253. Therefore, treatment of hypertension with generics 
is an ideal option to reduce health care costs in Ethiopia.  
Lack of an accredited bioequivalence centre in Ethiopia 
In most places in the world, an application for marketing approval of a new generic product 
must reference a corresponding product, which was approved on the basis of clinical trials to 
support claims of safety and efficacy. This means generics must show bioequivalence (BE) to 
a reference product and this is accepted by the European Union (EU) 254, the United States of 
America (USA) 231 and WHO18.  
However, due to the lack of a bioequivalence testing centre in Ethiopia, whether locally 
produced drugs are therapeutically equivalent, and thus interchangeable with the originally 
marketed products is  not known. One practical example for this, occurred when the Ethiopian 
medicines authority announced that production of one particular locally manufactured drug 
was banned when it received claims of ineffectiveness of the drug from various health 
professionals246. Several studies have also reported high levels of negative perceptions 
regarding generic drugs among health professionals and patients in Ethiopia124,255.   
What are N-of-1 trials? 
N-of-1 tests are double blinded, multiple crossover comparative trials of effect. They are 
indicated whenever there is substantial uncertainty regarding the comparative effectiveness of 
different treatments being considered for an individual patient.  Guidelines commissioned by 
the  US Department of Health and Human Services, and a recently published book have both 
documented the use of N-of-1 tests as a means of formally assessing the bioequivalence of 
generic drugs1,2. Researchers have used N-of-1 tests to prove therapeutic interchangeability of 
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generic warfarin114 and nifedipine3. An N-of-1 trial also concluded that follow up of 
hypertension using home blood pressure measurement is possible98.  
N-of-1 trials are suitable in the following conditions: stable or chronic conditions; treatments 
must have a rapid onset and offset of effect (short half-life) resulting in minimal washout 
periods. 115,117 and short cycle lengths. There should be a validated test of effect that can be 
applied repeatedly. Enalapril meets all the conditions of a treatment amenable to N-of-1 trials98. 
Anti-hypertensive medicines 
As discussed in chapter 2 (section 2.3.1), the lack of standard BE in Ethiopia particularly affects 
generic medicines like antihypertensive, which show substantial within-patient variation in 
treatment response. Thus, switching to the use of local medicines for economic reasons 
complicates a clinician’s effort to determine the extent and direction of treatment dose titration 
in individual patients, and could lead to delay in blood pressure control. Moreover, even short 
periods of uncontrolled BP in hypertension are associated with increased risk of major 
cardiovascular events.  
Enalapril 
Enalapril is an angiotensin-converting-enzyme (ACE) inhibitor used in the treat hypertension, 
symptomatic heart failure, and asymptomatic left ventricular dysfunction256. Onset of 
antihypertensive activity is at 1 hour, with peak reduction of blood pressure achieved by 4-6 
hours after administration. The extent of absorption of Enalapril from oral Enalapril tablets is 
approximately 60%. The effective half-life for accumulation of Enalapril following multiple 
doses of Enalapril is 11 hours. It is metabolized in in the liver and excretion is primarily 
renal256. One study demonstrated that the first dose of enalapril was effective and produced 
effects similar to those measured after 7 days, and after 1 month of treatment99.  In Ethiopa, 
Enalapril is commonly used to treat hypertension and is one of the first line treatment options 
in the routine management of patients with hypertension246.  
Justification for the trial 
High quality clinical evidence is required to prove the efficacy and safety of locally produced 
Enalapril compared with an accepted comparator, without a bioequivalence profile being 
present. Though they are cheap, people distrust local drugs. Conducting classical clinical trials 
is difficult in Ethiopia. N-of-1 tests are relatively easy to conduct and generate individual 
results for each person. N-of-1 tests are not common in Africa in general. There are no 
published reports of therapeutic equivalence trials (TET) using N-of-1 tests to assess drugs, the 
equivalence of a product without a bioequivalence profile against another medicine that has a 
bioequivalence profile. If the tests prove feasible and acceptable, they can provide a bridge 
between the less rigorous regulatory environment in many resource-poor countries, and one in 
the future where bioequivalence tests are the norm. 
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Therapeutic equivalence tests (N-of-1 tests) prove interchangeability in individual patients. 
Furthermore, when N-of-1 tests from multiple individuals are aggregated (aggregated N-of-1 
tests), generalizable data can be produced from a smaller sample size, compared to parallel 
RCTs 22, 116.  Therefore, as a proxy measure to a bioequivalence study, data from a modest 
number of patients who are involved in N-of-1 tests (which are then aggregated) could be used 
to determine overall therapeutic equivalence in the population. To inform the design of this 
study, we conducted a preliminary qualitative study to assess views of patients and phyicians 
on local drugs, and the potential faciliators and barriers to performing N-of-1 tests. We 
identifed that participants preferred imported drugs from western countries, particularly 
Germany. For this reason, the German version of Enalapril was chosen as a comparator drug 
for this trial.  
Objectives 
The objectives of the trial are to;  
(1) Compare the therapeutic equivalence of locally produced Enalapril and the German version 
of Enalapril using N-of-1 therapeutic equivalence tests.  (Both products are registered to treat 
hypertension in Ethiopia) 
(2) Assess whether N-of-1 therapeutic equivalence tests are feasible to generate bioequivalence 
information for untested generic drugs in resource poor settings. 
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METHODS 
Trial design  
This is a therapeutic equivalence study using N-of-1 trials or tests. Each N-of-1 test will be a 
randomized, partially-blind, multiple crossover study designed to simulate the routine clinical 
practice of switching a patient between generic and brand forms of Enalapril to assess efficacy.  
Each N-of-1 test will consist of three successive 14-day treatment pairs, each pair comprising 
7 days of Envas and 7 days of Ena-Denk in random order,  taken once daily in the morning. 
The order of treatments in each treatment pair will be determined by block randomization –
figure 7.1. 
Blood Pressure will be assessed morning and evening during the period, and by a study 
clinician at the end of each seven day period. Blood Pressure measurements taken in the first 
two days of each period will be discarded during analysis stage to allow for washout. See 
Figure 1 below for the study design showing a sample arrangement of treatment order.  
Study setting 
This is a single site hospital-based study that will be conducted in AHRI/ALERT centre, one 
of the government owned institutes located in the capital city of Ethiopia (Addis Ababa). The 
complex comprises the All Africa Leprosy, Tuberculosis and Rehabilitation Training Centre 
(ALERT) specialized hospital and the Armauer Hanson Research Institute (AHRI).  
 
 
 
 
 
 
 
 
 
Figure 7.1. Diagram of N-of-1 test for treatment of hypertension using two Enalapril 
formulations 
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Study participants  
Participants who fulfil the following inclusion criteria (1) Male and female patients with 
primary hypertension controlled on Enalapril/Enalapril containing regimen- those who have 
achieved a blood pressure target of 140/90 mmHg or less in at least the last 2 months (clinic 
readings) (2) The Enalapril dose is between 5mg-20mg daily. (3) Subjects who are between 18 
– 80 years of age (4) serum electrolyte and creatinine within the normal range (or the clinical 
investigator considers the deviation to be irrelevant for the purpose of the study) (5) normal 
ECG or stable abnormalities which the clinical investigator does not consider a disqualification 
for participation in the study. Exclusion criteria include (1) any evidence of clinically 
significant, poorly controlled hematologic, renal, hepatic, gastrointestinal diseases, or diabetes. 
(2) Any evidence within the last six months of clinically significant diseases involving the 
cerebrovascular, autoimmune, or cardiovascular systems, including poorly controlled angina 
pectoris, secondary hypertension, congestive heart failure, myocardial infarction or stroke (3) 
concomitant use of major psychotropic agents or antidepressant drugs or regular use of 
nonsteroidal anti-inflammatory agents, high-dose aspirin, or any agent that could raise or lower 
blood pressure within the last 2 months (4) a history of drug or alcohol abuse (5) sensitivity to 
angiotensin-converting enzyme (ACE) inhibitors (6) Pregnant (positive pregnancy test) or 
breast-feeding women or women who are planning to be pregnant during the trial period. 
INTERVENTIONS 
Investigational products 
This N-of-1 therapeutic equivalence study will compare two formulations of Enalapril (Envas 
and Ena-Denk). See Table 7.1. 
Table 7.1: Identity of investigational products 
Description Test product Reference product 
Name Envas Ena-Denk 
Drug substance Enalapril Enalapril 
Administration  Per oral Per oral 
Formulation Tablet Tablet  
Dose 5-20mg 5-20mg 
Manufactured by Cadila Pharmaceuticals Ltd, 
Ethiopia 
Denk Pharma, Germany 
Enalapril 
For each patient, individualized Enalapril at the dose currently used will be prescribed for the 
duration of the study (six weeks). Drugs will be bought from a well-regulated wholesale 
pharmacy. Study medications will be packed and labelled by an independent pharmacy unit in 
six bottles containing one week’s supply of medicines each, and randomly ordered.  
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Randomization  
 
We will use block randomization and with a block size of two by a statistician at The University 
of Queensland . The order in which patients receive drugs will be randomized by computer for 
each single case, such as BA-AB-BA or AB-BA-BA. The randomization schedule will be sent 
to a pharmacist who is independent of the study at the ALERT hospital. Prepared study 
medications will be stored and dispensed at the AHRI Pharmacy Unit.  Randomization codes 
will be kept by the ALERT pharmacy. The codes will be broken by the Data Safety and 
Monitoring Board (DSMB) if safety concerns arise. 
Blinding  
Due to lack of encapsulation machines or matching placebo tablets locally, this N-of-1 study 
is planned to be a partially-blinded trial. Patients may identify the physical differences between 
the two drugs, but will not know the identity of the medicines they are taking. However, the 
trial staff will remain blinded as study medications are prepared by a pharmacist who is 
independent of the trial. 
Selection of doses in the study 
Participants in this study are those whose blood pressure is currently controlled with a regime 
including Enalapril 5-20mg. They will continue on their current dose for the duration of the 
trial.  
Dose adjustment plan for uncontrolled BP 
Standard clinic BP measurement is made at the end of each 1-week treatment period. Patients 
included in the study are those whose BP is controlled at the current dose and form of Enalapril 
which they are taking. If patient’s BP becomes less-controlled, the dose of Enalapril will be 
adjusted according to a preplanned protocol (see table 7.2).  
Table 7.2: dose adjustment plan              
Change in Average BP  Initial dose      Dose adjustment      Maximum 
< +5 mmHg Current 
dose 
No Adjustment-complete the 
cycle  
20mg 
>  +5 mmHg Current 
dose 
Current dose+5mg 25mg 
< 5 mmHg fall Current 
dose 
No Adjustment-complete the 
cycle  
20mg 
>5 mmHg fall and 
asymptomatic 
Current 
dose 
No Adjustment-complete the 
cycle  
20mg 
> -5 mmHg and symptomatic Current 
dose 
Current dose -5mg 15mg 
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Concomitant medications 
No new medications that could affect blood pressure will be introduced for the duration of this 
study. Subjects should not take any traditional medicine for at least 2 weeks prior to 
commencing the study, and throughout the conduct of the study. During the study, subjects are 
advised not to take any other anti-hypertensive medications other than medications(s) they 
were on at the start of the study. If concomitant medication is unavoidable in case of 
emergency, the use must be reported in the patient’s diary (comment log) (dose and time of 
administration) and possible effects on the study outcome must be addressed. All other 
medicines the patient takes will remain constant for the duration of the equivalence test.  
Education and instruction for subjects 
To be included participants should be able to demonstrate that they can measure and record 
their BP appropriately. Before randomization, each eligible participant will be trained using a 
standardized protocol for home BP measurement. Subjects will be trained about the basic 
methods of BP self-measurement, the meaning of BP values, and the monitoring device to be 
used by the principal investigator and study physician. Each patient will be given a digital home 
blood pressure monitors. Subjects will be instructed to measure their BP three consecutive 
times in the sitting position in the morning before breakfast and in the evening after dinner. 
They will also be asked to visit the study site for follow up on a weekly basis.  They will be 
asked to take the respective study medication in the sitting position together with 250 ml water 
at the same time each day.  
Sample size estimation 
The sample size for the individual N-of-1 trial is 30 BP readings (two times a day, 3 times each 
time) taken from the last 5-days of each trial period.  The selection of a five day period of 
usable data in our study and the numbers of BP readings required to sufficiently determine 
whether the local Enalapril is based on a previous  N-of-1 trial of Enalapril by Chatellier et 
al98.  Their investigation included two successive studies. In study 1, the variance of systolic 
and diastolic BP and the choice of treatment period duration were determined in 35 
hypertensive patients who remained untreated during the measurements. In study 2, a series of 
individual N-of-1 trials of identical design was performed after study 1 completion in 44 other 
consecutive patients. The first phase of the study reported that a period of 5 consecutive days 
of BP measurement is sufficient to detect a drug-induced fall in BP in a single patient 
accurately, provided that there are at least 30 readings in each 5-day trial period. However, the 
study did not consider washout period and the individual agreement between the two cycles 
was only moderate at best. The authors recommended a trial of longer periods with three cycles. 
The 5-day period is a compromise between acceptability of the length of the individual trial 
and the reduction of variance allowed by the repetition of measurements with time. 
 
An audit of sample sizes for pilot and feasibility trials undertaken in the United Kingdom 
reported that the median sample size for pilot trials were 30 participants per arm257. We assume 
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that a sample size of 30 patients is adequate to assess feasibility. Considering a 10% drop out, 
a total of 33 participants will be included in the study. Only 10% drop out was considered based 
on low dropout rate history from a previous cholera trial258.  
Outcome measures  
The study physician will assess the patient before and after each treatment period (each week) 
and collect home BP measurement and side effect recording forms from the previous week.  
Primary Outcome:  
Therapeutic equivalence will be assessed by calculating change in mean seated systolic blood 
pressure (SBP). The minimal clinically important difference (MCID) is the smallest treatment 
effect that would lead to a change in a patient's management259. Based on the literature260, an 
average SBP difference of 5 mm Hg is accepted as MCID. A difference of <5 mm Hg SBP 
between the two treatments is therefore considered to be of no clinical importance. Clinically 
important differences can be defined using a predefined MCID and confidence interval of the 
difference of the two treatments261 -figure 7.2. 
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Clinical importance can take 4 forms, depending on the relationship of the point estimate and 
the 95% CI surrounding to the predetermined acceptable clinical difference (+ MICD)261: 
1. Definite – when the MCID is smaller than the lower limit of the 95% CI; 
2. Probable – when the MCID is greater than the lower limit of the 95% CI, but 
smaller than the point estimate of the efficacy of the intervention; 
3. Possible – when the MCID is less than the upper limit of the 95% CI, but greater 
than the point estimate of the efficacy of the intervention; and 
4. Definitely not – when the MCID is greater than the upper limit of the 95% CI. 
Criteria to establish therapeutic equivalence: 
a) Absence of a clinically important difference- for therapies to be considered equivalent, 
not only should the comparison of the efficacies of the two interventions not reach 
 131 | P a g e  
 
statistical significance, but also the upper limit of the confidence interval should be 
smaller than the predetermined MCID 
b) Equivalence should be evident in at least in two cycles out of three.  
Secondary Outcomes:  
1. Change in mean home diastolic blood pressure (DBP) for both evening and morning 
diastolic BP values 
2. Change in mean clinic DBP  
3. Change in mean clinic SBP  
4. Change in mean home DBP measured in the morning, 24 hours after drug intake. 
5. Change in mean home DBP measured in the evening, 12 hours after drug intake. 
6. Change in mean home SBP measured in the evening, 12 hours after drug intake. 
7. Change in mean home SBP measured in the morning, 24 hours after drug intake. 
 
8. Feasibility outcome: Based on literature262, the following criteria will be used to 
measure success/acceptability of the pilot study:  
 (a) Recruitment rate: at least 70% of all eligible patients can be recruited , 
 (b) Completion rate: at least 80% of all recruited subjects complete the study, 
 (c) At least 90% of patients took every scheduled dose of the study drug, and 
 (d) More than 80% of requested measurements are obtained and valid. 
Measurements are considered invalid when either or both of systolic and 
diastolic BP readings are not compatible (less than 20 mm Hg difference). 
(e) Patients and phycisians view on the trial 
9. Safety outcomes:  Adverse events (number, severity) identified by patients recording. 
AEs recorded by physician on AE CRF. 
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Figure 7.3. Flow of participants through study 
* This washout period does not exist physically, it is an analytic washout period. Blood 
Pressure measurements taken in the first two days of each period will be discarded during the 
analysis stage to allow for washout.  
Establishing controlled BP  
In this study, those with an average clinic BP measurement controlled at 140/90 mmHg or less 
for up to twelve months will be included.   This is because there is a considerable placebo effect 
for antihypertensive medicines, which increases after 1 year263.  Hypertensive patients who 
have follow-up in ALERT hospital usually have a monthly visit schedule.  To account for BP 
variations including seasonal ones, BP will be established by taking the average of three 
consecutive BP measurements taken in at least the last two months.  
Using home BP measurement  
BP self-measurement at home has been shown to be a sensitive tool, able to detect small 
changes, frequently resulting in reduced variability and greater reproducibility of 
measurements compared to office BP readings264,265. BP self-measurement eliminates the 
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white-coat effect266. It also provides better prediction of organ damage than clinic BP 
measurement267,268 and reduces the number of subjects necessary for meaningful results in drug 
trials269,270. The average systolic BP over five days is used to assess the effectiveness of 
treatment. Frequent measurement of BP over 5 days narrows the variability of BP around the 
true mean BP value271. Frequent measurement of BP improves diagnostic and management 
capacity272,273. BP should be recorded immediately in a study diary.  
BP self-monitoring device  
Clinically validated digital BP machine will be used for home blood measurement. Home BP 
measurement protocol is developed using standard methodology274. Before use by patients, the 
accuracy of each machine will be verified at the clinic/trial center. 
Safety Evaluation and monitoring 
Because this is a study of medication that the patient has been taking, the risk of serious adverse 
events is minimal. All abnormal or unpleasant effects from medications will be considered as 
side effects. Individual patients will collect common side effects using a questionnaire at home 
and bring it during their weekly visits. If a patient develops serious side effect, the study 
physician will take appropriate measure.  The most common side effects of Enalapril include 
increased serum creatinine (20%), dizziness (2–8%), low blood pressure (1–7%), syncope 
(2%), and dry cough (1–2%). The most serious common adverse event is angioedema 
(swelling) (0.68%) which often affects the face and lips, endangering the patient’s airway. 
The DSMB consists of two senior members with clinical and methodological expertise who 
are independent of the trial. They will review all documented harms during the study and 
adjudicate them with regard to causality. 
Study withdrawal or interruption 
If a concomitant medication has to be taken that might influence blood pressure that person 
will cease the trial until the new medicine has ceased or the dose has been stable for at least 
two weeks. If they wish, the participant can restart the study, substituting a new randomly 
packed cycle of medicines for the interrupted cycle.  Unused medicines from the trial will be 
discarded. If the person has to continue on the new medicine, the trial will cease, and the data 
collected will be analysed, if at least one cycle has been completed.  
Participants will also be withdrawn from the study under the following conditions:  
1) Patient request, patient non-compliance, or development of an exclusion criterion. 
2) If, in the opinion of the treating clinician, the patient's interests are best served by 
withdrawing from the trial. 
Data analysis and study result report 
Individual study result report  
At the end of the trial, BP measurements will be analyzed and the result will be given to the 
treating physician. After looking at these results, the patient and the treating physician will be 
able to decide if the local drug works for treating the hypertension. 
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Statistical methods  
Analysis will be conducted based on BP measurements taken in the last 5 days of each of the 
six periods.  The first two days’ BP measurements in each period will be discarded. Based on 
literature260, 6 mm Hg is accepted as MCID. Therefore a systolic blood pressure difference of 
>5 is considered clinically significant. A mean change in evening SBP of < 5 mm Hg between 
the two test medicines in at least two treatment cycles will be considered as representing 
therapeutic equivalence. 
Differences in treatment means will be explored graphically, and through the paired Student’s 
t test as appropriate. Significance will be set at P <0.05. The data will also be modelled within 
a linear mixed effects modelling framework to account for repeated measures over time such 
that between and within patient variability can be captured (and estimated).  From such a 
model, population and individual estimates of treatment means can be obtained, and the 
influence of additional variables such as treatment order can be accounted for (if needed).  This 
statistical analysis will be undertaken in the R package. 
The type and severity of possible side effects of the study medication and any serious adverse 
events will be tabulated for individual patients.  
Data management 
Data that will be generated in this study will be appropriately documented and checked for 
validity and accuracy. Study data will be managed using R-package.  Data from paper CRFs 
will be double entered into the database by two persons independently so that data will be 
matched and checked for validity and accuracy before being endorsed for analysis. Problems 
with incomplete and missing data will be resolved in the following ways. If a patient missed a 
day of BP measurement, we will provide a mean score for that period. However, if there are 
more than or equal to two days data missing, we will not provide a score for that period and 
that will be indicated in the patient’s report. As per ICH Good Clinical Practice (GCP) 
guidelines, the investigators will maintain information in the study subjects’ records which 
corroborates data collected and entered into the CRFs. 
Discussion 
The number of local pharmaceutical companies that market their products such as Enalapril 
without proof of bioequivalence is dramatically increasing. The Ethiopian guideline for 
registration of medicines requires clinical trial evidence on the occasions when 
pharmacokinetic bioequivalence is not available. The guideline states that when in vivo studies 
using plasma concentration time–profile data are not suitable, a comparative clinical trial then 
has to be performed to demonstrate equivalence between two formulations. However, as stated 
in the background, in East Africa including Ethiopia, local generics are marketed without 
evidence of effectiveness obtained through bioequivalence studies or clinical trials.  
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By bridging the information gap on bioequivalence, this trial will provide rigorous evidence on 
therapeutic equivalence of a local brand of Enalapril with a German brand in individuals. If 
there is no difference, the hypothesised result, then Ethiopian citizens can take the cheaper local 
medicine with confidence.  
 
Moreover, compared to parallel RCTs, aggregated N-of-1 BE trials can produce generalizable 
data using a smaller sample size, allowing efficient use of resources in developing countries.  
Hence, this trial will determine whether aggregated N-of-1 studies are feasible to provide a 
population level estimate of clinical equivalence for untested generic drugs in resource-limited 
countries, where bioequivalence testing centers are unavailable.  If therapeutic equivalence at 
a population level is shown, it will encourage use of cheaper local drugs by enhancing reliance 
on local pharmaceutical companies.  
 
Strengths and limitations of the study. 
Patients involved in this trial are not blinded. While double blinding is an ideal option, the need 
to adapt to local conditions is also very important. Apart from logistic issues (lack of 
encapsulation machine locally), keeping the design less complex would make the trial resemble 
the usual way of comparing medicine effectiveness in individuals by switching drugs,  except 
that it is pre-planned, randomised and closely monitored275. In this trial, blinding/unblinding of 
patients is a compromise between feasibility and minimal potential effects on reported 
outcomes. The outcome of the study (blood pressure) could be affected more than other 
possible, but not feasible, outcomes (e.g. renin levels or death). On the other hand, the use of 
electronic blood pressure devices will help in standardizing the measure. Study medications 
are prepared by an independent pharmacy unit. Therefore, study investigators and DSMB 
members will be blinded.  A review of relevant literature found that three N-of-1 papers, 
including one protocol publication on hypertension were not fully blinded3,98,275 .   
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Summary 
By drawing lessons from the qualitative feasibility studies, several amendments and 
improvements were made in the protocol before IRB application. The next chapter presented 
the results of the study along with unexpected regulatory challenges and regulatory decisions 
which came up at the final stage of patient recruitment.    
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CHAPTER 8: RESULT OF PILOT N-OF-1 BIOEQUIVALENCE TRIALS 
8.1. Background: bioequivalence analysis approaches 
In the protocol (chapter 7), two methods of establishing equivalence were proposed: one in 
which bioequivalence data in each of the three cycles per patient are considered separately and 
a second method where analysis is made based on the overall bioequivalent data combined 
from the three cycles per patient.  In this study, we decided that the use of the second approach 
(using an average total treatment difference calculated from the 3 cycles combined) was more 
logical and appropriate. This is because evaluation of bioequivalence by analysing BP 
difference in each cycle, especially combining data when bioequivalence results are not 
consistent across cycles, is difficult. For example, a patient could have the following 3 different 
results from the 3 cycles: possible, probable and definite anti-hypertensive equivalence. 
Moreover, depending on the purpose of analysis, two approaches of analysis were proposed in 
the protocol.  
Paired T test: First approach - a T test analysis using BP differences calculated from the 3 
cycles combined in each patient was used to demonstrate therapeutic equivalence of local drugs 
at an individual patient level i.e. to generate individual patient reports for the purpose of 
assisting clinical decision-making in each patient. An example of an individual patient report 
is attached (appendix G). In this approach, treatment (formulation) difference is considered as 
the only independent factor and does not account for block and period (treatment carryover) 
effects.    
Linear mixed model - a mixed effects model for BP difference was fitted for 3 cycles 
combined for 32 patients. The second objective of the pilot trial was to assess whether 
aggregated N-of-1 trials can be used to estimate BE i.e. to test the hypothesis that local 
medicines are as bioequivalent as the standard brand formulation. In this approach, in addition 
to the effect of treatment difference across all patients, other sources of variation- factors like 
formulation-by-subject interactions, block and period can be accounted for. Individual 
treatment (patient-by-formulation interaction) effects are assumed as a random effect. This 
model also allows analysis of missed data.  
8.2. Results 
8.2.1. Socio-demographic characteristics of participants  
A total of 33 patients completed the pilot- sex ratio 22 females: 11males, age range from 39-
75 years old (with average 60.23±9.77 years old), duration of hypertension from 1-27 years 
(mean: 7.84 years range 1-27) –Table -8.1.  
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Table 8.1: Characteristics of patients  
Variables Frequency  
Age  X± SD 60.23± 9.77 
Sex  F/M 22/11 
Literacy level Can read and write 20 
Can’t read and write 13 
Body mass Index (BMI) 18-25 21 
25-31 8 
>31 4 
X±SD 25.05±3.34 
Duration of HN (yrs.) X, range  7.84 , 1-27  
Anti-hypertensive medication the 
patient is taking 
Enalapril only 21 
Enalapril containing 
regimen 
12 
Dose of Enalapril 10mg 26 
5mg 7 
Form of Enalapril (Brand) patient 
was taking previously 
Local Enalapril version  33 
Imported Enalapril version  0 
Source of medication expenditure  Free-gov't scheme 32 
Out of pocket expenditure 1 
Insurance 0 
Out of the 33 patients enrolled, 31 patients completed the full 3 treatment cycles and 1 patient 
completed only the first treatment cycle (the patient withdrew on the second cycle because of 
exacerbation of gastritis which was not related to study medications).  The remaining patient 
withdrew on the first cycle because the assistant (the patient’s daughter) moved to another place 
for personal reasons and the patient could not complete study forms due to illiteracy. Hence, 
data from 32 patients were included in linear mixed model of analysis. Armauer Hanson 
Research Institute (AHRI) provided an N-of-1 trial service to the hospital through a patient 
referral-feedback model. 
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8.2.2. Therapeutic equivalence 
 
 
 
 
 
 
 
 
  
 
   
 
 
 
 
 
 
 
 
 
 
 
Systolic Blood Pressure (SBP)  
At group level  
The mixed model showed that there was 
no important SBP difference between the 
two formulations (P value, 0.203). Also 
there was no significant block/B/ effect (P 
value, 0.1529 and 0.4159 for B2 and B3 
respectively). However, there was a 
significant difference between morning 
and afternoon (P value, 0.007). A 
significant variability between variance of 
SBP within individuals and between 
individuals was observed. The intraclass 
correlation coefficient (ICC ID), which is 
the proportion of SBP variance due to 
individual difference is 54% - see table 8.2 
At individual level 
For the primary outcome measurement 
(SBP), there was large difference in 
average treatment difference between 
individuals:  the drugs were definitely 
equivalent in only 19/32 (59%) of 
patients. The proportion of patients where 
definite therapeutic equivalence was not 
achieved is large (13/32: 41%), but similar 
for the two formulations. I.e. both 
treatments were probably/possibly 
equivalent in these 13 patients 
(approximately equal numbers favoured 
the local and the imported)-Figure 8.1. In 
addition, both medicines effectively 
maintained BP at acceptable levels during 
the whole trial in all patients –table 8.3. 
                                                          
Table 8.2: A random mixed model for 
predictors of change in the average SBP 
among 32 patients 
Predictors Value       CI P value 
Treatment, B -0.84 -2.14 – 0.45 0.203 
Time, Morning -0.75 -1.30 – -0.21 0.007 
Block 2 -1.18 -2.01–-0.35 0.1529 
Block 3 -0.73 -1.62– 0.16 0.4159 
Gender, Male -0.89 -7.70 – 5.92 0.798 
Age 0.12 -0.21 – 0.45 0.468 
ICC ID : 0.54 
ICC ID 0.54 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 6 - Patient level random effect 
(95% CI for the ASBP difference) 
Envas Equivalence 
limit 
EnaDen
k 
MmHg 
8.1: 
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Table 8.3: Point estimate (PE) and 95% CI of mean difference (MD) in average 
systolic blood pressure (ASBP) in individual patients by time of the day 
Cases 
Evening Morning 
X (in mmHg) 
MD| (95%CI) 
X (in mmHg) 
MD| (95%CI) 
Envas EnaDenk Envas EnaDenk 
N101 102.23 94.82 7.40 (3.37,11.4) 99.09 97.08 2.01 (-1.79,5.81) 
N102 116.24 116.70 -0.47 (-4.35,3.42) 120.38 122.34 -1.96 (-5.80,1.89) 
N103 122.38 118.87 3.51 (-0.40,7.43) 110.47 113.84 -3.38 (-6.27,-0.49) 
N104 130.29 132.91 -2.63 (-5.11,-.14) 120.40 118.64 1.76 (-1.47,4.99) 
N105 116.91 118.67 -1.76 (-5.63,2.12) 122.24 126.40 -4.16 (-6.46,-1.85) 
N106 117.43 110.89 6.54 (2.39,0.68) 121.29 113.02 8.27 (2.98,13.55) 
N107 117.33 119.60 -2.26 (-6.14,1.61) 118.49 111.22 7.27 (3.63,10.89) 
N108 111.51 111.91 -0.40 (-4.40,3.60) 114.82 116.02 -1.20 (-5.19,2.79) 
N109 138.33 147.11 -8.78 (-14.15,-3) 137.33 146.89 -9.56 (-16.2,-2.95) 
N110 139.60 140.76 -1.16 (-6.79,4.5) 146.38 140.64 5.73 (-0.89,12.4) 
N111 115.84 121.76 -5.91 (-9.88,-1.9) 121.47 124.98 -3.51 (-7.75,0.73) 
N112 112.69 116.02 -3.33 (-7.95,1.28) 105.16 111.78 -6.62 (-11.4,-1.87) 
N113 122.00 118.78 3.22 (0.75,5.69,) 112.84 111.56 1.29 (-1.64,4.21) 
N114 137.70 140.47 -2.77 (-7.11,1.57) 126.83 132.13 -5.30 (-10.9,0.31) 
N115 128.76 128.67 0.10 (-3.19,3.38) 130.58 130.56 0.02 (-2.75,2.79) 
N116 123.04 125.96 -2.91 (-8.51,2.69) 114.44 117.62 -3.18 (-7.46,1.10) 
N117 110.44 107.62 2.82 (0.06,5.58) 107.87 110.27 -2.40 (-4.26,-.54) 
N118 124.91 127.98 -3.07 (-6.55,0.41) 125.71 127.48 -1.77 (-6.59,3.06) 
N119 112.60 112.60 0.00 (-5.97,5.97) 113.40 113.47 -0.07 (-5.13,5.0) 
N120 114.80 109.07 5.73 (1.83,9.64) 111.29 115.80 -4.51 (-7.77,-1.25) 
N121 109.36 108.04 1.31 (-0.53,3.15) 104.29 106.78 -2.49 (-5.12,0.14) 
N122 114.56 118.60 -4.04 (-6.32,-1.8) 110.40 109.91 0.49 (-1.84,2.82) 
N123 128.98 125.24 3.74 (-0.59,8.07) 127.69 132.04 -4.36 (-9.22,0.50) 
N124 128.02 127.93 0.09 (-5.35,5.53) 123.59 116.84 6.74 (3.16,10.32) 
N125 119.80 125.82 -6.02 (-11.2,-.89) 123.18 127.27 -4.09 (-9.09,0.92) 
N126 119.38 121.91 -2.53 (-8.57,3.49) 123.76 123.84 -0.09 (-4.79,4.61) 
N127 116.43 110.70 5.73 (1.75,9.71) 118.07 122.60 -4.53 (-8.64,-.42) 
N128 111.82 111.38 0.44 (-2.75,3.64) 109.98 111.13 -1.16 (-4.04,1.73) 
N129 116.00 114.87 1.13 (-2.70,4.96) 126.29 115.11 1128 (5.29,17.07) 
N130 119.56 130.16 -10.6 (-16.4,-4.8) 132.56 138.18 -5.62 (-10.3,-.97) 
N131 138.33 140.80 -2.47 (-6.42,1.48) 135.90 143.27 -7.37 (-12.15,-2.6) 
N133 128.53 134.47 -5.93 (-9.69,-2.2) 119.91 120.73 -0.82 (-5.08,3.44) 
Overall 120.5 122.1 
 
-1.7 (-2.3,0.4) 119.8 120.4 -0.65 (-1.7, 0.3) 
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Diastolic Blood Pressure (DBP)  
At group level, the model showed that there 
was no important difference between the two 
formulations (P value, 0.203) in terms of 
controlling DBP-see Table 4 below.  In 
addition to the group level analysis, 
individual analysis showed that both 
treatments were definitely equivalent in all 
individual patients in terms of controlling 
DBP- figure 8.2. Although, there was a slight 
difference between morning and afternoon 
DBP (table 8.5), it was not statistically 
significant (P value, 0.898) - Table 8.4. 
However, a significant variability within 
individuals was observed. The intraclass 
correlation coefficient (ICC ID), which is the 
proportion of DBP variance due to individual 
difference is 49% - see Table 8.4.  
Table 8.4: A random mixed model for 
predictors of change in the average DBP 
among 32 patients.  
Predictors Value       CI P 
value 
Treatment, B -0.33 -1.03 – 0.37 0.356 
Time, Morning -0.02 -0.35 – 0.30 0.898 
Block 2 -0.48 -0.88 – 0.58 0.19 
Block 3 -0.81 -1.22 – 0.40 0.6 
Random Effects 
ICC ID 0.49 
    
 
 
F 
 
 
 
Figure 8.2- Patient level random effect                    
(95% CI for the average DBP) 
 
Envas 
Equivalence 
limit 
EnaDenk 
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Table 8.5: Point estimate (PE) and 95% CI of mean difference (MD) in average 
diastolic blood pressure (ADBP) in individual patients by time of the day 
Cases 
Evening Morning 
X (in mmHg) 
MD| (95%CI) 
X (in mmHg) 
MD| (95%CI) 
Envas EnaDenk Envas EnaDenk 
N101 70.29 66.84 3.44 (1.35,5.53) 67.02 66.29 0.73 (-1.12,2.59) 
N102 86.28 83.09 3.19 (0.74,5.64) 87.60 88.62 -1.02 (-3.78,1.73) 
N103 85.53 84.56 0.98 (-1.26,3.21) 83.53 83.87 -0.33 (-2.15,1.48) 
N104 85.38 86.00 -0.62 (-2.53,1.29) 77.79 75.84 1.94 (-0.0,3.88) 
N105 85.26 86.11 -0.85 (-2.75,1.06) 76.29 77.24 -0.96 (-2.93,1.01) 
N106 65.88 65.11 0.77 (-1.39,2.93) 67.38 66.73 0.64 (-1.37,2.66) 
N107 78.11 76.64 1.47 (-1.61,4.54) 78.49 72.29 6.20 (3.59,8.80) 
N108 71.49 72.76 -1.27 (-3.44,0.91) 75.04 76.20 -1.16 (-3.09,0.78) 
N109 74.78 76.93 -2.16 (-4.71,0.40) 74.87 77.93 -3.07 (-5.41,-0.72) 
N110 74.07 77.04 -2.98 (-5.61,-0.3) 80.67 80.93 -0.27 (-2.87,2.34) 
N111 78.36 81.56 -3.20 (-5.47,-0.9) 79.47 81.98 -2.51 (-5.18,0.16) 
N112 65.36 67.00 -1.64 (-4.5,1.21) 63.67 68.27 -4.60 (-7.95,-1.24) 
N113 81.49 80.93 0.56 (-1.03,2.16) 78.04 75.93 2.11 (0.87,3.34) 
N114 82.00 84.03 -2.03 (-4.55,0.48) 82.03 74.63 7.40 (3.06,11.73) 
N115 84.05 84.22 -0.17 (-2.27,1.93) 87.69 87.27 0.42 (-1.24,2.08) 
N116 84.69 86.56 -1.87 (-5.64, 1.9) 80.96 79.18 1.78 (-0.81,4.36) 
N117 75.76 75.80 -0.04 (-1.80,1.71) 75.38 77.67 -2.29 (-3.63,-0.9) 
N118 85.90 90.18 -4.27 (-6.30,-2.2) 90.20 90.50 -0.30 (-2.41,1.81) 
N119 59.60 64.73 -5.13 (-8.89,-1.4) 64.87 65.40 -0.53 (-2.86,1.79) 
N120 88.40 83.38 5.03 (2.42,7.62) 88.47 90.84 -2.38 (-4.34,-0.41) 
N121 77.87 77.00 0.87 (-1.09,2.83) 73.13 75.76 -2.62 (-4.48,-0.7) 
N122 87.17 88.31 -1.14 (-2.76,0.48) 84.87 83.47 1.40 (0.11,2.69) 
N123 83.67 84.76 -1.10 (-3.32,1.13) 85.56 87.24 -1.69 (-3.89,0.51) 
N124 76.05 73.78 2.27 (0.49,4.04) 74.20 70.29 3.91 (-0.62,8.45) 
N125 78.40 79.84 -1.44 (-4.85,1.97) 80.18 81.64 -1.47 (-3.72,0.78) 
N126 68.29 68.53 -0.25 9-4.49,3.9) 70.45 69.89 0.56 (-3.03,4.15) 
N127 66.26 64.97 1.29 (-1.42,4.00) 66.47 68.30 -1.83 (-5.32,1.66) 
N128 77.55 77.71 -0.17 (-1.41,1.74) 71.71 74.96 -3.24 (-5.25,-1.2) 
N129 71.93 72.07 -0.14 (-2.48,2.21) 79.02 72.18 6.84 (3.83,9.85) 
N130 73.44 76.79 -3.35 (-5.86,-0.8) 78.60 81.22 -2.62 (-4.53,-0.7) 
N131 73.53 79.07 -5.53 (-8.48,-2.6) 78.27 80.73 -2.47 (-5.35,0.42) 
N133 71.47 74.17 -2.70 (-5.58,0.18) 78.20 79.93 -1.73 (-3.99,0.53) 
Overall 77.5 78.2 -0.7 ( -1.4, -0.1) 77.8 77.9 -0.03 (-0.7,0.6) 
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8.2.3. Safety assessment  
There was no safety difference between the two generic formulations as measured by number 
of cycles in which the difference in number of side effects between the formulations is <1, 
which is at least two out of the three cycles (appendix C-individual safety result for 32 patients). 
There was no serious adverse event related to either generic formulation. To assist clinical 
decision making, the number and type of side effects were included in the patient report Table 
8.6.  
Table 8.6: an example safety evaluation in individual patient report 
Number of Cycles/treatment pairs 
Number of side effects 
Envas EnaDenk 
Treatment pair 1 0 0 
Treatment pair 2 0 0 
Treatment pair 3 0    2* 
*(mild headache for 1 day, dizziness for 2 days) 
8.2.4. Feasibility success factors 
Most N-of-1 trials design (randomization, repetition, washout, blinding (partially), and 
systematic outcomes measurement as well as BE specific methodological requirements 
(selection of reference drug, study endpoint(s), bioequivalence limit and statistical analysis) 
were met. This feasibility study had successful recruitment (33/35:94%) and completion rates 
(31/33: 93%). There was a satisfactory level of protocol adherence as measured by number of 
BP measurements and scheduled doses taken. Based on the primary outcome (SBP), 5522 of 
the 5760 (95.8%) measurements requested were obtained. Similarly, out of the 960 scheduled 
doses, only 6 were missed.   
Limited feedback data are available from patients and physicians. Early indications are that 
patients have more confidence in the locally produced product than before.  Physicians 
similarly felt more empowered.  
Management of missed data  
Patient N119: At the end of the third treatment period, this patient withdrew from the study as 
she was suffering from gastritis which was not related to the study. The first 3 weeks data were 
included in the analysis.  
Patient N132: During the 4th treatment period, the patients BP was noticed to be high and upon 
detailed examination of trial records, it is observed that the patient’s BP was uncontrolled since 
enrolment. Hence, based on the study protocol, starting from the 4th period, study medication 
for this patient was increased by 5mg to 10mg daily. Similarly, only the first 3 weeks’ data 
were included for this patient.  
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Patient N114: During the first week clinic visit, it was confirmed that this patient has continued 
taking the test drug she had been taking before while stopping the other antihypertensive drugs 
(nifedipine), a drug which she was advised to continue taking. As well, both legibility of 
records and number of BPs taken were not appropriate in the first treatment cycle). Therefore, 
data from the first cycle was not included in the analyses.   
Patient N127: Due to inconveniences related to patient assistant, the last period (6 week) data 
was not obtained from this patient, hence was not included in the analysis.  
Patient N121: Due to a randomization error, during the 4th treatment period, the patient was 
randomized to the same drug that the patient had been administered. To manage this, data for 
period (week) 4 was discarded and cycle 3 was extended to 3 periods. During the 
analysis phase, cycle 1 was analysed normally, Cycle 2 – treatment from the first week was 
compared with treatment in the second week of cycle three and compared with the response to 
treatments from week 5 and week 7 of Cycle 3. 
8.2.5. Unanticipated decision by the Ethiopian regulatory authority 
The regulatory authority became aware of the trial when it was nearly completed, and made an 
official decision that the study required their approval and oversight. The authority restricted 
the dissemination of trial data for any purpose. 
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CHAPTER 9- DISCUSSION 
This project examined three broad factors (need, method and barriers), which are affected by 
different parameters, to determine the feasibility of using N-of-1 bioequivalence (BE) trials to 
assess equivalence of local medicines in use in clinical practice in Ethiopia.  
The central aim of the studies presented in Chapters 4-6 was to demonstrate research need and 
to explore and address key barriers that could impact the use of the N-of-1 BE approach for 
testing local medicines. The overarching aim of the study presented in Chapter 8 was to assess 
the practical feasibility of the proposed bioequivalence method. This chapter discussed the key 
feasibility areas: factors that were addressed in this project and those identified as areas that 
needed improvement (Figure 9.1). The most pressing issues that impeded the feasibility of N-
of-1 BE trials came from the local regulatory authority, which is the primarily responsible body 
for ensuring the availability, quality and safety of medicines in the country. Therefore, this 
chapter focusses on the regulatory authority’s views and decisions, followed by future 
directions in the design and implementation of N-of-1 BE trials in Ethiopia.   
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Figure 9.1: Summary of feasibility factors and areas in which major changes are 
needed 
Study Findings in different study feasibility areas 
Areas in which major 
changes are needed 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Acceptability 
of N-of-1 BE 
study and its 
implementat-
ion. 
 
1-The need for and acceptability of the 
proposed N-of-1 BE method  
(a)-Uncertainty about local medicines: 
There is concern by many patients, physicians and 
IRB members. However, the regulatory authority 
believed these drugs to be therapeutically 
equivalent.  
(b)-Acceptability of N-of-1 BE method: 
A Considerable support from IRB members, 
patients and physicians. A few physicians were 
concerned that the cheaper local drugs may be less 
effective. However, the regulatory authority did 
not support the proposed study and emphasised the 
negative implications of the study. 
 
Views about 
local 
generic 
medicines 
 
Barriers to 
conducting 
trials in 
developing 
countries  
 
2-Barriers to conduct of the study 
(a)-Ethical feasibility: IRB participants 
believed that IRB approval was sufficient 
during the qualitative interview and later 
provided an approval letter to conduct the pilot 
study.         
(b)-Regulatory feasibility: Members of the 
authority made an inconclusive brief comment 
during interview but issued a notification letter 
not to disseminate trial results at the final stage 
of the pilot study. 
(c)-Other implementation barriers: 
Structural and operational issues including lack 
of encapsulation machine and international 
standard comparator drug not available in the 
local market. 
(1)-Lack of consensus 
regarding concerns 
about and the need for 
testing local medicines 
between regulatory and 
other parties. 
(2)-Lack of consensus 
on ethical and regulatory 
requirements between 
IRB and the regulatory 
authority.  
(3)- Issues in selection of 
reference comparator 
drug and study blinding. 
(4)- Cost reimbursement 
issues for expensive 
drugs.   
 
 
 
 
 
 
3.  
 
 
Pilot N-of-1 
BE trials 
3 - Methodological feasibility success 
factors 
 (a)-Most design and methodological 
requirements of BE studies as well as those 
specific to N-of-1 trials were met; 
 (b)-Successful recruitment (94%) and 
completion rate (93%); and 
 (c)-High level of protocol adherence. 
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9.1. Research need about local medicines  
BE testing is a requirement for effective generic drug substitution. Therefore, the need to 
research  local medicines is partly based on general negative perceptions about local medicines, 
as well as specific views and the consensus of stakeholders regarding the BE evidence gap 
related to these drugs.  Therefore, a qualitative study276 which involved a total of 31 
participants: 5 key informant interviews (two senior regulatory authority members and 3 IRB 
members) and 26 participants (14 physicians and 12 patients) in focus group discussions was 
conducted. The study identified four major themes; awareness of lack of bioequivalence 
profiles associated with local medicines, perceptions about the quality and effectiveness of 
local medicines, quality and efficacy of imported medicines from developing countries and 
quality and efficacy of cheaper medicines.  
The findings presented in Chapter 4 show, except for the two key informants of the regulatory 
authority and female patient participants who have a distinctly positive view, the majority of 
stakeholders involved in the study, including the IRB, were not confident about local 
medicines. Consistent with other studies in both developed and developing countries about 
perceptions of generic drugs164-166, there was higher rate of concern among physicians 
participating in this study. Besides, many physicians lacked detailed knowledge about 
bioequivalence and its clinical relevance, similar to previous studies which also reported low 
levels of knowledge about bioequivalence.  The issue of physicians lacking awareness of 
bioequivalence evidence is particularly important in clinical practice using local medicines. 
One study concluded that many physicians are making decisions regarding generic products on 
the basis of inaccurate perceptions and beliefs that assume more rigid standards for 
bioequivalence than the local authority generally requires180.   
Overall, the findings of the needs assessment demonstrated different expectations and priorities 
about local medicines between officials of the regulatory authority and other stakeholders (IRB 
members, physicians and patients). Lack of consensus on research need can be a major 
challenge for comparative studies of alternative treatments whenever there is confusion among 
experts regarding interpretation of the state of current evidence9. Therefore, the views of the 
authority would be a major challenge to the acceptability and implementation of quality 
assurance tools to address local evidence gaps. However, the need for bioequivalence evidence 
is evident in the local medicine regulatory authority guideline for registration of generic 
medicines5 and it is important to adhere to, and effectively implement it. Moreover, in the era 
of evidence-based medicine, health care systems are required to assess and address patients’ 
and clinicians’ beliefs, concerns and experiences of generic drug practice10,141. From this 
perspective, the availability of mixed views (between the authority and other stakeholders) is 
an opportunity to address quality issues by supporting and strengthening local regulatory 
infrastructure. The challenge is to create an atmosphere that encourages constructive debate 
and nurtures mutual responsibility among the regulatory authority, physicians, patients and 
IRB members, with the aim of improving the quality of local drugs. 
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9.2. Acceptability of the N-of-1 BE method and its implementation  
The central aim of Chapter 6 was to assess acceptability and identify key uncertainties around 
implementation of N-of-1 BE using the same qualitative method described in Chapter 4. The 
study showed substantial support from all stakeholders except key informants from the 
regulatory authority. Potential benefits of the study included: to identify affordable generic 
medicines, to check equivalence of drugs, to improve physician research skills and to address 
issues related to branding (due to the availability of different of generic formulations with 
different costs). There were mixed views regarding the effect that the study would have on the 
doctor-patient relationship. Some physicians were concerned because the study may affect the 
physician-patient relationship negatively if findings required patients to using a more expensive 
medicine.  
However, the study also identified issues for adopting this approach. In general, the issues can 
be grouped into four areas: (1) related to the intervention (2) related to the N-of-1 BE method 
(3) recruitment and retention and (4) ethical and regulatory issues. A summary of learnings for 
future trials is presented in Chapter 6, Table 2. The major learnings for the improvement and 
conduct of the proposed N-of-1 trial protocol included: including patients whose conditions are 
stable; requiring patient assistants for illiterate patients; establishing an N-of-1 delivery service; 
and information sharing including follow up discussion with IRB members.  However, as 
discussed in chapter 3, analysis and understanding of regulatory concerns and perspectives, 
particularly those related to the ethics of N-of-1 trials, remained uncertain during the decision-
making process about whether to proceed to the proposed pilot trial. This finding supported the 
result of the review article presented in Chapter 4142, which reported that regulatory challenges 
were among the top three barriers identified. However, apart from the need for a debate on 
whether IRB approval was necessary at all, imposing strict regulatory approval had not been 
reported as a challenge in the medical literature regarding N-of-1 trials1,129.  An in-depth 
discussion of issues and potential solutions, which are the key aspects of a feasibility study, 
was not possible due to a lack of willingness by the regulatory authority. On the other hand, 
addressing the needs and interests of patients and physicians10 as well as proper generic 
medicine practice according to the local guideline5 (the use of clinical BE approaches to 
demonstrate bioequivalence when the pharmacokinetic approach was not possible) 
necessitated implementation and evaluation of the practical feasibility of N-of-1 BE trials. 
Further discussion regarding the final regulatory decision, consequences and future 
recommendations is presented in the following sections.  
9.3. Feasibility of N-of-1 BE trials to assess anti-hypertensive equivalence of local 
medicines 
Chapters 7 and 8 presented the protocol and the results of N-of-1 BE trial respectively. The 
project explored the practical feasibility of the N-of-1 bioequivalence method (including the 
aggregated approach) to test local medicines in hypertension management, by assessing 
method, protocol adherence, recruitment and completion rates. A total of 33 patients was 
enrolled, and data from 32 patients were included in the analysis. Armauer Hanson Research 
Institute (AHRI) provided an N-of-1 trial service to the hospital through a patient referral-
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feedback model. The primary measure used to assess the bioequivalence of the local 
formulation (Envas) versus Ena-Denk was SBP.  
In the protocol, two methods of establishing equivalence were proposed: one in which 
bioequivalence data in each cycle are considered separately and a second method where 
analyses were made based on the overall bioequivalence data from the three cycles.  In this 
study, we decided that the use of the second approach was more logical and appropriate. First, 
one of the advantages of the mixed model of data analysis is that it can include factors like 
subjects, block, period and other potential sources of variability. Second, cycle-based analysis 
of data is not convenient to combine, and interpreting bioequivalence results can be challenging 
when results are not consistent across cycles. For example, a patient could have the following 
three different results in the three cycles: possible, probable and definite anti-hypertensive 
equivalence. 
The fixed effects linear model for all patients combined showed that, on a group level, the two 
Enalapril formulations were therapeutically equivalent. Both medicines also maintained BP at 
acceptable levels in all patients. However, at the individual level, definite equivalence (based 
on clinical bioequivalence limit of +/- 5mmHg difference between BP readings on each brand) 
was observed in 59% of patients only. In this study, the intra and inter subject variabilities were 
considerable. Intra-subject variability affects the result of a crossover BE study181. Variability 
could be due to intra-drug (intra-subject variability in responding to the active substance), intra-
formulation and inter-formulation differences181. Therefore, while it is possible that differences 
in individual BE could be due to inter-formulation (subject-by-formulation interaction) 
differences, the individual‐specific variabilities in average SBP are likely due to a combined 
effect of subject‐by‐formulation interaction, intra-subject variability in pharmacokinetics of 
Enalapril and intra-formulation/product variability (different batches of the same product).  
A similar crossover study among patients switched between two bioequivalent Nifedipine 
formulations concluded that while the average effect of formulation switches was minimal at 
the individual level, switching was associated with a 39% likelihood of an increase >6 mmHg 
nocturnal SBP (and hence a risky substitution)52. Heterogeneity in response to antihypertensive 
therapy has been known for decades, and several researchers who investigated factors that 
contributed to the inter-subject variability identified pharmacokinetics as one of the major 
causes of the variability in antihypertensive response79,80,100.  There, formulation and excipient 
differences could play a clinically significant role in individual pharmacokinetic and drug 
response differences. 
The significant difference in morning and evening measurements noted in the study indicates 
that the effect of once daily Enalapril blood pressure control did not last 24 hours in either 
formulation. A similar N-of-1 study on Enalapril reported that the fall in blood pressure was 
not maintained in the morning before the next dose was due, 24 hours after drug 
intake98. Hence, administration of anti-hypertensive medications should be in such a way that 
the maximum antihypertensive response occurs during time of likely rise in blood pressure 
(first thing in the morning), and the minimum effect during trough blood pressure values so as 
to reduce the risk of excessive hypotension99. As a result, twice-daily administration of 
Enalapril could be more effective than once-daily administration99.  
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Overall, the study showed that N-of-1 BE trials are methodologically feasible in resource 
limited settings. This finding supported the findings of similar studies which explored the 
feasibility of the N-of-1 approach to assess the effect of formulation differences in generic 
treatments in individual patients3,114.  Moreover, previous studies conducted both in developing 
and developed countries also concluded that N-of-1 trials are useful and applicable in 
hypertension studies3,98,121. However, the design and conduct of individual N-of-1 BE trials 
may not always be feasible in resource limited settings, where clinical uncertainty is due to a 
general lack of evidence. Therefore, one of the secondary objectives was to assess the 
feasibility of N-of-1 generating a population bioequivalence measure. The study achieved 
successful recruitment (94%) and completion rates (93%). Also, there was a high level of 
protocol adherence as measured by number of BP measurements and scheduled doses taken. 
9.4. Problems that occurred during the study 
As discussed, the first sections of the discussion chapter (more detail is available in chapters 4 
and 6), there were disagreements between the regulatory authority and other stakeholders – 
Table 9.1 summarizes areas of disagreement identified in the qualitative studies and their 
relationship to the final regulatory decision. As discussed in the methods chapter, Chapter 3, 
we thought we had addressed this problem when we made a decision to progress to pilot the 
proposed trial. And we thought we had all the necessary approvals. However, the regulatory 
authority became aware of the trial when it was nearly completed, and made an official decision 
that the study required their approval and oversight. 
We couldn’t fully understand the views and motives of the authority following the qualitative 
research work. Below are the main questions that needed to be analysed to understand what the 
problems were so that we can focus on what needs to be done next.  
® Was it lack of understanding regarding the proposed study?  
® Was it really a dispute about the research need?  
® Was it the authority’s lack of commitment to support studies that contribute knowledge 
to fill evidence gaps about local medicines?  
® Was regulatory approval mandatory to conduct N-of-1 BE trials in Ethiopia? 
 
9.5. Analysis of regulatory views, concerns and decisions-what they are and they are 
not?  
As shown in chapter 5, there was already public suspicion regarding the system’s capacity to 
provide quality medicines. The authority clearly understands the evidence gap and the public 
concern –the lack of willingness to comment on the bioequivalence evidence gap (chapter 4) 
emphasises the possible negative consequences of the proposed bioequivalence approach.  
Furthermore, the justification that the government has its own priority – encouraging the 
availability and use of local medicines - suggests that lack of consensus was probably not 
related to the research question. Hence the dispute is about the need for regulatory oversight, 
and not about the need for research. The authority was sensitive because they did not want to 
escalate public concern over local medicines. The approval and oversight of such studies would 
authorise them to regulate the process and control risks that they thought might happen. As a 
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result, the authority decided that the ethical approvals of both UQ and the local IRB were not 
sufficient.  
A recent review article by the African Medicines Regulatory Harmonization Initiative (AMRH) 
also concluded that there was lack of role clarity and transparency between national medicines 
regulatory authorities and national ethics committees182. Similarly, regulatory issues identified 
both from the qualitative study (chapter 6) and feasibility trial support the findings of 
the review paper regarding this barrier to conducting clinical trials in developing countries. 
However, this is the first study to report regulatory issues related to N-of-1 trials. One recent 
study in Netherlands130 reported a lack of consensus among health authorities on use of 
aggregated N-of-1 trials data.  However, the disagreement was not related to approval and 
oversight mandates. The Dutch Medicines Evaluation Board was presented with a hypothetical 
case to use the results of N-of-1 data aggregated from four patients for licensing and 
reimbursing purposes. However, the authority said that they would not be able to use such 
results in practice as they did not believe the design was appropriate to generate adequate 
effectiveness and safety evidence130.  
9.6. Why did the authority refuse AHRI’s appeal to reconsider their decision? 
In this section we discuss the possible reasons for not accepting the appeal made by the local 
institute hosting the research. First, the lack of BE evidence clouds the purpose of the study 
from the very start. Moreover, this PhD trial project was funded by the University of 
Queensland and hosted by a local research institute which is a pioneer in conducting clinical 
trials in Ethiopia. Hence, there may have been confusion by the authority regarding the purpose 
of the study: improving quality or generating evidence. Then, at the final stage of the pilot trial, 
the authority reviewed the protocol and made a decision that it was a clinical trial that needed 
their approval. The lack of skilled regulatory expertise182 compounded by the relative novelty 
of some of the components of the protocol, especially the purpose of aggregation and the linear 
mixed model proposed for this purpose, would have influenced the authority’s first decision 
and then later the decision to reject AHRI’s appeal to reconsider and review their decision. 
There were also concerns over who would cover the cost of expensive medication, if the study 
result turned out to be negative for a particular patient. However, ineffectiveness of an 
affordable local product does not have to be a serious problem. If cost was an issue for 
switching to the more expensive brand of Enalapril, it might mean that the physician has to 
consider an alternative (generic) medicine – for example a beta blocker or calcium channel 
blocker.  
9.7. Regulatory decisions and their implications for care and for addressing evidence 
gaps for current treatments-the need for addressing challenges urgently 
Regulatory issues about pragmatic research regarding the availability of treatment options need 
urgent attention. Developing countries are already behind the global clinical trial platform. Our 
review article identified several structural barriers which are complex to address, at least in the 
short term. Comparative research like N-of-1 tests can be done relatively easily with available 
resources and institutions. They require small numbers of participants, and it is easy to track 
patients and maintain clinical oversight of them during the trial. By contrast, regulatory 
oversight of conventional clinical trials may be considered more reasonable as there is limited 
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capacity to review and assess the safety issues associated with complex trials.   
Pragmatic trials of available, approved treatments conducted in clinical settings provide a 
feasible opportunity to improve care without the infrastructure, financial and human capacity 
required for bigger and more complex clinical trials. Part of the motivation for this study came 
from reports of a local pharmacovigilance system – a national system that gathers and 
disseminates treatment issues in clinical practice to regulatory authority. Thus, N-of-1 trials 
could be integrated to strengthen the local pharmacovigilance strategy.  
9.8. Our experience of the pilot trial and its correlation with findings of the barriers 
systematic review  
In chapter 5, a systematic review to assess barriers facing clinical researchers in developing 
countries for conducting clinical trials in their countries was reported. The findings of this study 
included five thematic barriers (lack of financial and human capacity, ethical and regulatory 
system obstacles, lack of research environment, operational barriers and competing demands). 
The review showed that the limited human and other resource capacity available in developing 
countries were the most important barriers. In contrast, a systematic review which reviewed 
barriers physicians face in conducting clinical trials identified lack of time as a major barrier 
in the developed world177. The emphasis must therefore be on training and strengthening 
research and regulatory capacity in developing countries.  
9.9. Using N-of-1 tests to improve drug quality and patient care- the way forward: 
the promise of the aggregated N-of-1 approach 
From the regulatory perspective, approval and oversight could be a strategy to address the 
quality expectations of society while supporting the local pharmaceutical industry at the same 
time. Compared with individual N-of-1 trials, the design and conduct of aggregated N-of-1 BE 
trials are more appealing as they allow direct engagement of the regulatory authority and local 
companies. Thus, the aggregated approach may be useful to create a balance between access 
and quality, a challenge facing many developing countries. Moreover, it would be a cost-
effective way to provide precision medicine while reducing evidence gaps.  
9.10. Strengths of the study 
The pilot trial had three methodological strengths: 
Complies both with N-of-1 and bioequivalence trial methodological requirements  
The pilot N-of-1 BE trial, which is the first of its kind in Africa, addresses the five elements of 
a well-designed N-of-1 trial in a reasonable manner. It also complies with most of the specific 
recommendations of bioequivalence studies.   
Use of a comprehensive data evaluation and reporting method  
A comprehensive reporting method that improves the translation of N-of-1 BE trial results into 
clinical practice is imperative. We proposed an integrated model of data evaluation with a 
treatment decision tree to enhance clinical decision making. The integrated model of data 
interpretation and reporting uses both clinical importance (based on a predetermined MICD) 
and statistical significance (CI) parameters to provide more flexible treatment outcomes261.  
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Since the model captures these four range of equivalence effects (ranging from rom definitely 
not equivalent, to possible or probable to definitely equivalent), a small difference in 
antihypertensive equivalence between two generic formulations can be included in the 
individual patient reports-see the attached patient report.  
Use of flexible criteria for safety (upper bioequivalence limit) and efficacy (lower 
bioequivalence limit) based on intra-subject variability, characteristics of the drug and its 
therapeutic window, was recommended. For example, when there is a small difference in 
controlling BP (eg when a cheaper generic medicine has a probably therapeutical equivalent 
anti-hypertensive effect, a small additional antihypertensive effect from a comparable but more 
expensive generic drug is not a sufficient factor to make treatment choice. In this case, the 
choice of drug should consider safety, patient condition, cost and acceptance by patient. To 
guide the clinical decision-making process effectively using the integrated model of data 
interpretation, we have developed a treatment decision tree tailed to the four possible BP 
bioequivalence results.  Appendix E - The use of the proposed model along with the treatment 
has three potential benefits; 
I. Clinical relevance: when there is no safety difference and the patients’ BPs are 
acceptably controlled, patients can be reassured that the local drug is safe and is reliable 
for controlling their BP effectively. For example, bias about local drugs can influence 
the optimal effect of BP control from these drugs. This clinical information is important 
to avoid negative attitudes and optimize treatment effects of local drugs.  
II. Accounts for cost and other factors in the treatment choice process: As mentioned, one 
of the concerns that physicians (and presumably one of the major factors contributing 
to the making of the negative regulatory decision) was related to the risk of negative 
bioequivalence results and their consequences on patient management and local 
pharmaceutical companies (Chapter 4 and 6).  
III.  The application of the integrated model would partly address the above concerns and 
maximize usability of N-of-1 BE results, while increasing reliability and evidence-based 
use of local medicines. At the same time, this will in turn enhance the acceptability of 
N-of-1 BE studies.  
 
The use of a linear mixed model to estimate individual and group level bioequivalence 
This is the first N-of-1 BE study to apply linear mixed modelling (LMM) to estimate individual 
and group level bioequivalence. This has a significant effect in terms of expanding N-of-1 BE 
services in resource limited countries in the following ways: 
Generates overall drug BE suitable for regulatory decision making: The general lack of 
bioequivalence information about local drugs is a major issue, and the contribution of 
individual N-of-1 BE studies in filling this huge gap is very limited. However, by using data 
from relatively few individual N-of-1 BE trials, this statistical model helps to generate 
population-level bioequivalence estimates which are suitable for regulatory decision making. 
This would potentially enhance the impact, acceptability and usability of N-of-1 BE services. 
For various reasons, the regulatory authority may not be convinced about the primary purpose 
of the N-of-1 BE approach alone, which is generating patient centred BE data to inform patient 
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care. However, if we are required to adhere to evidence-based medicine, we are optimistic that 
the authority would support N-of-1 BE approaches that contribute both to care and evidence 
that can inform regulatory decision making. Future discussions with the authority related to N-
of-1 BE proposals would be beneficial in applying LMM. This is because from the regulatory 
perspective, aggregated N-of-1 BE studies would enhance feasibility of future similar studies.  
I. Estimate BE at individual level: This is one of the primary reasons for conducting 
individual N-of-1 BE studies. When there is no clinically and statistically significant 
difference in bioequivalence, quality concerns about manufacturing can be ruled out. 
Simultaneously, the result of bioequivalence distribution (variability) at individual level 
could provide important information to inform clinical decision making.  
II. Cost of running N-of-1 trials is challenges in expanding N-of-1 services even in the 
developed world. The influence of financial barriers for conducting N-of-1 trials is 
much higher in developing countries than developed countries (Chapter 4). Therefore, 
when applicable, the use of LMM to estimate population bioequivalence is an efficient 
strategy to spend limited-resources in developing countries on N-of-1 BE studies.  
9.11. Limitations of the study 
The interpretation of this bioequivalence study is potentially compromised by several factors:  
1. First, to satisfy the IRB recommendations made during the qualitative studies, only 
patients whose BP was controlled were included in the study. This could create a bias 
towards a conclusion of equivalence. This is because there is a considerable placebo 
effect for antihypertensive medicines, which increases after 1 year263. To reduce this 
effect, patients whose BP was controlled in the last 3 months were included in this 
study.   
2. Second, the washout period in the study was slightly less than that the recommended. 
The washout periods should be at least 5 times the elimination half-life of the parent 
drug or active metabolite74. Based on this guidance, a minimum of 55 hours was needed 
for Enalapril. However, this study used two days (48 hours) of washout for pragmatic 
reasons- 7 hours before the standard elimination time. Third, due to lack of information 
to determine the sample size, the sample size was based on literature. However, this 
was mitigated by designing a trial of longer duration with three cycles, according to the 
recommendation made by the authors98.  
3. Fourth, the standard reference drug was not used in this bioequivalence study. 
According to the Ethiopian guideline, the innovator product is usually the most logical 
comparator product and a generic product should not be used as a comparator as long 
as an innovator product is available. As the innovator Enalapril brand (Vasotec) was 
not available in Ethiopia, a drug imported from a country with strong medicines 
regulation was used as a comparator based on participants’ (physicians) preferences 
during the qualitative study276.  
4. Fifth, while not blinding medications was an advantage from the perspective of 
feasibility and similarity to routine clinical practice, some of the results where the Envas 
was not as equivalent as Ena-denk could be the result of bias. However, lack of blinding 
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was mitigated by the use of ambulatory blood pressure measurement (ABPM) to reduce 
bias. The use of ABPM has been shown to produce similar results to prospective, 
randomized, open-label, blinded-endpoint studies compared with conventional double-
blind, placebo-controlled trials183. Also, the importance of maintaining blinding was 
part of patient education during trial preparation phase. Finally, in those patients where 
there was lack of full bioequivalence, the numbers of patients that favoured either Envas 
or Eva-Denk were almost identical  
5. Finally, an integrated method was used to evaluate and interpret anti-hypertensive 
equivalence results between the two drugs. However, interpretation of a super-
equivalent result is problematic especially for drugs with a narrow therapeutic window.  
In this case, interpretation of the results of a test drug needs to be made with caution as 
this could result in higher drug exposure than the upper limit of effectiveness (risk of 
overdose). Hence, comparison of safety data was one component of this study. 
Generally, safety data is not collected in BE studies- the assumption is if two drugs are 
bioequivalent then they would have a comparable safety. Besides, the integrated 
approach of interpretation is pragmatic in clinical settings but if the intention is to 
estimate a population equivalence, the equivalence criteria should adhere to the 
established BE approach.  
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9.12. Contributions of this project 
1. We formally assessed bioequivalence of two forms of Enalapril in individuals,  
2. We have shown that Nof-1 trials (when aggregated) can be used demonstrate 
population-level bioequivalence of generic drugs in resources limited settings. 
3. We demonstrated that the conventional principle of ethics in N-of-1 trials may not be 
applicable in generic drug research in developing countries.   
4. Not only the presence of but the source of uncertainty (contextual or limitation of the 
standard evidence base) are important regarding ethics and regulation of N-of-1 BE 
methods.  
5. Regulatory challenges are important issues as long as the authority has a direct 
influence on the approval and availability of generic drugs.  
Conclusions 
Methodological feasibility: the feasibility study has shown that the N-of-1 BE trials can be 
used to advance clinical practice in resource poor settings and address local evidence gaps in 
use of generic medicines. The conduct of N-of-1 trials in Ethiopia is difficult.  
Therapeutic equivalence of locally produced Enalapril: at group level in this pilot, the two 
formulations are therapeutically equivalent. Regarding variability in treatment response, it is 
possible that some of the between-subject variabilities could be due to inter-formulation 
differences. But is it is more likely due to a combined effect of subject‐by‐formulation 
interaction, intra-subject variability in pharmacokinetics of Enalapril and intra-
formulation/product variability.  The significant difference in morning/evening effect indicates 
that the effect of once daily Enalapril blood pressure control did not last 24 hours. 
Barriers for adopting N-of-1 trials in resource limited settings: there were several 
implementation challenges this study could not address. Lack of consensus on ethics is 
especially critical in influencing clinician’s motivation to advance their practice, 
implementation and expansion of N-of-1 services across clinical settings. Effective 
implementation of N-of-1 BE trials of local medicines in clinical practice will not be successful 
without active involvement, communication and consensus of the regulatory authority –see 
figure 9.2.  
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Therefore, while adopting N-of-1 trials is imperative to support and embrace evolving 
individualised medicine and increasing patient expectations, the researcher needs to consider 
local priorities and contextual barriers. There is a need to find common ground for prioritizing 
research areas and adopting N-of-1 trials in clinical practice of generic medicines in resource 
limited settings.   
Implications for clinical practice  
This thesis demonstrates that N-of-1 BE methods are methodologically feasible to assess 
bioequivalence of local medicines in resource limited settings. Chapter 8 confirms that an N-
of-1 BE service in clinical practice can be facilitated through a patient referral-feedback model 
between health care settings and research institutes. As such, by establishing clinical 
bioequivalence of inexpensive local medicines, N-of-1 methods have the potential to improve 
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Figure 9.2: Lack of consensus regarding need and ethics of the proposed study and 
subsequent regulatory decision and its consequences  
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care and correct errors in generic medicines practice. However, several challenges that impact 
their feasibility need to be addressed.  
Physicians’ lack of detailed knowledge about bioequivalence is one of the barriers for 
expanding N-of-1 BE services. Hypertension is one of the major causes of morbidity and 
mortality in Ethiopia. Effective control of BP in Ethiopia requires development and 
implementation of effective generic drug substitution strategies. Hence, guidance for 
physicians in generic medicine practice would be valuable. One approach would be to integrate 
the concepts of drug prescribablity and switchablity into generic medicines practice. Some 
considerations in switching anti-hypertensives include: maintenance of an appropriate 
medication dose during the switching process; drug equivalence in terms of clinical 
effectiveness; safety issues; differences in the ‘inactive’ components of drug formulations; 
quality of generic formulations as well as patient factors that may impact on substitution 
including adherence, health and economic status184. High burden of workload and physician’s 
lack of awareness regarding research methods are other challenges reported in this thesis. The 
thesis provided detailed recommendations to address these problems.   
The decisions that healthcare authorities make about priorities, commitments and support are 
also critical for health care providers to change clinical practice and adopt new innovations185.  
In this regard, addressing regulatory issues would be highly important. Designing an effective 
communication strategy with the local regulatory authority and developing an implementation 
approach that does not counteract the government effort and contribution of local 
pharmaceutical companies would be helpful.  In developing countries like Ethiopia, the system 
is not yet well developed. Often, there is a grey area in procedure and regulations. Hence, 
understanding the local context and discussions alone can resolve many issues. Local initiatives 
are key in developing smooth communication with the local authorities. Communication to 
find an optimal balance between ethical and regulatory requirements, as well as initiatives that 
enhance access to and quality of medicines is critical to enhance the feasibility of quality 
improvement tools like N-of-1 trials. For example, as pointed out by one of IRB members, 
workshops lead by a local senior expert and leaders in clinical trials who are known and trusted 
are beneficial. Such platforms are important to designing an approval system that facilitates 
wider application of the N-of-1 method (indeed any new method) to inform clinical care and 
quality assurance systems in a constructive and responsive way. 
Finally, the rigor and standard of N-of-1 BE methods can further be improved: i) Quality of 
data can be made more reliable and accurate by using mobile health technology and digital BP 
machines with memory. From an equity perspective, use of digital BP machines with memory 
also allow the participation of illiterate patients who have no capacity for blood pressure 
reading and recording. ii) As bioequivalence testing is not a trial to determine treatment 
response, non-responders should be excluded by including a third placebo arm. In this 
particular study, this was addressed by including only patients whose hypertension had been 
controlled by the same drug under investigation, which is Enalapril.  However, in addition to 
standardizing and increasing the validity of bioequivalence results, inclusion of placebo in N-
of-1 BE trials has addition clinical values: individual variability/ sensitivity for the drug (who 
responds and who doesn’t) and individual variability for the different formulations of the drug 
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(who better responds for which formulation) can also be assessed. However, from a feasibility 
perspective in a developing county, this brings more complexity in the design, ethics and time 
and cost of running the trial. iii) Inclusion of different batches of generic products will address 
whether there is intra-product variability or not.  
Implications for research  
Beyond their applicability to generate individual evidence to support clinical decision making, 
this thesis confirms that the potential of aggregated N-of-1 BE method to produce a population 
level bioequivalence estimate.  Chapter 8 demonstrates that the linear mixed model method can 
be used to analyse aggregated BE data. As such, regulatory authorities and local companies 
can be engaged in developing an aggregated N-of-1 BE approach, and this could be a way of 
creating a balance between access and quality, a challenge facing many developing countries. 
Moreover, the aggregated approach would be a more cost-effective way to provide precision 
medicine while contributing to filling the evidence gap.  However, full-scale BE studies are 
needed to confirm the suitability of this analysis method. Moreover, research is needed to 
explore the most optimal methods of analysis. Because of their potential both to analyse and 
meta-analyse results of N-of-1 trials, the use of the Bayesian method is becoming more 
appealing.  In this statistical model, each N-of-1 trial can inform the next by using existing 
information both from individual patients and prior information.  Hence it allows the conduct 
and generation of BE evidence using minimal resources, which is particularly advantageous 
for developing countries. However, this analysis method is more complex and prior 
information of parameters is often unavailable as was the case of this N-of-1 BE study 
conducted in Ethiopia.  
Funding issues which we didn’t have to deal with in this particular feasibility study is a big 
problem in developing countries. Analyses of key therapeutic areas and prioritization of trial 
topics would be beneficial. In this regard, future N-of-1 researchers need to link and show their 
contributions to the huge evidence gap available in these settings.  
Implication for medicine regulatory system in resource limited settings  
The lack of a local PK BE testing facility is the major challenge to enforce proof of BE profile 
in locally produced medicines. The thesis demonstrates that, by generating population BE 
evidence, aggregated N-of-1 BE methods could bridge the lack of PK BE testing until such 
facility is established.  As such, the method can be useful to support and strengthen medicine 
regulation in Ethiopia. However, research is needed to assess its feasibility further, and to 
develop an implementation guide to use N-of-1 BE methods to support regulatory 
infrastructure. One approach would be to link the N-of-1 BE method with the existing national 
pharmacovigilance system.   
Implication for implementation of N-of-1 BE method in other East African countries 
The problem of lack of a bioequivalence testing facility is not limited to Ethiopia- it is a 
problem that affect other East African countries. This thesis confirms that by filling BE 
evidence gaps, N-of-1 BE methods have the potential to promote effective generic drug 
substitution, improve the confidence of patients taking less costly local medicines and  support 
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the regulatory system in resource limited countries. Hence, adoption of N-of-1 research 
methods in similar settings could improve generic drug practices significantly. However, while 
there are similarities related to implementation of this clinical care tool in resource limited 
countries, there would also be differences within these countries with regard to specific barriers 
and implementation approaches. Hence, development of flexible implementation strategies 
relevant to the context of each country is needed. Strategies should appreciate the importance 
of relationship and communication with the respective local medicine regulatory authority. 
Generally, implementation approaches in each country depends on several factors including 
acceptability of the N-of-1 BE method, the culture of individual health care facilities for 
adoption of novel methods, and local policies and guidelines regarding regulation of pragmatic 
clinical researches and generic drug practices as well as leadership commitment for them. 
Identification champion hospitals and research institutes that advocate this method would be 
helpful to encourage and set up the initial N-of-1 BE services.  Further research is needed to 
refine the feasibility and implementation recommendations approaches in Ethiopia to adopt of 
N-of-1 BE methods in other East African countries.  
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Appendix A. Characteristics of studies of N-of-1 tests in developing countries118 
 
Author, 
country  
Design  Rationale Participants Measures Intervention Outcomes 
Haiyin 
Huang, 
et al, 
China 
(2014)  
Randomiz
ed, 
double-
blind, 
crossover, 
within 
individual 
patient 
Lack of sufficient 
evidence on 
effectiveness on the 
therapy 
1 male, 2 females, aged 
18–75 years, diagnosed 
with stable 
bronchiectasis  
Primary: Patient self-
rated symptom score 
for cough, 
expectoration, 
shortness of breath, 
chest pain, and fatigue 
Secondary: 24 hr 
sputum volume and 
drug safety  
Herbal 
decoction vs 
control 
decoction  
All three patients 
showed non-significant 
improvement from the 
test TCM.   
One patient preferred 
the herbal decoction 
over the standard one 
after trial completion 
Huang 
Yuhong
, et al, 
China, 
(2012)  
Randomiz
ed, 
double-
blind, 
crossover, 
within 
individual 
patient 
Lack of sufficient 
evidence on 
effectiveness on the 
therapy 
15 males, 35 females, 
aged 25–65 years, with a 
clinical diagnosis of 
deficiency of kidney Yin  
Primary: Individual 
completion rates, 
response rate, and 
post-n-of-1 RCTs 
decision  
Secondary: Self rated 
symptom score on 
Likert scale and SF-36 
questionnaire to  
measure perceived 
health and quality of 
life 
Liuwei 
Dihuang 
decoction 
(LDD) vs 
placebo 
Only 3 (6.38%) 
responded, 28 (59.57%) 
didn’t respond, and 16 
(34.05%) were possible 
responders. 29 (66%) of 
patients changed 
medication after the 
trial. 
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Wang 
Hui et 
al, 
China 
(2010)  
Randomiz
ed, 
double-
blind, 
crossover, 
within 
individual 
patient 
 
Lack of sufficient 
evidence on 
effectiveness on the 
therapy 
6 males, 5 females, age g
roup 45-66 years, with 
diagnosis of mild-
moderate HN 
Effectiveness: Change 
in blood pressure 
(home and clinic 
measurements)  
Safety:respiratory 
rate, heart rate, routine 
blood test for liver and 
kidney function,  urine 
test, routine ECG,  
High dose vs 
low dose 
Bezoar Anti-
hypertension 
Capsule plus 
simulation 
placebo 
Home BP 
measurements showed 
significant reduction 
only in SBP. Clinic BP 
measurements showed 
significant reduction 
both in SBP & DBP 
from the high dose 
TCM (P < 0.001).  
There was no increased 
risk of adverse events 
from high dose Bezoar. 
Yu 
Dajun  
et al, 
China 
(2012)  
Randomiz
ed, 
 crossover, 
within 
individual 
patient 
 
Lack of sufficient 
evidence on 
effectiveness on the 
therapy 
3 males, age: 52,57 and 
59 years with diagnosis 
of chronic kidney disease 
(CKD) of third stage 
Individual patient 
main symptom score  
Change in serum 
creatinine and 
creatinine clearance 
rate 
Chinese 
medicinal 
decoctions 
plus the 
routine basic 
treatment vs 
only the 
routine basic 
treatment 
Individual patients’ 
main symptom was 
significantly improved 
in the treatment phase 
(P<0.01). 
Two patients showed 
improved serum 
creatinine and 
creatinine clearance 
rate.  
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Zhang 
X et al, 
China 
(2012)  
 
 
 
 
Randomiz
ed, 
 crossover, 
within 
individual 
patient 
 
Lack of sufficient 
evidence on 
effectiveness on the 
therapy 
4 patients, all male, ages 
50,61,68 and 76 years, 
with diagnosis of 
hypertensive 
intracerebral 
haemorrhage 
Patient main 
symptoms; IL-6, 
morphology index and 
clinical curative effect 
evaluation (the degree 
of encephaledema and 
cerebral infarction). 
Standard 
treatment 
plus TCM, 
acupuncture 
and 
moxibustion; 
Traditional 
Chinese 
manipulation 
vs standard 
treatment 
plus TCM  
TCM symptom scores 
of all patients were 
significantly improved 
(P<0.01). 
IL-6 of all patients was 
significantly reduced 
(P<0.01). 
Scores of Morphology 
Index and Clinical 
Curative Effect were 
also improved from the 
treatment phase 
Louly  
Priscila 
Gebrim 
et al, 
Brazil 
(2009)  
Randomiz
ed, 
double-
blind, 
crossover, 
within-
individual 
patient 
Lack of optimal 
therapy to treat cough 
in patient 
55 year old female 
patient with dry cough 
secondary to 
interstitial pneumopathy  
Primary outcome: The 
intensity of daytime 
and night-time cough 
measured by a visual 
analog scale and 
patient’s perception 
regarding her health 
state. 
Tramadol 50 
mg compared 
with placebo 
The patient’s condition 
as measured by visual 
analog scale 
significantly improved 
from the test drug (P < 
0.001) 
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Appendix B: Ethical Approvals for N-of-1 trial 
Appendix B1: Approval from UQ Ethics Review Committee, Australia 
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Appendix B1: Approval from AHRI/ALERT Ethics Review Committee, Ethiopia 
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Appendix C: The Ethiopian regulatory authority (FMHACA) notification letter 
regarding the pilot N-of-1 trial 
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Appendix D: AHRI response letter to the Ethiopian regulatory Authority regarding the 
pilot N-of-1 trial 
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Appendix E: Cover letter –Response to FMHACA 
Background 
Around the world, physicians face uncertainties in their daily clinical care decision making for 
individual patients. To deal with these, development of clinical care tools that help physicians 
to generate objective evidence at the point of care is imperative.  N-of-1 tests are indicated 
whenever there is uncertainty regarding the comparative effectiveness of different treatments 
being considered for an individual patient.  Uncertainty can result from individual variations 
in response to treatment, which are often completely unpredictable.  
Ethics in N-of-1: Summary Guide to 
 
It is important to differentiate between the need for regulatory authority approval and the need 
for ethics committee approval and oversight. 
 
There is no full consensus as to whether N-of-1 tests should constitute clinical research or care. 
The ethics of N-of-1 tests mainly depends on the trial’s intention: research versus clinical care. 
Where the intent is to generate generalizable knowledge, IRB approval should be sought. 
However, due to the unique scope and purpose of the design in improving quality of clinical 
care in individual patients, the issue of regulatory approval has not been raised anywhere. Two 
of my advisers have co-authored an article entitled ‘Do n-of-1 trials need IRB review?’ Two 
types of research are possible. 
 
1. Comparative efficacy testing. As N-of-1 tests are tests of two or more treatments in an 
individual, the only way of generating comparative effectiveness data relevant to a 
population is to combine the results of multiple individual N-of-1 tests.  Ethics and possibly 
regulatory authority approval should then be sought. Regulatory approval is essential if the 
research is testing the efficacy of a medicine for a different indication to the one for which 
an existing medicine is licenced.  
2. Research questions about the N-of-1 tests in clinical decision making. Ethics authority 
only should be sufficient when the research question relates to how patients and clinicians 
use the N-of-1 test to assist in making clinical decisions for medicines that are used for the 
condition for which they are licenced. The research question is about the decision making 
process, not the effectiveness of the drug itself for a given condition.  
If the intent of the N-of-1 study is to assist in the conduct patient care in the course of normal 
clinical practice, and a research question is not involved, then IRB approval should not be 
required at all.  Regulatory approval should not be required either, as the medicines are being 
used for their licenced indication.   
N-of-1 trial intention and IRB approval are the major issues in the current global experience 
and literature regarding the ethics of N-of-1 trials.   The current trial is about clinical decision 
making at an individual level. 
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N-of-1 trials as a clinical care tool: The case of piloting N-of-1 tests in Ethiopia 
Physicians around the world are encouraged to prescribe inexpensive, bioequivalent, local 
generic drugs. However, lack of bioequivalence data on generic drugs, along with genetic and 
racial differences in the metabolism and excretion of medicines, may contribute to treatment 
variability between medicines in individual patients. By bridging the information gap on 
bioequivalence, the pilot test is intended to give evidence on therapeutic equivalence of locally 
produced Enalapril in the treatment of hypertension in individual patients. If there is no 
difference, the hypothesised result, then individual patients can take the local cheaper medicine 
with confidence. They are more likely to be compliant, and therefore reduce the risk of serious 
long term consequences.  
The following points summarize what we are doing; 
We are conducting a pilot study of individual N-of-1 trials/tests using 33 patients to inform 
clinical decision making. At the end of each test, individual patient reports will be prepared 
and will be given to each patient and treating physician. The draft report for the first patient 
is attached as an example. For this purpose, two physicians from ALERT hospital are part of 
the study. Data generated FROM each patient will be used to make a clinical decision TO that 
individual patient only. It is important to note that most patients involved in this study are also 
taking other anti-hypertensive drugs like thiazides and nifedipine. This N-of-1 test can’t 
provide evidence on the efficacy of the two brands of enalapril, outside of the individual in 
whom the test has been conducted. It can only tell us if the local version can be used 
interchangeably in each individual patient who has been involved in the test. Though, the 
uncertainty lies on lack of bioequivalence, we are interested in piloting clinical care tools that 
physicians can use to promote individualized patient care.  Such individual N-of-1 trials to 
prove the interchangeability of drugs which are already in use by patients largely constitute a 
quality assurance activity. According to the Ethiopian National Ethics Review 
Guideline/2014, these sort of studies that are exempted from IRB review.  
N-of-1 trials as a means of producing population level bioequivalence data:  the case of 
AGGREGATED N-OF-1 TRIALS 
The role of INDIVIDUAL N-OF-1 TESTS is discussed in the previous section. In addition to 
their use in providing evidence on EFFICACY OF TREATMENTS FOR INDIVIDUAL 
PATIENTS, when applicable, results from individual N-of-1 studies can be combined to 
produce a population estimate of effect similar in strength to randomized controlled trials.  
When applicable, AGGREGATED N-OF-1 TRIALS could be used to generate data on 
therapeutic efficacy of drugs, in this case about the efficacy of locally produced Enalapril. This 
could be possible in the future, however, at the moment, the design and the statistical methods 
of aggregated N-of-1 trials for the purpose of verifying therapeutic equivalence of drugs are 
not developed. OUR STUDY WILL NOT BE AGGREGATING N-OF-1 TRIALS.  
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Appendix F: N-of-1 Patient Information and Consent Forms: English Version 
                
 
PARTICIPANT INFORMATION SHEET 
 
STUDY TITLE:  A series of N-of-1 trials to assess therapeutic interchangeability of two 
Enalapril formulations in the treatment of hypertension in Addis Ababa, Ethiopia: study 
protocol for a randomised controlled trial 
 
 
List of investigators:  
 Name Affiliation Email Contact 
Mr Chalachew 
Alemayehu (Chief 
investigator) 
School of Medicine        
University of Queensland 
c.alemayehu@ 
uq.edu.au 
Tel: +251-
911535973 
Prof Geoff Mitchell School of Medicine        
University of Queensland 
g.mitchell@uq.edu.au Tel:                      
07 33811363 
Dr. Abraham 
Aseffa 
Armauer Hanson 
Research institute  
aseffaa@gmail.com Tel:  (251)-
113483752 
Associate Professor 
Alexandra 
Clavarino 
School of Pharmacy        
University of Queensland 
a.clavarino@pharmac
y.uq.edu.au 
Tel: 
 7-334-61979 
Dr James McGree Queensland Univerity of 
Technology 
james.mcgree@qut.ed
u.au  
Tel: 07 3138 
2313 
Dr Jane Nikles UQCCR uqjnikle@uq.edu.au Tel: 073346 
5025 
  
 Invitation 
We are inviting you to participate in N-of-1 tests to assess whether two Enalapril formulations 
work equally well in the treatment of hypertension in Ethiopia. These tests are useful to see 
whether the local product works as well as the imported one and if so, it could be taken 
confidently by individual patients like you.  
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The study is being conducted by Mr Chalachew Alemayehu, a PhD student at The University 
of Queensland, Australia, in collaboration with The Armauer Hansen Research Institute 
(AHRI) in Ethiopia.   
Project overview 
Many patients with hypertension take Enalapril to control their blood pressure. Using locally 
produced Enalapril is a cheaper option for patients with hypertension. However, there is no 
evidence that proves that locally produced Enalapril works as well as the original (standard) 
Enalapril.  The aim of the trial is to test whether locally produced Enalapril works as well as 
imported Enalapril in the treatment of hypertension. 
What is Enalapril? 
Enalapril is the preferred drug for the management of hypertension and a commonly prescribed 
drug for the treatment of hypertension in Ethiopia. You may be taking this medication either 
singly or combined with other anti-hypertensive drugs/s.  
What is Nof-1 test? 
N-of-1 tests are a means of assessing whether a medication works for the patient who takes the 
medicine.   N-of-1 tests systematically assess the relative effectiveness of various treatment 
options in an individual patient so as to identify the best treatment option. If two treatment 
options work as well as each other, the less costly drug can be chosen. 
The N-of-1 test will take six weeks and will use locally produced Enalapril and imported 
Enalapril alternatively on a weekly basis. 
Why the Nof-1 test is needed? 
Currently, CADILA Pharmaceuticals Ltd (Ethiopia) produce Enalapril (Envas) in Ethiopia.  
However, to ensure its effectiveness,   the comparative efficacy and safety of this drug againist 
the original (standard) product should be tested.. Currently, appropriate tests to prove 
effectiveness are not available in Ethiopia.  
What happens if I decide to participate?  
Before trial commencement: 
Screening phase 
We want the participants in this study to meet a certain level of health. Therefore, a screening 
examination will be done two days before the start of the study. We will do a physical 
examination to check your general health condition. We will take one blood sample (10 ml/2 
tsp) from your arm, and we also want you to take one urine sample (15 ml/3 tsp). We will then 
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analyse the blood and urine samples with standard clinical tests to assess your liver and kidney 
functions and blood values.  
An electrocardiogram will be also performed to assess whether there are significant cardiac 
abnormalities.  If you are a female, we will also perform a pregnancy test. If you are pregnant 
or plan to become pregnant during the next 2 months you cannot participate in this study.  
If you can’t read and write, you should have a willing assistant that can help you manage BP 
monitoring and data collection forms throughout the course the study.  
Final eligibility assessment 
If you pass the above screening phase, a BP training session will be conducted one day before 
the start of the study. The training is about the basic methods of BP self-measurement, the 
meaning of BP values, and the monitoring device to be used. Your or your assistant’s 
competence and skill will be assessed after the training. Then if you are eligible, you will be 
included.  
During the trial phase 
Seven tablets of Enalapril (either test product or the reference product) will be dispensed to 
you each week for six weeks. You will be taking each medication in random (mixed up) 
order. .  
Example arrangement of treatment order 
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 
Treatment 
1 
Treatment 
2 
Treatment 
3 
Treatment 
4 
Treatment 
5 
Treatment 
6 
 
     
Ena-Denk 
 
Envas 
 
Envas 
 
Ena-Denk 
 
Ena-Denk 
 
Envas 
 
 
            You will be given a home BP monitoring device and recording form. You will measure your 
BP three consecutive times in the sitting position in the morning before breakfast and in the 
evening after dinner. You will measure your BP at home for successive six weeks. You will 
record your BP immediately after each measurement in a study diary.  The average systolic 
(top) and diastolic (bottom) BP at home over five days will be used to assess the effectiveness 
of treatment.  You will bring your BP recording diary during your weekly clinic visit.  
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You will abstain from taking any new medication (prescription and nonprescription drugs) 
without notifying the study staff. If you smoke and/or take alcohol, you need to minimize your 
consumption.   
You will visit the study site for follow up on a weekly basis. During these visits, you are 
expected to bring recordings which are made during the last week. During the trial phase, you 
will visit the clinic six times.             
 Visit 1: At the end of the first week (Day 7) 
 Visit 2: At the end of the second week (Day 14) 
 Visit 3:  At the end of the third week (Day 21) 
 Visit 4: At the end of the fourth week (Day 28) 
 Visit 5: At the end of the fifth week (Day 35) 
 Visit 6: At the end of the sixth week (Day 42) 
 
What would happen after the N of -1 trial? 
At the end of this trial, the treating physician will be told when you were taking the locally 
Enalapril (Envas) and the time you were taking the reference Enalapril. Your BP measurements 
will be analysed and the result will be given to the treating physician. After looking at these 
results, you and the treating physician will be able to decide if the local drug works as well as 
the reference medication for your hypertension. 
You will be asked to fill a short questionnaire at the end of the study, to ask you about your 
experiences of being in the study. It should take no more than ten minutes.   
Potential risks 
Enalapril is the drug you have already been taking to control your BP. In general, it is one of 
the safe drugs to take. If you have not experienced side effects till now, it is most unlikely you 
will start to experience them in the trial.  
But still, as with any drug, there are some side effects. The most common side effects of 
Enalapril include mildly reduced kidney function (20%), dizziness (2–8%), low blood pressure 
(1–7%), syncope (fainting) (2%), and dry cough (1–2%). The most serious common adverse 
event is swelling of the mouth and lips (0.68%), which can make breathing difficult. All 
unpleasant effects from medications will be considered as side effects. You are encouraged to 
record any unpleasant effects and take the record to your weekly clinic visit. A side effect 
questionnaire will be given to you.  
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What I should do if I have any concerns about medication side effects? 
If you have any concerns about the medication please contact the chief investigator on the 
phone number at the beginning of this information sheet.  
Benefits to the participant: 
This trial will give you and the treating physician clear information as to whether there is any 
clinically important difference between the two forms of Enalapril. If not, then the treating 
physician will be able prescribe the less costly drug and you will be able to take it confidently.  
Moreover, during the course of the study, you and the treating physician will be able to 
frequently monitor your blood pressure - which is vital to be able to understand your condition 
well.  
Expenses and compensation 
You will be reimbursed for the direct expenses related to travel to the study site and loss of 
earnings during the visit days. The total amount of money to be compensated is 150 Eth Birr 
per visit. 
Confidentiality and data protection 
All personal records will be kept confidential and kept locked in cabinets. Your identity and 
other identifiable information will only be known to the clinical trial staff. Data from this 
project may be published or presented. No personal information will appear in any report from 
this study. All test results will be treated confidentially with use of coded labels on samples. A 
separate file with no identifying data will be made for analysis.  
What happens if I don’t want to take part in this study? 
Your participation in this study is absolutely voluntary. If you decide not to participate, it will 
not affect the treatment you receive now or in the future. If you decide to stop participating 
during the study, you can leave the study at any time without providing any reason. 
Consent 
A Consent Form must be signed. 
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Ethics approval 
Ethics approval for this project has been granted from The University of Queensland Human 
Research Ethics Committee (Australia). Additionally, this project has been approved in 
Ethiopia by AHRI/ALERT ethics committee.  
If you would like to contact AAERC secretariat, use this number: +251-118-962183 or you can 
speak to an officer of the University not involved in the study, you may contact the Ethics 
Officer on +61 7 3365 3924 or you can email for the human ethics office: 
humanethics@research.uq.edu.au.  ) 
This study has been supported by The University of Queensland 
Feedback to participants 
Once the last participant has finished the study treatment and all data from this research have 
been analysed, we will be able to discuss the overall findings with you the treating physician 
on request.   
If you have any reservations about you and/or the treating physician being informed about this 
study and the results, please let us know of your concerns.  
You are encouraged to ask questions at any time during your participation in the study.  
You are of course, free to discuss your participation in this study with Mr Chalachew 
Alemayehu on +251-911535973.  
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                         PARTICIPANT CONSENT FORM 
 
STUDY TITLE:  A series of N-of-1 trials to assess therapeutic interchangeability of two 
Enalapril formulations in the treatment of hypertension in Addis Ababa, Ethiopia: study 
protocol for a randomised controlled trial 
 
I confirm that: 
 I have read, or have had read to me, and I understand the Participant Information and 
Consent Form;  
 Had any questions or queries answered to my satisfaction; 
 Been informed that one blood sample (10 ml/2 tsp) and one urine sample (15 ml/3 tsp) are 
required and an electrocardiogram will be performed during the screening phase; 
 Been informed that there will be a BP training session one day before the start of the study; 
 Been informed of the possible risks or side effects of the medications, tests or procedures 
being conducted; 
 Understood that participating in this study will require me to take a tablet every day that 
will contain either the local Enalapril (Envas) or reference drug (Ena-Denk);  
 Been informed that a total of 150 Eth Birr per visit will be reimbursed for my direct 
expenses related to travel to the study site and loss of earnings during the visit days; 
 Been informed that, during the trial phase, a total of six visits are required to the study site;  
 Been informed that I will measure my BP two times a day for consecutive six weeks at 
home; 
 Been informed that the confidentiality of my information will be maintained and 
safeguarded; and  
 Agreed to participate in the study.  
 I am happy for the treating physician to be told of my  results:     Yes          No  
 It is explained to me that in case I can’t read and write there will be a witness (who does 
not belong to the investigators) whose role will be to read, understand and explain the study 
concept to me. To this end, it has been read to me before my participation to the study. 
 It is explained to me that in case I can’t read and write I should have a willing assistant who 
can help me throughout the duration of the study.  
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I: _______________________________________________________freely choose to take 
part in this study. 
       (Name and surname of participant in capitals) 
Participant's signature: ________________________________________________________ 
Date:  _____/_____/______  
 
I: ___________________________________________________ was present when the form 
was completed and confirms the participant has understood. 
(Name and surname of witness in capitals) 
Witness' signature: __________________________________________________________ 
Date:  _____/_____/______  
I: __________________________________________________________________                                                                
(Name and surname of the Principal Investigator or appointed person) 
Have carefully explained the requirements, risks and benefits foreseen in the study to the 
aforementioned persons and I was present when this form was completed. 
Signature of Principal Investigator (or appointed person):_______________________ 
Date: _____/_____/______  
 
 A copy of the Information sheet and the signed Consent Form will be provided to the 
participant. 
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Appendix G: Individual Patient Report Summary 
Dear Dr. X  
Date:  
Regarding Patient Number____ 
 
Your patient participated in an N-of-1 therapeutic equivalence trial to evaluate if Envas (10mg 
mg) as effective as Enadenk (10mg) in treating her/his hypertension. Below, please find 
graphical representation of the weekly average SBP while on Envas and while on EnaDenk. We 
have also provided a summary of adverse effects experienced and our evaluation based on the 
available data. 
 
 
We would be pleased to answer any questions you may have - please contact Mr Chalachew 
Alemayehu on 0942207528. 
 
Signature _______________________Date_______07.06.2017__________________  
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Trial results summary 
Target for therapeutic equivalence 
The patient was on 10mg mg Envas (Ethiopian version of Enalapril).  Before the start of the 
trial, the baseline average clinic BP measurement was 121/60. Target therapeutic equivalence 
is absence of clinically important difference, which is defined as difference of < 5mmhg in 
average systolic blood pressure between the two treatments. Equivalence should be evident in 
at least in two cycles out of three.  
 Table: Difference in average systolic blood pressure in each and across treatment pairs 
No. of Cycles/treatment 
pairs 
Average Systolic blood pressure 
(ASBP) Change in ASBP in 
each cycle Envas EnaDenk 
Treatment pair 1 106.50 99.00 2.26 
Treatment pair 2 92.50 96.50 8.47 
Treatment pair 3  103.60    97.20 -0.86 
Overall  100.87 97.57 
3.31 ,CI 95% (.993,  
5.58)  
 
This patient had 21 nights on Envas, and 21 nights on EnaDenk. 
 
Therapeutic equivalence target:  The number of cycles average systolic blood pressure 
difference between Envas and EnaDenk was < 5mmhg. 
Number of cycles the patient met equivalence target::    2 out of 3 cycles. 
Adverse reactions 
Safety Target: The Number of cycles number of side effects difference between Envas and 
EnaDenk is <1.  If the difference is < 1 in at least two cycles, the two drugs will be 
considered to have comparable safety.  
 
No. of Cycles/treatment pairs 
No of side effects 
Envas EnaDenk 
Treatment pair 1 0 0 
Treatment pair 2 0 0 
Treatment pair 3  0    2* 
 
*(headache, dizziness) 
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Evaluation  
According the target clinical equivalence criteria: Based on Safety evaluation 
criteria: 
      Envas is DEFINITELY MORE EFFECTIVE than 
EnaDenk 
 Envas is AS SAFE AS    
EnaDenk 
        Envas is PROBABLY MORE EFFECTIVE than 
EnaDenk 
   Envas is NOT AS SAFE as 
EnaDenk 
  Envas is as DEFINITELY AS EFFECTIVE as 
EnaDenk 
    Envas is MORE SAFE than 
EnaDenk 
Envas is PROBABLY  AS EFFECTIVE as 
EnaDenk 
 
Envas is PROBABLY  NOT AS EFFECTIVE as 
EnaDenk 
         Envas is DEFINITELY NOT AS EFFECTIVE 
as EnaDenk 
 
 
While Envas may not be as effective as EnaDenk, both agents maintained the BP below 
the threshold of SBP <140mmHg for hypertension. The patient can safely continue on 
Envas if he/she wishes. 
 
Graphic presentation 
 
 
100.73
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98.47 97.53 96.76 97.57
80
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130
Treatment pair 1 Treatment pair 2 Treatment pair 3 Overall
Fig:  Weekly and Overall Average Systolic Blood Pressure Envas vs  
Ena-Denk
Envas EnaDenk
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Appendix H: Comparative safety assessment of between Envas and EnaDenk in 
individual patients  
Cases 
No. of Cycles/treatment pairs 
No. of side effects Safety Evaluation 
Envas EnaDenk 
1.  Treatment pair 1 0 0 Envas is as safe as 
EnaDenk Treatment pair 2 0 0 
Treatment pair 3  0    2 
2.  Treatment pair 1 0 1 Envas is as safe as 
EnaDenk Treatment pair 2 3 0 
Treatment pair 3  0    0 
3.  Treatment pair 1 3 3 Envas is as safe as 
EnaDenk Treatment pair 2 1 0 
Treatment pair 3  0    0 
4.  Treatment pair 1  0    0 Envas is as safe as 
EnaDenk Treatment pair 2  0    0 
Treatment pair 3  0    0 
5.  Treatment pair 1  0    0 Envas is as safe as 
EnaDenk Treatment pair 2  0    0 
Treatment pair 3  0    0 
6.  Treatment pair 1  3 3 Envas is as safe as 
EnaDenk Treatment pair 2  3 2 
Treatment pair 3  2 3 
7.  Treatment pair 1 0 0 Envas is as safe as 
EnaDenk Treatment pair 2  0 1 
Treatment pair 3  0 0 
8.  Treatment pair 1 0 0 Envas is as safe as 
EnaDenk Treatment pair 2  0 0 
Treatment pair 3  0 0 
9.  Treatment pair 1 0 0 Envas is as safe as 
EnaDenk Treatment pair 2  0 0 
Treatment pair 3  0 0 
10.  Treatment pair 1 0 0 Envas is as safe as 
EnaDenk Treatment pair 2  0 0 
Treatment pair 3  0 0 
11.  Treatment pair 1 0 0 Envas is as safe as 
EnaDenk Treatment pair 2 0 0 
Treatment pair 3  0    0 
12.  Treatment pair 1 2 0 Envas is as safe as 
EnaDenk Treatment pair 2  0 0 
Treatment pair 3  0 0 
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13.  Treatment pair 1 0 0 Envas is as safe as 
EnaDenk Treatment pair 2  0 0 
Treatment pair 3 4 0 
14.  Treatment pair 1  - - Envas is as safe as 
EnaDenk Treatment pair 2  0 0 
Treatment pair 3  0    2 
15.  Treatment pair 1 1 0 Envas is as safe as 
EnaDenk Treatment pair 2  0 0 
Treatment pair 3  0 0 
16.  Treatment pair 1 4 3 Envas is as safe as 
EnaDenk Treatment pair 2  3 3 
Treatment pair 3  3 4 
17.  Treatment pair 1 0 0 Envas is as safe as 
EnaDenk Treatment pair 2 - - 
Treatment pair 3 - - 
18.  Treatment pair 1 2 1 Envas is as safe as 
EnaDenk Treatment pair 2 2 1 
Treatment pair 3 0 0 
19.  Treatment pair 1 0 0 Envas is as safe as 
EnaDenk Treatment pair 2  0 0 
Treatment pair 3 2 - 
20.  Treatment pair 1 - - Envas is as safe as 
EnaDenk Treatment pair 2  0 0 
Treatment pair 3  0 0 
21.  Treatment pair 1 0 0 Envas is as safe as 
EnaDenk Treatment pair 2 0 0 
Treatment pair 3  0    0 
22.  Treatment pair 1 0 0 Envas is as safe as 
EnaDenk Treatment pair 2  0 0 
Treatment pair 3 1 0 
23.  Treatment pair 1 0 0 Envas is as safe as 
EnaDenk Treatment pair 2  0 0 
Treatment pair 3 2 0 
24.  Treatment pair 1  0 0 Envas is as safe as 
EnaDenk Treatment pair 2  0 0 
Treatment pair 3  0    2 
25.  Treatment pair 1 1 0 Envas is as safe as 
EnaDenk Treatment pair 2  0 0 
Treatment pair 3  0 0 
26.  Treatment pair 1 2 1 Envas is as safe as 
EnaDenk Treatment pair 2  3 3 
Treatment pair 3  3 3 
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27.  Treatment pair 1 0 0 Envas is as safe as 
EnaDenk Treatment pair 2 0 0 
Treatment pair 3 0 - 
28.  Treatment pair 1 0 0 Envas is as safe as 
EnaDenk Treatment pair 2 0 0 
Treatment pair 3 0 0 
29.  Treatment pair 1  0 0 Envas is as safe as 
EnaDenk Treatment pair 2  0 0 
Treatment pair 3  0    2 
30.  Treatment pair 1 1 0 Envas is as safe as 
EnaDenk Treatment pair 2  0 0 
Treatment pair 3  0 0 
32. Treatment pair 1  0 0 Envas is as safe as 
EnaDenk Treatment pair 2  0 0 
Treatment pair 3  0 0 
33. Treatment pair 1  0 0 Envas is as safe as 
EnaDenk Treatment pair 2  0 0 
Treatment pair 3  0 0 
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   Appendix I. Model (linear mixed model) fit outcomes   
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Treatment outcome
Envas is inferior to EnaDenk
Can the patient afford EnaDenk?
Yes
Prescribe EnaDenk
No
Is the patient BP in acceptable range ? 
(depending on baseline BP and the size of 
treatment effect difference)
Yes
Prescribe  Envas/regular follow up
No
Are there similar previous N-of-1 
studies  on Envas?  
Yes
Did it work for the majority of patients?
No
Prescribe other cheaper bioequivalent Enalapril 
brands 
Envas could be Substandared product -Link to 
the pharmacolvigillance report
Yes
Concider EnaDenk with financial support or 
check suitablity of other clasess of generic 
brands. Eg. Calcium channel blockers
Patient chraccterstics   could  lead to this 
response
No
Prescribe other 
cheaper bioequivalent 
Enalapril brands/other 
classes eg. Calcium 
channel blockers
Envas is better than/= EnaDenk
Prescribe Envas
Appendix J: Treatment Decision Model in Using N-of-1 tests to assess Suitability of local drug substitution in hypertension 
management 
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Appendix K: Alemayehu C, Nikles J, Mitchell G. N-of-1 trials in the clinical care of patients 
in developing countries: a systematic review. Trials. 2018 Dec; 19 (1):246 
 
Abstract 
Background: N-of-1 trials have a potential role in promoting patient centred medicine in 
developing countries. However, there is limited literature regarding the use of N-of-1 trials in 
the clinical care of patients in resource poor settings.  
Objective: To assess the extent of use, purpose and treatment outcome of N-of-1 trials in 
developing countries.  
Method: Systematic review of clinical N-of-1 trials conducted between 1985 and September 
2015 using PubMed, Embase, CINAHL, Web of Science and Cochrane Central Register of 
Controlled Trials. Grey literature databases and clinical trial registers were also searched.  This 
review included randomized, multicycle, crossover within individual patient trials involving 
drug intervention.  Quality assessment and data extraction were conducted by two independent 
reviewers. 
Result: Out of 131 N-of-1 trials identified, only 6 (4.5%) were conducted in developing 
countries. The major reason N-of-1 trials were used was to provide evidence on feasibility, 
effectiveness and safety of therapies. A total of 72 participants were involved in these trials. 
Five of the studies were conducted in China and all evaluated Chinese traditional medicine. 
The remaining study was conducted in Brazil. The completion rate was 93%. More than half, 
46 (69%) of subjects made medication changes consistent with trial results after trial 
completion.  
A number of threats to the validity of the included evidence limited the validity of the evidence. 
In particular, the estimated overall effect in five of the included studies could have been 
affected by the 'carry over' of the previous treatment effect as there is no adequate 
pharmacokinetic evidence regarding traditional medicines was presented.  
Conclusion: The prevalence and scope of N-of-1 trials in developing countries is low. A 
coordinated effort among government, clinicians, researchers and sponsor organizations is 
needed to increase their uptake and quality in developing countries. 
Systematic review registration: PROSPERO CRD42015026841. 
Keywords: N-of-1 trials, clinical trials, developing countries, systematic review 
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Background 
Many people take medications that will not help them1-3. This is because current medical care 
primarily relies on Randomized Controlled Trials (RCTs), which, under the assumption of no 
heterogeneity, estimate a constant effect size or difference between control and intervention 
populations. By contrast, physicians in routine clinical practice deal with individual patients 
whose responses may differ markedly from the average. The US Food and Drug Administration 
guideline on personalized medicine acknowledges that there are considerable numbers of non-
responders to medications used for chronic diseases4. Moreover, drug toxicity can vary among 
racial and ethnic groups5.This challenge moved the world into a new perspective, whereby 
clinical practice developed increased appreciation of individual variation,  creating the platform 
of Patient Centered Medicine (PCM) 6,7.There is also an increasing demand for objective 
evidence to make clinical decisions - the quest for solid criteria to claim that one intervention 
works better than the other.  
PCM in developed countries has reached a level where individual genetic variations that 
contribute to disease can be identified and targeted for treatment. For example, in the USA, 
legislation to promote research and practices aimed at personalizing medicine8 and guidelines 
to include pharmacogenomics biomarkers on drug labels6 has been introduced. In 2010, 11 % 
of the labels of the top 200  medications sold in the US included pharmacogenetics information, 
a 10-fold increase from the 2003 estimation9.  The development of pharmacogenetics based 
PCM has paramount importance for the developing world.  However, for several reasons, 
patients in developing countries are far from being able to utilize advancements in genetic 
medicine. According to the World Health Organization (WHO), use of  costly initiatives like 
pharmacogenomics by countries able to afford this will widen the existing equity gap between 
developed and developing countries10.  
Moreover, there are other challenges such as traditional medicine use and use of untested 
generic drugs. Insufficient medicine regulation and enforcement in developing countries raise 
uncertainty about the quality of clinical care physicians give to individual patients. Due to cost 
and resource constraints, the contribution of western-style pharmacogenetics medicine to 
address the lack of evidence will be low. 
According to the World Bank, most developing countries have a low Gross National Income 
per capita - under US$4,03611. They have a disproportionately high burden of non-
communicable chronic disease (NCD)12. These countries often lack strong medicine regulation 
and enforcement13. There are times where this leads retail pharmacies and drug stores to 
welcome poor quality generic drugs whose interchangeability against branded products is not 
well established14,15.  
N-of-1 trials  
Where appropriate, another type of PCM, namely N-of-1 trials, offers an objective, efficient, 
and cost‐effective method of personalising treatment and improving the quality of clinical care. 
N-of-1 trials can provide a pragmatic clinical means of addressing individual variation in 
treatment response. N-of-1 trials are multi-cycle, double-blinded, controlled cross-over trials 
conducted within individual patients16-18. They provide the strongest available evidence of 
treatment efficacy to inform decisions for the individual patient 19. As a principle, N-of-1 trials 
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require relatively stable symptoms or diseases, and test medications with short half-lives and 
rapid measurable responses 18,20.  
Chronic disease management using N-of-1 trials can improve patient management and save 
health costs 21,22.  Thus far, N-of-1 trials have been used to address several challenges in clinical 
care; to determine optimal therapy for individual patients23, to identify cost effective treatment 
options23 and to prove therapeutic equivalence of generic drugs24,25.  
The pragmatic use of N-of-1 trials for assessing the comparative effectiveness of different 
therapeutic options and as a means of formally assessing the interchangeability of different 
brands of the same medicine is documented26,27. A recent article reported a comprehensive 
review of three types of cross over designs, including N-of-1 randomized trials for addressing 
drug interchangeability28.  
To date, using the principle of N-of-1 trials, some developed countries have accumulated 
decades of experience in improving quality of clinical care for individual patients. However, 
N-of-1 trials are not known in most developing countries. As the philosophy and practice of 
treatment optimization is less developed in developing countries, tailoring patient treatment is 
not often done proactively. When it is done, it comes at the expense of patient suffering and 
economic cost (See Box 1). Patients in resource poor settings have the right to be provided the 
best possible available cost effective treatment that works for them.  By promoting 
individualized patient care, N-of-1 trials have the potential to improve the quality of clinical 
care given for individual patients in developing countries.  
What is not known is the extent to which N-of-1 trials are already employed in developing 
countries, and the uses to which they are put.   
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Methods 
 
Overview 
We conducted a systematic review of n-of-1 clinical trials published in journals indexed by the 
PubMed, CINAHL, Web of Science, and Cochrane Central Register of Controlled Trials as 
well as publications from grey literature and unpublished sources from International Trial 
Registry Platforms between 1985 and 2015.  The protocol for this review was developed based 
on the PRISMA statement29 and is registered on PROSPERO (PROSPERO 
CRD42015026841). The PRISMA checklist can be found in Additional file 1. The review did 
not require Human Subjects Approval. 
Eligibility criteria 
To be included in the review, a trial had to meet the following criteria; the trial had to: 
(a) be conducted in humans  
(b) be conducted in  developing countries as defined by the World bank11 
(c) involve randomization of treatments within blocks or pairs, crossover of interventions, 
individual patients or series of patients, and single patients as the unit of analysis 
(d) evaluate pharmacological interventions (both modern and traditional medicine) 
(d) report the purpose of the trial, number of patients involved, completion rate, number of 
subjects who responded to the test drug and post- trial completion decision.   
Information Sources and searches 
Studies published in English were considered for inclusion in this review. Besides, articles 
published in a language other than English were considered if they had published English 
language abstracts. Studies published between 1985 and September 2015 were included in this 
review.  The search strategy covered both published and unpublished studies. A three-step 
search strategy was utilized for published articles. Firstly, an initial limited search of 
MEDLINE and EMBASE was undertaken, followed by analysis of the text words contained in 
the title and abstract, and of the index terms used to describe articles. A second search using 
all identified keywords and index terms was then undertaken across all included databases. 
Finally, the reference lists of all identified reports and articles were hand searched for additional 
studies. Unpublished studies were searched for in ClinicalTrials.gov and the WHO 
International Clinical Trials Registry Platform. The following grey literature databases were 
also searched: OAIster, Open Grey, National Library of Australia Trove, and Proquest Digital 
Dissertations. Search terms included a range of terms describing potential N-of-1 trials in the 
title or abstract: n-of-1, single case trial, single subject research, single case experimental 
design, single patient study, single patient trials, single case trials, and single patient trial.  
Assessment for inclusion and data collection 
Titles and abstracts of all the retrieved bibliographic records were screened for potentially 
relevant articles. Full texts of potentially eligible records passing the title and abstract screening 
process were retrieved and examined according to the Cochrane Handbook Section 8.5.a for 
RCTs and section 16.4.3 for cross-over trials30. A PRISMA flow chart outlines the study 
selection process29 (figure 1). 
Quantitative data were extracted from papers included in the review using an extraction tool 
adapted from the PRISMA statement 29, and the CONSORT extension for reporting N-of-1 
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trials (CENT) 31 checklist (tables 1 and 3). We defined an N-of-1 as a trial that employed 
randomized treatment episodes to evaluate pharmacological interventions in a single patient.  
Included papers were reviewed by two independent reviewers (CA, JN) and records were 
compared between reviewers to ensure accuracy of data extraction. Any disagreements that 
arose between the reviewers were resolved through discussion. The data extracted included 
design, participants, measures, type of intervention, outcomes, number of planned treatment 
cycles, treatment length, washout, blinding, outcome measurement, responder definition, 
method of analysis, number of individuals completing the trial and number of post-N-of-1 
RCTs decisions which favour trial results. 
Data synthesis 
The findings are presented in narrative form summarizing the data, which are presented in table 
form. Frequencies and percentages are reported. The goal of the review was to summarize the 
extent of N-of-1 use, purpose for conducting them, outcomes and the subsequent treatment 
decisions after the trial. For this reason, we did not conduct a meta-analysis. 
Results  
Study selection 
After removing the duplicates, the topic and abstracts of 1,395 published and unpublished 
articles were reviewed to determine which were within the scope of this review. Figure 1 shows 
the study selection approach and the number of publications obtained. The initial assessment 
excluded 642 irrelevant publications.   
Of the remaining 753 articles, the design and intervention of 131 articles met our definition for 
n-of-1 clinical studies. These articles were then subjected to review by the country in which 
they were conducted. One hundred and twenty-eight articles which were/are being conducted 
in developed countries were excluded.  The remaining 3 articles were examined and included 
in the review32-34. To capture any additional N-of-1 trials, we hand searched references of 
excluded reviews and the 3 articles included the review.  Twenty eight additional articles were 
identified in this process. Out of the 28 articles identified, the abstracts of 3 articles35-37 met our 
inclusion criteria. However, the full texts of these articles were published in Chinese journals 
in Mandarin. Thus, these 3 articles35-37 were translated to English by a native Chinese speaker. 
A total of six (five articles conducted in China32,33,35-37 and one article from Brazil34) were 
included in this systematic review. Characteristics and synthesis of these included studies are 
displayed in Tables 1, 2 and 3 respectively. 
There were also three literature reviews on N-of-1 trials both in and outside the medical 
field23,38,39. The first review, published in 2010, was a systematic review of N-of-1 trials with 
and without pharmacological intervention23. In 2013, Duan et al reviewed some literature to 
critically evaluate the need for further methodological developments38. It was not a full 
systematic review. Third, a systematic review which included n-of-1 articles with 
psychological and behavioral interventions was published recently39 .  
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Risk of bias within studies 
A domain level assessment of risk of bias was done to evaluate the following eight potential 
sources of bias for N-of-1 trials30(Table 2).: random sequence generation,  allocation 
concealment,  incomplete outcome data, selective reporting, blinding of participants and 
personnel,  number of treatment cycles, appropriateness of treatment for the design and adequacy 
of washout period.  
The number and the scope of N-of-1 trials in developing countries is low. Of the 131 n-of-1 
articles identified, only 6 (4.5%) were conducted in developing countries. Five of them were 
conducted in China to evaluate Traditional Chinese Medicine32,33,35-37. The sixth study34 which 
evaluated modern medicine was conducted in Brazil (table 1). Seventy-two patients, with a 
range of 1-47 participants in each study, were involved in the studies.  
The main reason for using N-of-1 trials in developing countries has been lack of evidence- that 
is “uncertainty due to lack of RCT evidence”. Five of the studies were done with the intention 
to test the efficacy of TCM. Quality use and tailoring of TCM to individual needs are crucial 
partly because many developing countries still rely on traditional medicine and partly because 
there is a significant lack of RCT evidence in this area. N-of-1 trials are indicated whenever 
there is lack of evidence regarding the comparative effectiveness of treatments being 
considered for an individual patient40. Johnston  and Mills (2004)17 specifically recommended 
the use of N-of-1 trials to make traditional and complementary medicine more widely available 
to appropriate patients without incurring undue public health consequences. 
One of the trials33 enrolled the majority (47) of participants.  In this study no one responded to 
the placebo, but more than half, 28 (60%) did not benefit from the active treatment. 
Interestingly, all were willing to stop the medicine. After completing the trial, around two thirds 
(69%) of participants changed their medication in a direction consistent with the trial results. 
Only one patient was involved in the sixth34 study. This patient was suffering from dry cough 
secondary to interstitial pneumopathy and she had not responded to several treatments 
including antitussive agents. Following the n-of-1 trial of tramadol vs placebo, her cough and 
quality of life improved and the patient continued taking tramadol.  
Discussion 
This review assessed the extent of use, purpose and treatment outcome of N-of-1 trials in 
developing countries. We concluded that the degree to which N-of-1 trials have been used was 
low. We identified and discussed three potential uses of N-of-1 trials to improve the standard 
of clinical care in poor resource settings.  
Only six studies were identified, with five from China (Table 1). In contrast, many developed 
countries (Australia, New Zealand, Canada, United States and countries in Europe)  have been 
involved in a range of N-of-1 trials of modern medicines23. This difference is due to the high 
reliance on traditional medicine in developing countries, but with insufficient evidence of their 
effectiveness41.  
The overall completion rate was  93%, which is better than the figure reported in a  previous 
review of N-of-1 trials in the medical literature (80%)23. Slightly higher than two thirds (69%) 
of participants changed their medication in a direction consistent with the trial results (table 3), 
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which is higher than the previous review which reported that 54% of participants made 
subsequent treatment decisions consistent with the results of the trial.23   
 
N-of-1 trials require that the  intervention has a rapid onset and washout16-18,42. A particular 
concern in these studies is the possibility of a ‘carry over’ of treatment effect which can 
compromise the validity of the result due to a bias towards the null. Due to lack of 
pharmacokinetic data available on the TCM therapies, which are often mixtures of herbs, it is 
impossible to assess whether the studies included in this review33,35-37 were of appropriate 
period length and whether the washout periods were adequate. It is therefore impossible to 
assess the validity of their findings. To address this, Johnston  and Mills17 recommends 
initiation of these tests only after an initial trial of therapy to assess effectiveness, onset of 
action and probable washout time, so as to produce a credible trial design. Only one study 
conducted a symptom based preliminary study32 to determine the onset and washout 
characteristics of the therapy under investigation.  
There are many opportunities to apply N-of-1 tests in resource limited countries. First, 
physicians can use them as a clinical care tool to provide optimal therapy for individual 
patients. For example, researchers in Brazil were able to find an optimal therapy (tramadol) for 
a patient who had been suffering from dry cough who was not responsive to several antitussive 
drugs34 (Table 1). One of the problems in clinical care is heterogeneity of treatment effects 
among individual patients43-49. As the majority of clinical trials are carried out in Caucasian 
populations and take little account of factors that affect response to a medicine (other 
populations’ genetics, environments and lifestyles), there could be a higher risk in applying 
results of these trials directly to the medical care of patients in developing countries. Therefore, 
if clinically appropriate, N-of-1 trials could play a significant role in promoting safe, 
individualized medicine.  
Additionally, Traditional Herbal Medicine (THM) use is common in developing countries, use 
ranging from 40% of people in China to 80% of people in Africa41. Though the contribution of 
traditional medicines to public health in developing countries is significant, evidence from 
RCTs or other controlled trials is either insufficient or lacking in most cases.  In this review, 
five of the studies included32,33,35-37 have used N-of-1 trials in THM (table 1).  
Second, N-of-1 trials can contribute to quality assurance of medicines in developing countries. 
These countries lack adequate capacity to control the quality, safety and efficacy of the 
medicines circulating in their market50. Some of these countries do not require proof of 
bioequivalence to ensure quality of generic drugs. For example, a 2014 report stated that drugs 
exported from India to Africa were of poorer quality than those sent elsewhere14. The 
application of this tool by health care professionals could be useful to recognize clinically 
inferior drugs and thus contribute to identification of sub-standard products26.  Currently, a 
pilot N-of-1 trial is underway in Ethiopia, to test the feasibility of these studies to generate 
therapeutic equivalence data on generic drugs that do not have proof of bioequivalence.  
Third, aggregating multiple N-of-1 trials18,51 is useful to address lack of evidence on therapy.  
In this review, two of the trials conducted in China33,35 reported a population treatment effect 
by meta-analysis.   
Fourth, N-of-1 trials can be used to identify cost effective medications. Often, chronic diseases 
require lifelong treatment, but there is limited capacity for people in developing countries to 
afford even essential medicines. Beyond their potential for promoting patient-centred care, N-
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of-1 trials may have additional pragmatic value in identifying affordable treatment 
options21,22.26  Compared to drugs made in developing countries (both locally made and 
imported from other developing countries), drugs imported from developed countries are 
highly expensive. High drug expenses for those of limited resources may mean a choice 
between medicines and necessities such as food or clothing52. By objectively evaluating 
effectiveness  of drugs made in developing countries53, N-of-1 trials can help physicians choose 
the cheapest of the effective drugs available.   
To address the clinical inconvenience factor from the additional trial periods and subsequent 
length of N of 1 trials compared to the standard trial of therapy, a major barrier for  their 
widespread adoption, researchers have suggested the use of a novel n of 1 trial designs such as 
a mixed-methodology add-on N-of-1 trial54. It involves conducting N-of-1 trials among 
apparent responders from a parent traditional RCT in research settings. This design address 
many of the concerns with both conventional RCTs and N-of-1 trials.  has different uses in 
complementary and alternative medicine research54. Also, literature that guides design, 
analysis and reporting of N-of-1 trials 26,27,31,55,56 are widely available. The development of this 
groundwork can guide the broader applications of N-of-1 trials in resource poor settings, 
becoming more important with the increasing focus on individualized medicine. 
However, there are considerable operational and strategic barriers to consider in developing 
them.  
 Logistic (a well-equipped research facility, placebo etc) and operational (administrative 
and patient recruitment) challenges. 
 Regulatory issues which is complicated by lack of laws on emerging clinical trial methods 
such as N-of-1 trials.  
 Most physicians in developing countries have limited access and knowledge of interpreting 
the results of RCTs, which would also apply to N-of-1 trials;   physicians in resource poor 
settings may have difficulties in getting information about N-of-1 trials and may have little 
knowledge of the added-value N-of-1 trials can provide.  
 Moreover, the barriers already documented to conducting clinical trials in developing 
countries 37,57,58 and the specific barriers reported for implementing N-of-1 trials in  
developed countries (doctors’ time, doctors’ acceptance, drug companies’ acceptance, 
patient willingness, and cost59 60,61) may challenge the wider use of N-of-1 trials in this 
setting.  
Limitations 
This review has some limitations. Even though we included many databases, language was a 
major barrier in searching local databases. This may have excluded potentially useful articles 
from developing countries. Most of the conclusions of this review are derived from only six 
articles with potentially a high risk of bias in most of them.  
Future directions 
The key implication of the sparse literature included in this review is that N-of-1 trials, designed 
and conducted well, could be possible in developing countries.  
 
Physicians in developing countries may be able to use these trials to optimize clinical care for 
individual patients, while at the same time contributing to quality assurance.  
 217 | P a g e  
 
Below are some strategies that can address operational and strategic barriers: 
 Development of local initiatives on patient centred research along with international 
and local partnership for capacity building and funding is needed.   
 Collaboration and resource sharing to establish and standardize regulatory structures 
that appreciates the various spectrum of emerging research designs. 
 Education/training of health professionals would be required.  
Conclusion  
This paper reviewed the use and scope of N-of-1 trials in resource poor settings and highlighted 
the potential roles of N-of-1 trials in clinical care in developing countries.  In the context of the 
increasing trend towards personalized medicine and concerns about the quality of drugs in 
developing countries, N-of-1 trials may be feasible tools to introduce patient centred medicine 
and improve the quality of medicines in developing countries, if the substantial barriers can be 
addressed.  
Abbreviations: RCT- randomized controlled trial, CENT- CONSORT extension for reporting 
N-of-1 trials, EBM-evidence based medicine, PM- personalized medicine, WHO-World Health 
Organization, FDA- Food and Drug Administration, US-United States, GNI-Gross National 
Income, HN-Hypertension  
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Figure title and legend 
    Figure 1: PRISMA flow chart for study selection  
Additional file title and legend 
   Additional file 1: PRISMA 2009 checklist 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Box 1 – Issues with the current process of assessing medicine effectiveness- factors that 
hamper appropriate medical care of patients in developing countries  
Process /system factors: Accessibility of health facilities, lack of updated treatment 
guidelines, cost of treatment.  
Doctor factors: Lack of knowledge on evidence based medicine and research, 
misconceptions of doctors on patient’s treatment claims, no/low accountability of doctors 
for inappropriate treatment, lack of time.    
Patient factors: misconceptions of medicines and health conditions, low literacy level, low 
economic condition. 
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 Table 1. Characteristics of studies of N-of-1 tests in developing countries 
 
1ST 
Author, 
country  
Design  Rationale Participants Measures Intervention Outcomes 
Haiyin 
Huang, 
et al, 
China 
(2014)32 
Randomiz
ed, 
double-
blind, 
crossover, 
within 
individual 
patient 
Lack of sufficient 
evidence on 
effectiveness on the 
therapy 
1 male, 2 females, aged 
18–75 years, diagnosed 
with stable 
bronchiectasis  
Primary: Patient self-
rated symptom score 
for cough, 
expectoration, 
shortness of breath, 
chest pain, and fatigue 
Secondary: 24 hr 
sputum volume and 
drug safety  
Herbal 
decoction vs 
control 
decoction  
All three patients 
showed non-significant 
improvement from the 
test TCM.   
One patient preferred 
the herbal decoction 
over the standard one 
after trial completion 
Huang 
Yuhong
, et al, 
China, 
(2012)33 
Randomiz
ed, 
double-
blind, 
crossover, 
within 
individual 
patient 
Lack of sufficient 
evidence on 
effectiveness on the 
therapy 
15 males, 35 females, 
aged 25–65 years, with a 
clinical diagnosis of 
deficiency of kidney Yin  
Primary: Individual 
completion rates, 
response rate, and 
post-n-of-1 RCTs 
decision  
Secondary: Self rated 
symptom score on 
Likert scale and SF-36 
questionnaire to  
measure perceived 
health and quality of 
life 
Liuwei 
Dihuang 
decoction 
(LDD) vs 
placebo 
Only 3 (6.38%) 
responded, 28 (59.57%) 
didn’t respond, and 16 
(34.05%) were possible 
responders. 29 (66%) of 
patients changed 
medication after the 
trial. 
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Wang 
Hui et 
al, 
China 
(2010)35 
Randomiz
ed, 
double-
blind, 
crossover, 
within 
individual 
patient 
 
Lack of sufficient 
evidence on 
effectiveness on the 
therapy 
6 males, 5 females, age g
roup 45-66 years, with 
diagnosis of mild-
moderate HN 
Effectiveness: Change 
in blood pressure 
(home and clinic 
measurements)  
Safety:respiratory 
rate, heart rate, routine 
blood test for liver and 
kidney function,  urine 
test, routine ECG,  
High dose vs 
low dose 
Bezoar Anti-
hypertension 
Capsule plus 
simulation 
placebo 
Home BP 
measurements showed 
significant reduction 
only in SBP. Clinic BP 
measurements showed 
significant reduction 
both in SBP & DBP 
from the high dose 
TCM (P < 0.001).  
There was no increased 
risk of adverse events 
from high dose Bezoar. 
Yu 
Dajun  
et al, 
China 
(2012)36 
Randomiz
ed, 
 crossover, 
within 
individual 
patient 
 
Lack of sufficient 
evidence on 
effectiveness on the 
therapy 
3 males, age: 52,57 and 
59 years with diagnosis 
of chronic kidney disease 
(CKD) of third stage 
Individual patient 
main symptom score  
Change in serum 
creatinine and 
creatinine clearance 
rate 
Chinese 
medicinal 
decoctions 
plus the 
routine basic 
treatment vs 
only the 
routine basic 
treatment 
Individual patients’ 
main symptom was 
significantly improved 
in the treatment phase 
(P<0.01). 
Two patients showed 
improved serum 
creatinine and 
creatinine clearance 
rate.  
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Zhang 
X et al, 
China 
(2012)37 
 
 
 
 
Randomiz
ed, 
 crossover, 
within 
individual 
patient 
 
Lack of sufficient 
evidence on 
effectiveness on the 
therapy 
4 patients, all male, ages 
50,61,68 and 76 years, 
with diagnosis of 
hypertensive 
intracerebral 
haemorrhage 
Patient main 
symptoms; IL-6, 
morphology index and 
clinical curative effect 
evaluation (the degree 
of encephaledema and 
cerebral infarction). 
Standard 
treatment 
plus TCM, 
acupuncture 
and 
moxibustion; 
Traditional 
Chinese 
manipulation 
vs standard 
treatment 
plus TCM  
TCM symptom scores 
of all patients were 
significantly improved 
(P<0.01). 
IL-6 of all patients was 
significantly reduced 
(P<0.01). 
Scores of Morphology 
Index and Clinical 
Curative Effect were 
also improved from the 
treatment phase 
Louly  
Priscila 
Gebrim 
et al, 
Brazil 
(2009) 
34  
Randomiz
ed, 
double-
blind, 
crossover, 
within-
individual 
patient 
Lack of optimal 
therapy to treat cough 
in patient 
55 year old female 
patient with dry cough 
secondary to 
interstitial pneumopathy  
Primary outcome: The 
intensity of daytime 
and night-time cough 
measured by a visual 
analog scale and 
patient’s perception 
regarding her health 
state. 
Tramadol 50 
mg compared 
with placebo 
The patient’s condition 
as measured by visual 
analog scale 
significantly improved 
from the test drug (P < 
0.001) 
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Table 2:  Quality of studies included  
 
Author 
(date) 
Sources of risk of bias 
Selection 
bias 
(Random 
sequence 
generation) 
Selection 
bias 
(Allocation 
concealment) 
Reporting 
bias 
(Incomplete 
outcome 
data) 
Reporting 
bias 
(Selective 
reporting) 
Performance 
bias 
(blinding of 
participants 
and 
clinicians) 
Inadequate 
cycles 
(risk of 
Error – 
especially 
type 2) 
Appropriateness 
of treatment for 
design 
Appropriate 
washout 
period 
Haiyin 
Huang, et al 
(2014)32 
Low*  Low Low Low Low Low Unclear Low  
Huang 
Yuhong, et 
al (2012)33 
Low  Low Low Low Unclear Low Unclear High  
Wang Hui et 
al (2010)35 
Low  Low Low Low Low Low Unclear High  
Yu Dajun  et 
al (2012)36 
Low  Unclear Low Low High Low Unclear High  
Zhang X et 
al (2012)37 
Low  Unclear Low Low High Low Unclear High  
Louly  
Priscila 
Gebrim et al 
(2009) 34  
Low  Low Low Low Low Low Low Low  
 
* Level of risk 
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Table 3: Treatment characteristics of N-of-1 tests in developing countries 
Variable     Number (%) 
Type of medical intervention  
        Traditional  medicine 5 (83%) 
        Modern medicine 1(17%) 
Number of planned treatment cycles  
          3 cycles 6 (100%) 
Number of crossovers  
         2 6 (100%) 
Treatment length  
        >Two weeks     6(100%) 
Washout  
          5-9 days 4 (67%) 
          Two days  2 (33%) 
Number of trials blinded 4 (67%) 
Outcome measurement (multiple answer)  
       Patient self-rated symptom score 6 (100%) 
       Other measurement tools or questionnaires 5 (83%) 
Responder definition  
       P value < 0.05 4 (67%) 
      Visual analogue scale (not statistical) difference specified 2 (33%) 
      Clinical (not statistical) difference specified 2 (33%) 
Method of analysis 
 
 
         Pooled analysis (using methods other than Bayesian) 2 (33%) 
         Wilcoxon signed rank test/non-parametric 1 (17%) 
         Mean difference 2 (33%) 
     Paired t test 4 (67%) 
Number of individuals who were participated  72 
Proportion (%) of individuals completing the trial (completion rate)  67 (93) 
Proportion (%) of post-n-of-1 RCTs decisions which favour trial results 46 (69) 
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Appendix table: Detailed assessment of study quality 
Author 
(date) 
Sources of risk of bias 
Selection bias 
(Random 
sequence 
generation) 
Selection 
bias 
(Allocation 
concealmen
t) 
Reporting 
bias 
(Incomplete 
outcome 
data) 
Reporting 
bias 
(Selective 
reporting) 
Performance 
bias 
(blinding of 
participants 
and 
clinicians) 
Inadequate 
cycles 
(risk of 
Error – 
especially 
type 2) 
Appropriaten
ess of 
treatment for 
design 
Appropriate 
washout 
period 
Haiyin 
Huang, et al 
(2014)32 
Low  
Method of 
random 
sequence 
generation is 
described. 
Low 
Independent 
pharmacist 
assigned 
treatments 
Low 
All outcome 
data are 
reported 
Low 
All outcome 
data are 
reported 
 
Low 
Method of 
blinding is 
adequately 
described 
Low 
Three cycles 
were 
conducted 
 
Unclear 
Biochemical 
and 
pharmacokine
tic information 
of the TM is 
not known 
 
Low risk 
Adequate 
washout 
period   based 
on 
preliminary 
study 
 
Huang 
Yuhong, et al 
(2012)33 
Low  
Method of 
random 
sequence 
generation is 
described. 
 
 
Low 
Independent 
pharmacist 
assigned 
treatments 
Low 
Acceptable 
reasons for 
missing data 
are given 
Low 
All outcome 
data are 
reported 
 
Unclear 
Method of 
blinding is not 
adequately 
described 
Low 
Three cycles 
were 
conducted 
 
Unclear 
Biochemical 
and 
pharmacokine
tic information 
of the TM is 
not known 
 
High  
Two days of 
washout 
period 
decided 
speculatively 
Wang Hui et 
al (2010)35 
Low 
Method of 
random 
sequence 
generation is 
described. 
 
Low 
Independent 
pharmacist 
assigned 
treatments 
Low 
Acceptable 
reasons for 
missing data 
are given 
Low 
All outcome 
data are 
reported 
 
Low 
Method of 
blinding is 
adequately 
described 
Low 
Three cycles 
were 
conducted 
 
Unclear 
Biochemical 
and 
pharmacokine
tic information 
of the TM is 
not known 
High  
The length of 
washout 
period is not 
well justified. 
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Yu Dajun  et 
al (2012)36 
Low  
Method of 
random 
sequence 
generation is 
described. 
  
Unclear 
The 
independenc
e of the 
person who 
assigned 
treatments is 
not well 
described 
Low 
All outcome 
data are 
reported 
 
Low 
All outcome 
data are 
reported 
 
High 
Method of 
blinding is not 
adequately 
described 
Low 
Three cycles 
were 
conducted 
 
Unclear 
Biochemical 
and 
pharmacokine
tic information 
of the  TM is 
not known 
 
High  
The length of 
washout 
period is not 
well justified. 
Zhang X et al 
(2012)37 
Low  
Method of 
random 
sequence 
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